The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist

DOI: 10.1126/science.1164772
Science, 2008, 322, 1211-7.

#	Paper	IF	Citations
1628	Discovery of Novel Adenosine Receptor Antagonists through a Combined Structure- and Ligand-Based Approach Followed by Molecular Dynamics Investigation of Ligand Binding Mode.		
1627	.		
1626	Purification of the human G protein-coupled receptor adenosine A(2a)R in a stable and functional form expressed in Pichia pastoris. **2012**, Chapter 29, Unit 29.4		2
1625	Radioligand binding analysis as a tool for quality control of GPCR production for structural characterization: adenosine A(2a)R as a template for study. **2012**, Chapter 29, Unit 29.3		
1624	G Protein-Coupled Receptors. **2004**, 1-11		
1623	. **2009**,		14
1622	Adenosine. **2009**, 158, S16-S17		78
1621	Computing highly correlated positions using mutual information and graph theory for G protein-coupled receptors. **2009**, 4, e4681		20
1620	Comparative sequence and structural analyses of G-protein-coupled receptor crystal structures and implications for molecular models. **2009**, 4, e7011		63
1619	Diseases associated with mutations of the human lutropin receptor. **2009**, 89, 97-114		27
1618	Molecular modeling and QSAR-based design of histamine receptor ligands. **2009**, 4, 1061-75		3
1617	Multifaceted approach to determine the antagonist molecular mechanism and interaction of ibodutant ([1-(2-phenyl-1R-[[1-(tetrahydropyran-4-ylmethyl)-piperidin-4-ylmethyl]-carbamoyl]-ethylcarbamoyl)-cyclopentyl]-amide) at the human tachykinin NK2 receptor. **2009**, 329, 486-95		12
1616	Helix 8 of leukotriene B4 type-2 receptor is required for the folding to pass the quality control in the endoplasmic reticulum. **2009**, 23, 1470-81		23
1615	Structural basis of the interaction between chemokine stromal cell-derived factor-1/CXCL12 and its G-protein-coupled receptor CXCR4. **2009**, 284, 35240-50		118
1614	Structural rearrangements of rhodopsin subunits in a dimer complex: a molecular dynamics simulation study. **2009**, 27, 127-47		40
1613	The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex. **2009**, 106, 9501-6		186
1612	The magnitude of the light-induced conformational change in different rhodopsins correlates with their ability to activate G proteins. **2009**, 284, 20676-83		43

1611	Characterization of the A2B adenosine receptor from mouse, rabbit, and dog. **2009**, 329, 2-13	31
1610	Identification of two distinct inactive conformations of the beta2-adrenergic receptor reconciles structural and biochemical observations. **2009**, 106, 4689-94	247
1609	Probing the role of the cation-pi interaction in the binding sites of GPCRs using unnatural amino acids. **2009**, 106, 11919-24	61
1608	Conserved waters mediate structural and functional activation of family A (rhodopsin-like) G protein-coupled receptors. **2009**, 106, 8555-60	201
1607	The C-terminal tail of CRTH2 is a key molecular determinant that constrains Galphai and downstream signaling cascade activation. **2009**, 284, 1324-36	51
1606	Thyroid stimulating autoantibody M22 mimics TSH binding to the TSH receptor leucine rich domain: a comparative structural study of protein-protein interactions. **2009**, 42, 381-95	27
1605	Structural and kinetic modeling of an activating helix switch in the rhodopsin-transducin interface. **2009**, 106, 10660-5	43
1604	8-azapurine nucleus: a versatile scaffold for different targets. **2009**, 9, 1367-78	13
1603	Customizing G Protein-coupled receptor models for structure-based virtual screening. **2009**, 15, 4026-48	62
1602	Chapter 11 Bacterial Membrane Proteins. **2009**, 63, 269-297	0
1601	Elucidation of binding sites of dual antagonists in the human chemokine receptors CCR2 and CCR5. **2009**, 75, 1325-36	48
1600	Small-molecule agonists for the thyrotropin receptor stimulate thyroid function in human thyrocytes and mice. **2009**, 106, 12471-6	85
1599	Activation induces structural changes in the liganded angiotensin II type 1 receptor. **2009**, 284, 26603-12	12
1598	Position 5.46 of the serotonin 5-HT2A receptor contributes to a species-dependent variation for the 5-HT2C agonist (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one: impact on selectivity and toxicological evaluation. **2009**, 76, 1211-9	9
1597	Rastering strategy for screening and centring of microcrystal samples of human membrane proteins with a sub-10 microm size X-ray synchrotron beam. **2009**, 6 Suppl 5, S587-97	138
1596	Selection and characterization of DARPins specific for the neurotensin receptor 1. **2009**, 22, 357-66	31
1595	Topology of class A G protein-coupled receptors: insights gained from crystal structures of rhodopsins, adrenergic and adenosine receptors. **2009**, 75, 1-12	97
1594	New directions in conventional methods of protein crystallization. **2009**, 101, 3-12	45

1593	Engineering of recombinant crystallization chaperones. **2009**, 19, 449-57	115
1592	Membrane protein crystallization from lipidic phases. **2009**, 19, 372-8	68
1591	Engineering G protein-coupled receptors to facilitate their structure determination. **2009**, 19, 386-95	157
1590	Structural snapshots of conformational changes in a seven-helix membrane protein: lessons from bacteriorhodopsin. **2009**, 19, 433-9	59
1589	Discovery of new GPCR biology: one receptor structure at a time. **2009**, 17, 8-14	165
1588	A role for a specific cholesterol interaction in stabilizing the Apo configuration of the human A(2A) adenosine receptor. **2009**, 17, 1660-1668	100
1587	Passing the baton in class B GPCRs: peptide hormone activation via helix induction?. **2009**, 34, 303-10	162
1586	A G protein-coupled receptor at work: the rhodopsin model. **2009**, 34, 540-52	289
1585	G-protein-coupled receptor-focused drug discovery using a target class platform approach. **2009**, 14, 231-40	138
1584	A chemogenomic approach to drug discovery: focus on cardiovascular diseases. **2009**, 14, 479-85	52
1583	Identification of transmembrane domain 6 & 7 residues that contribute to the binding pocket of the urotensin II receptor. **2009**, 77, 1374-82	10
1582	X-ray structure breakthroughs in the GPCR transmembrane region. **2009**, 78, 11-20	96
1581	Structures of micelle-bound selected insect neuropeptides and analogues: implications for receptor selection. **2009**, 10, 2644-53	5
1580	Adenosine A2A receptor antagonists: new 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson's disease. **2009**, 4, 1010-9	27
1579	Ligand and structure-based models for the prediction of ligand-receptor affinities and virtual screenings: Development and application to the beta(2)-adrenergic receptor. **2010**, 31, 707-20	36
1578	Prokaryotic expression, in vitro folding, and molecular pharmacological characterization of the neuropeptide Y receptor type 2. **2009**, 25, 1732-9	20
1577	Homology modelling of the human adenosine A2B receptor based on X-ray structures of bovine rhodopsin, the beta2-adrenergic receptor and the human adenosine A2A receptor. **2009**, 23, 807-28	33
1576	Computation of 3D queries for ROCS based virtual screens. **2009**, 23, 853-68	23

1575	Structural determinants for selective recognition of peptide ligands for endothelin receptor subtypes ETA and ETB. **2009**, 15, 479-91	23
1574	G-protein-coupled receptor structures were not built in a day. **2009**, 18, 1335-42	26
1573	Progress toward heterologous expression of active G-protein-coupled receptors in Saccharomyces cerevisiae: Linking cellular stress response with translocation and trafficking. **2009**, 18, 2356-70	45
1572	Engineering a G protein-coupled receptor for structural studies: stabilization of the BLT1 receptor ground state. **2009**, 18, 727-34	13
1571	Biophysical dissection of membrane proteins. **2009**, 459, 344-6	223
1570	The structure and function of G-protein-coupled receptors. **2009**, 459, 356-63	1583
1569	GPCRs: insane in the membrane. **2009**, 6, 929-933	8
1568	Crystallizing membrane proteins using lipidic mesophases. **2009**, 4, 706-31	516
1567	Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008. **2009**, 8, 455-63	236
1566	High-level production and characterization of a G-protein coupled receptor signaling complex. **2009** , 276, 4515-28	5
1565	Comparative analysis of GPCR crystal structures. **2009**, 85, 425-30	39
1564	G-protein-coupled receptor heteromers or how neurons can display differently flavoured patterns in response to the same neurotransmitter. **2009**, 158, 23-31	16
1563	7TM RECEPTORS. **2009**, 158, S5-S101	2
1562	A highly conserved tryptophan residue in the fourth transmembrane domain of the A adenosine receptor is essential for ligand binding but not receptor homodimerization. **2009**, 110, 1352-62	11
1561	Antagonists of the human A(2A) receptor. Part 5: Highly bio-available pyrimidine-4-carboxamides. **2009**, 19, 2664-7	25
1560	Recent Advances in the Application of Solution NMR Spectroscopy to Multi-Span Integral Membrane Proteins. **2009**, 55, 335-360	132
1559	Toward the three-dimensional structure and lysophosphatidic acid binding characteristics of the LPA(4)/p2y(9)/GPR23 receptor: a homology modeling study. **2009**, 28, 70-9	7
1558	Docking and chemoinformatic screens for new ligands and targets. **2009**, 20, 429-36	147

1557	8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. **2009**, 17, 2812-22	44
1556	Molecular recognition in the P2Y(14) receptor: Probing the structurally permissive terminal sugar moiety of uridine-5'-diphosphoglucose. **2009**, 17, 5298-311	29
1555	Introduction to adenosine receptors as therapeutic targets. **2009**, 1-24	78
1554	NMR characterization of membrane protein-detergent micelle solutions by use of microcoil equipment. **2009**, 131, 18450-6	23
1553	On transversal hydrophobicity of some proteins and their modules. **2009**, 49, 1821-30	6
1552	[Prediction of the spatial structure of proteins: emphasis on membrane targets]. **2009**, 35, 744-60	
1551	Functionalized congeners of A3 adenosine receptor-selective nucleosides containing a bicyclo[3.1.0]hexane ring system. **2009**, 52, 7580-92	40
1550	Allosteric functional switch of neurokinin A-mediated signaling at the neurokinin NK2 receptor: structural exploration. **2009**, 52, 5999-6011	12
1549	New insight into the binding mode of peptide ligands at Urotensin-II receptor: structure-activity relationships study on P5U and urantide. **2009**, 52, 3927-40	21
1548	Enhanced potency of nucleotide-dendrimer conjugates as agonists of the P2Y14 receptor: multivalent effect in G protein-coupled receptor recognition. **2009**, 20, 1650-9	21
1547	Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies. **2009**, 52, 2407-19	33
1546	PEGylated dendritic unimolecular micelles as versatile carriers for ligands of G protein-coupled receptors. **2009**, 20, 1888-98	30
1545	Functionalized congener approach to the design of ligands for G protein-coupled receptors (GPCRs). **2009**, 20, 1816-35	41
1544	Elucidation of the molecular basis of cholecystokinin Peptide docking to its receptor using site-specific intrinsic photoaffinity labeling and molecular modeling. **2009**, 48, 5303-12	22
1543	Amphipol-assisted in vitro folding of G protein-coupled receptors. **2009**, 48, 6516-21	90
1542	Anticonvulsant Met-enkephalin analogues containing backbone spacers reveal alternative non-opioid signaling in the brain. **2009**, 4, 659-71	11
1541	Chapter 13 Recent Advances in Adenosine Receptor (AR) Ligands in Pulmonary Diseases. **2009**, 265-277	5
1540	Nucleoside-5'-monophosphates as prodrugs of adenosine A2A receptor agonists activated by ecto-5'-nucleotidase. **2009**, 52, 7669-77	56

1539	Molecular basis of glucagon-like peptide 1 docking to its intact receptor studied with carboxyl-terminal photolabile probes. **2009**, 284, 34135-44	35
1538	From purified GPCRs to drug discovery: the promise of protein-based methodologies. **2009**, 9, 629-35	29
1537	Comparison of functional non-glycosylated GPCRs expression in Pichia pastoris. **2009**, 380, 271-6	34
1536	Fluorescence-based optimization of human bitter taste receptor expression in Saccharomyces cerevisiae. **2009**, 382, 704-10	13
1535	Ligand binding and micro-switches in 7TM receptor structures. **2009**, 30, 249-59	269
1534	Multiple switches in G protein-coupled receptor activation. **2009**, 30, 494-502	99
1533	The promiscuous mGlu5 receptor--a range of partners for therapeutic possibilities?. **2009**, 30, 617-23	40
1532	Distinct binding mode of 125I-AngII to AT1 receptor without the Cys18-Cys274 disulfide bridge. **2009**, 158, 14-8	2
1531	Expression, purification and in vitro functional reconstitution of the chemokine receptor CCR1. **2009**, 66, 73-81	26
1530	Role of helix 8 in G protein-coupled receptors based on structure-function studies on the type 1 angiotensin receptor. **2009**, 302, 118-27	47
1529	Thermostabilization of the neurotensin receptor NTS1. **2009**, 390, 262-77	133
1528	Uropathogenic E. coli adhesin-induced host cell receptor conformational changes: implications in transmembrane signaling transduction. **2009**, 392, 352-61	39
1527	Ligand entry and exit pathways in the beta2-adrenergic receptor. **2009**, 392, 1102-15	80
1526	In silico study of naphtha [1, 2-d] thiazol-2-amine with adenosine A 2A receptor and its role in antagonism of haloperidol-induced motor impairments in mice. **2009**, 463, 215-8	14
1525	Evaluation of homology modeling of G-protein-coupled receptors in light of the A(2A) adenosine receptor crystallographic structure. **2009**, 52, 3284-92	85
1524	Identification of amino acids at two dimer interface regions of the alpha-factor receptor (Ste2). **2009**, 48, 7132-9	29
1523	Chapter 4 Monoacylglycerols. **2009**, 63, 83-108	27
1522	Structure of a double transmembrane fragment of a G-protein-coupled receptor in micelles. **2009**, 96, 3187-96	30

1521	Location, structure, and dynamics of the synthetic cannabinoid ligand CP-55,940 in lipid bilayers. **2009**, 96, 4916-24	32
1520	Overview of computational methods employed in early-stage drug discovery. **2009**, 1, 49-63	8
1519	2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition. **2009**, 52, 7640-52	51
1518	Tuning microbial hosts for membrane protein production. **2009**, 8, 69	60
1517	Crystallizing membrane proteins for structure determination: use of lipidic mesophases. **2009**, 38, 29-51	183
1516	Molecular modeling and docking studies of human 5-hydroxytryptamine 2A (5-HT2A) receptor for the identification of hotspots for ligand binding. **2009**, 5, 1877-88	32
1515	Definition of the G protein-coupled receptor transmembrane bundle binding pocket and calculation of receptor similarities for drug design. **2009**, 52, 4429-42	86
1514	Strategies for the cloning and expression of membrane proteins. **2009**, 76, 43-86	10
1513	Predictions of binding for dopamine D2 receptor antagonists by the SIE method. **2009**, 49, 2369-75	22
1512	Modern homology modeling of G-protein coupled receptors: which structural template to use?. **2009**, 52, 5207-16	139
1511	Sequence-derived three-dimensional pharmacophore models for G-protein-coupled receptors and their application in virtual screening. **2009**, 52, 2923-32	60
1510	Dopamine D2, D3, and D4 selective phenylpiperazines as molecular probes to explore the origins of subtype specific receptor binding. **2009**, 52, 4923-35	75
1509	Computational Approaches in Peptide and Protein Design: An Overview. **2009**, 5-48	2
1508	Design of Cyclic Peptides. **2009**, 133-176	17
1507	Increasing selectivity of CC chemokine receptor 8 antagonists by engineering nondesolvation related interactions with the intended and off-target binding sites. **2009**, 52, 7706-23	26
1506	Computational molecular biology approaches to ligand-target interactions. **2009**, 3, 228-39	10
1505	High-throughput protein crystallization. **2009**, 77, 1-22	16
1504	GRIP: a server for predicting interfaces for GPCR oligomerization. **2009**, 29, 312-7	18

1503	Chapter 8. Activation mechanisms of chemokine receptors. **2009**, 461, 171-90	11
1502	Chapter 12. The use of receptor homology modeling to facilitate the design of selective chemokine receptor antagonists. **2009**, 461, 249-79	21
1501	Modeling small molecule-compound binding to G-protein-coupled receptors. **2009**, 460, 263-88	17
1500	Purification of recombinant G-protein-coupled receptors. **2009**, 463, 631-45	42
1499	Transferability of thermostabilizing mutations between beta-adrenergic receptors. **2009**, 26, 385-96	46
1498	Chemokine receptors and other G protein-coupled receptors. **2009**, 4, 88-95	32
1497	Current World Literature. **2009**, 4, 159-64	
1496	Unraveling the structure and function of G protein-coupled receptors through NMR spectroscopy. **2009**, 15, 4003-16	24
1495	The biology of CCR5 and CXCR4. **2009**, 4, 96-103	125
1494	Human A3 adenosine receptor as versatile G protein-coupled receptor example to validate the receptor homology modeling technology. **2009**, 15, 4069-84	9
1493	Progress in elucidating the structural and dynamic character of G Protein-Coupled Receptor oligomers for use in drug discovery. **2009**, 15, 4017-25	11
1492	Computer-aided identification of ligands for GPCR anti-obesity targets. **2009**, 9, 539-53	3
1491	G Protein-Coupled Receptors: target-based in silico screening. **2009**, 15, 4049-68	30
1490	Rhodopsin and the others: a historical perspective on structural studies of G protein-coupled receptors. **2009**, 15, 3994-4002	56
1489	G protein coupled receptors -in silico drug discovery and design. **2010**, 10, 638-56	23
1488	New tools for membrane protein research. **2010**, 11, 156-65	6
1487	GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity?. **2010**, 10, 799-813	40
1486	GPCR Homology Model Development and Application. **2010**, 279-300	3

1485	Structural Genomics, Its Application in Chemistry, Biology, and Drug Discovery. **2010**, 569-600	
1484	Receptor Targets in Drug Discovery. **2010**, 499-548	
1483	Structure and Modeling of GPCRs: Implications for Drug Discovery. **2010**, 385-433	2
1482	X-Ray Structure Developments for GPCR Drug Targets. **2010**, 434-459	1
1481	The Evolving Pharmacology of GPCRs. **2010**, 27-60	2
1480	One-Micron Beams for Macromolecular Crystallography at GM/CA-CAT. **2010**,	9
1479	Methods for combinatorial and parallel library design. **2011**, 672, 387-434	4
1478	Beyond rhodopsin: G protein-coupled receptor structure and modeling incorporating the beta2-adrenergic and adenosine A(2A) crystal structures. **2011**, 672, 359-86	13
1477	Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. **2010**, 53, 1799-809	211
1476	Normal mode analysis of biomolecular structures: functional mechanisms of membrane proteins. **2010**, 110, 1463-97	383
1475	The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA(3) adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition. **2010**, 53, 3361-75	36
1474	Crystallography of membrane proteins: from crystallization to structure. **2010**, 654, 79-103	3
1473	Structures of membrane proteins. **2010**, 43, 65-158	108
1472	Update 1 of: Over one hundred peptide-activated G protein-coupled receptors recognize ligands with turn structure. **2010**, 110, PR1-41	58
1471	Superactive mutants of thromboxane prostanoid receptor: functional and computational analysis of an active form alternative to constitutively active mutants. **2010**, 67, 2979-89	12
1470	Applications of fluorescence and bioluminescence resonance energy transfer to drug discovery at G protein coupled receptors. **2010**, 398, 167-80	32
1469	Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. **2010**, 45, 3459-71	27
1468	Novel 8-(furan-2-yl)-3-substituted thiazolo [5,4-e][1,2,4] triazolo[1,5-c] pyrimidine-2(3H)-thione derivatives as potential adenosine A(2A) receptor antagonists. **2010**, 18, 2491-500	25

1467	Design, synthesis, and binding of homologated truncated 4'-thioadenosine derivatives at the human A3 adenosine receptors. **2010**, 18, 7015-21	12
1466	New vistas in GPCR 3D structure prediction. **2010**, 16, 183-91	21
1465	Distinct interactions between the human adrenergic beta(2) receptor and Galpha(s)--an in silico study. **2010**, 16, 1307-18	6
1464	In silico binding characteristics between human histamine H1 receptor and antagonists. **2010**, 16, 1529-37	5
1463	Study of a structurally similar kappa opioid receptor agonist and antagonist pair by molecular dynamics simulations. **2010**, 16, 1567-76	24
1462	Pharmacophore modeling of human adenosine receptor A(2A) antagonists. **2010**, 16, 1867-76	10
1461	A Plug-Based Microfluidic System for Dispensing Lipidic Cubic Phase (LCP) Material Validated by Crystallizing Membrane Proteins in Lipidic Mesophases. **2010**, 8, 789-798	30
1460	The N-terminal end truncated mu-opioid receptor: from expression to circular dichroism analysis. **2010**, 160, 2175-86	8
1459	Allosteric antagonist binding sites in class B GPCRs: corticotropin receptor 1. **2010**, 24, 659-74	10
1458	Ligand-guided optimization of CXCR4 homology models for virtual screening using a multiple chemotype approach. **2010**, 24, 1023-33	21
1457	Third joint Italian-German Purine Club meeting: "Purinergic receptors: new frontiers for novel therapies". **2010**, 6, 49-115	1
1456	Influence of MT7 toxin on the oligomerization state of the M1 muscarinic receptor. **2010**, 102, 409-20	10
1455	VPAC1 receptor binding site: contribution of photoaffinity labeling approach. **2010**, 44, 127-32	24
1454	The crystallographic structure of the human adenosine A2A receptor in a high-affinity antagonist-bound state: implications for GPCR drug screening and design. **2010**, 20, 401-14	39
1453	Unlocking the eukaryotic membrane protein structural proteome. **2010**, 20, 464-70	28
1452	Internally bridging water molecule in transmembrane alpha-helical kink. **2010**, 20, 456-63	14
1451	Oligomeric forms of G protein-coupled receptors (GPCRs). **2010**, 35, 595-600	79
1450	Lighting up multiprotein complexes: lessons from GPCR oligomerization. **2010**, 28, 407-15	72

1449	A novel chemogenomics analysis of G protein-coupled receptors (GPCRs) and their ligands: a potential strategy for receptor de-orphanization. **2010**, 11, 316	40
1448	Model of the complex of Parathyroid hormone-2 receptor and Tuberoinfundibular peptide of 39 residues. **2010**, 3, 270	3
1447	Modulation of bitter taste perception by a small molecule hTAS2R antagonist. **2010**, 20, 1104-9	118
1446	Dynamics and flexibility of G-protein-coupled receptor conformations and their relevance to drug design. **2010**, 15, 951-7	21
1445	Novel Alexa Fluor-488 labeled antagonist of the A(2A) adenosine receptor: Application to a fluorescence polarization-based receptor binding assay. **2010**, 80, 506-11	41
1444	Comparison of the pharmacological properties of human and rat histamine H(3)-receptors. **2010**, 80, 1437-49	27
1443	Role of the extracellular amino terminus and first membrane-spanning helix of dopamine D1 and D5 receptors in shaping ligand selectivity and efficacy. **2010**, 22, 106-16	12
1442	Site-directed mutagenesis and PBAN activation of the Helicoverpa zea PBAN-receptor. **2010**, 584, 1212-6	15
1441	Molecular modeling studies on the human neuropeptide S receptor and its antagonists. **2010**, 5, 371-83	15
1440	Agonist-selective signaling of G protein-coupled receptor: mechanisms and implications. **2010**, 62, 112-9	36
1439	Specific ligands as pharmacological chaperones: The transport of misfolded G-protein coupled receptors to the cell surface. **2010**, 62, 453-9	9
1438	The G-protein-coupled receptor, GPR84, is important for eye development in Xenopus laevis. **2010**, 239, 3024-37	10
1437	High Throughput Screening Approach to Lead Discovery. **2010**, 21-71	4
1436	Fragment-Based Lead Discovery. **2010**, 105-139	3
1435	Drug Design for G-Protein-Coupled Receptors by a Ligand-Based NMR Method. **2010**, 122, 1468-1471	8
1434	Drug design for G-protein-coupled receptors by a ligand-based NMR method. **2010**, 49, 1426-9	40
1433	An Improved Weighted-Residue Profile Based Method of Using Protein-Ligand Interaction Information in Increasing Hits Selection from Virtual Screening: A Study on Virtual Screening of Human GPCR A2A Receptor Antagonists. **2010**, 29, 781-91	2
1432	Molecular modelling of central nervous system receptors. **2010**, 20, 243-248	3

1431	Enhancer and competitive allosteric modulation model for G-protein-coupled receptors. **2010**, 267, 663-75	6
1430	Structure and function of G protein-coupled receptors using NMR spectroscopy. **2010**, 57, 159-80	32
1429	Mammalian G protein-coupled receptor expression in Escherichia coli: II. Refolding and biophysical characterization of mouse cannabinoid receptor 1 and human parathyroid hormone receptor 1. **2010**, 401, 74-80	43
1428	2-Dialkynyl derivatives of (N)-methanocarba nucleosides: 'Clickable' A(3) adenosine receptor-selective agonists. **2010**, 18, 508-17	22
1427	Synthesis and pharmacological characterization of a new series of 5,7-disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazine derivatives as adenosine receptor antagonists: A preliminary inspection of ligand-receptor recognition process. **2010**, 18, 2524-36	29
1426	Affinity of aporphines for the human 5-HT2A receptor: insights from homology modeling and molecular docking studies. **2010**, 18, 5562-75	29
1425	Structure-activity relationships in 1,4-benzodioxan-related compounds. 10. Novel □-adrenoreceptor antagonists related to openphendioxan: synthesis, biological evaluation, and □d computational study. **2010**, 18, 7065-77	12
1424	Building a MCHR1 homology model provides insight into the receptor-antagonist contacts that are important for the development of new anti-obesity agents. **2010**, 18, 7365-79	8
1423	Synthesis of novel 7-imino-2-thioxo-3,7-dihydro-2H-thiazolo [4,5-d] pyrimidine derivatives as adenosine A2A receptor antagonists. **2010**, 20, 1214-8	30
1422	Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists. **2010**, 20, 5690-4	21
1421	Elucidation of the active conformation of the amino terminus of receptor-bound secretin using intramolecular disulfide bond constraints. **2010**, 20, 6040-4	5
1420	A reconstitution protocol for the in vitro folded human G protein-coupled Y2 receptor into lipid environment. **2010**, 150, 29-36	28
1419	Crystallization of small proteins assisted by green fluorescent protein. **2010**, 66, 1059-66	28
1418	Forced unbinding of GPR17 ligands from wild type and R255I mutant receptor models through a computational approach. **2010**, 10, 8	25
1417	Nucleoside conjugates of quantum dots for characterization of G protein-coupled receptors: strategies for immobilizing A2A adenosine receptor agonists. **2010**, 8, 11	10
1416	The importance of valine 114 in ligand binding in beta(2)-adrenergic receptor. **2010**, 19, 85-93	8
1415	A synergistic approach to protein crystallization: combination of a fixed-arm carrier with surface entropy reduction. **2010**, 19, 901-13	112
1414	GPCR 3D homology models for ligand screening: lessons learned from blind predictions of adenosine A2a receptor complex. **2010**, 78, 197-211	111

1413	Modeling the possible conformations of the extracellular loops in G-protein-coupled receptors. **2010**, 78, 271-85	25
1412	Modeling G protein-coupled receptors for structure-based drug discovery using low-frequency normal modes for refinement of homology models: application to H3 antagonists. **2010**, 78, 457-73	23
1411	FoldGPCR: structure prediction protocol for the transmembrane domain of G protein-coupled receptors from class A. **2010**, 78, 2189-201	31
1410	The impact of GPCR structures on pharmacology and structure-based drug design. **2010**, 159, 986-96	109
1409	Identification of a novel snake peptide toxin displaying high affinity and antagonist behaviour for the β2-adrenoceptors. **2010**, 161, 1361-74	31
1408	Mapping the druggable allosteric space of G-protein coupled receptors: a fragment-based molecular dynamics approach. **2010**, 76, 201-17	91
1407	The birth and postnatal development of purinergic signalling. **2010**, 199, 93-147	89
1406	Structure determination of the seven-helix transmembrane receptor sensory rhodopsin II by solution NMR spectroscopy. **2010**, 17, 768-74	181
1405	The quest to understand heterotrimeric G protein signaling. **2010**, 17, 650-2	48
1404	Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. **2010**, 463, 108-12	393
1403	Expression of G-protein coupled receptors in Escherichia coli for structural studies. **2010**, 75, 881-91	26
1402	Structural biology: The gatekeepers revealed. **2010**, 465, 823-6	11
1401	Structural basis of G protein-coupled receptor-G protein interactions. **2010**, 6, 541-8	68
1400	Functional studies of isolated GPCR-G protein complexes in the membrane bilayer of lipoprotein particles. 32-52	
1399	Interferon-gamma inhibits adenosine A2A receptor function in hepatic stellate cells by STAT1-mediated repression of adenylyl cyclase. **2010**, 2010, 113-126	7
1398	Insights into the binding of Phenyltiocarbamide (PTC) agonist to its target human TAS2R38 bitter receptor. **2010**, 5, e12394	87
1397	Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. **2010**, 5, e12403	90
1396	Static magnetic field exposure reproduces cellular effects of the Parkinson's disease drug candidate ZM241385. **2010**, 5, e13883	46

1395	Study of bioengineered zebra fish olfactory receptor 131-2: receptor purification and secondary structure analysis. **2010**, 5, e15027	13
1394	Hydrophobicity profiles in G protein-coupled receptor transmembrane helical domains. **2010**, 2010, 123-133	4
1393	Functional differences of invariant and highly conserved residues in the extracellular domain of the glycoprotein hormone receptors. **2010**, 285, 34813-27	15
1392	Analysis of transmembrane domains 1 and 4 of the human angiotensin II AT1 receptor by cysteine-scanning mutagenesis. **2010**, 285, 2284-93	12
1391	Impact of the DRY motif and the missing "ionic lock" on constitutive activity and G-protein coupling of the human histamine H4 receptor. **2010**, 333, 382-92	48
1390	Evolution-guided discovery and recoding of allosteric pathway specificity determinants in psychoactive bioamine receptors. **2010**, 107, 7787-92	72
1389	Proteins of the Hedgehog signaling pathway as therapeutic targets against cancer. **2010**, 7, 601-12	2
1388	Tasser-Based Protein Structure Prediction. **2010**, 219-242	2
1387	Reversible, allosteric small-molecule inhibitors of regulator of G protein signaling proteins. **2010**, 78, 524-33	65
1386	Ligand-supported purification of the urotensin-II receptor. **2010**, 78, 639-47	4
1385	International Union of Basic and Clinical Pharmacology. LXXX. The class Frizzled receptors. **2010**, 62, 632-67	161
1384	A conserved aromatic lock for the tryptophan rotameric switch in TM-VI of seven-transmembrane receptors. **2010**, 285, 3973-3985	107
1383	Ligand-induced rearrangements of the GABA(B) receptor revealed by fluorescence resonance energy transfer. **2010**, 285, 10291-9	29
1382	Third extracellular loop (EC3)-N terminus interaction is important for seven-transmembrane domain receptor function: implications for an activation microswitch region. **2010**, 285, 31472-83	19
1381	Nitro-oleic acid inhibits angiotensin II-induced hypertension. **2010**, 107, 540-8	96
1380	A lipid pathway for ligand binding is necessary for a cannabinoid G protein-coupled receptor. **2010**, 285, 17954-64	166
1379	Highly conserved tyrosine stabilizes the active state of rhodopsin. **2010**, 107, 19861-6	63
1378	Mapping the binding pocket of dual antagonist almorexant to human orexin 1 and orexin 2 receptors: comparison with the selective OX1 antagonist SB-674042 and the selective OX2 antagonist N-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmethyl-acetamide (EMPA). **2010**, 78, 81-93	35

1377	Mobility of G proteins is heterogeneous and polarized during chemotaxis. **2010**, 123, 2922-30	15
1376	New Techniques to Express and Crystallize G Protein-Coupled Receptors. **2010**, 324-384	1
1375	Virtual Screening. **2010**, 1-46	1
1374	Evidence that interaction between conserved residues in transmembrane helices 2, 3, and 7 are crucial for human VPAC1 receptor activation. **2010**, 78, 394-401	28
1373	Adenosine A2A receptor is involved in cell surface expression of A2B receptor. **2010**, 285, 39271-88	59
1372	Characterization of the beta-D-glucopyranoside binding site of the human bitter taste receptor hTAS2R16. **2010**, 285, 28373-8	73
1371	Interactions between intracellular domains as key determinants of the quaternary structure and function of receptor heteromers. **2010**, 285, 27346-27359	86
1370	GPRC6A mediates the non-genomic effects of steroids. **2010**, 285, 39953-64	132
1369	In Cubo Crystallization of Membrane Proteins. **2010**, 237-272	5
1368	QSAR AND PHARMACOPHORE MODELING OF 4-ARYLTHIENO [3, 2-d] PYRIMIDINE DERIVATIVES AGAINST ADENOSINE RECEPTOR OF PARKINSON'S DISEASE. **2010**, 09, 975-991	10
1367	Conserved water-mediated hydrogen bond network between TM-I, -II, -VI, and -VII in 7TM receptor activation. **2010**, 285, 19625-36	39
1366	Ligand binding and subtype selectivity of the human A(2A) adenosine receptor: identification and characterization of essential amino acid residues. **2010**, 285, 13032-44	77
1365	The annexin I sequence gln(9)-ala(10)-trp(11)-phe(12) is a core structure for interaction with the formyl peptide receptor 1. **2010**, 285, 14338-45	28
1364	Ligand-specific conformation of extracellular loop-2 in the angiotensin II type 1 receptor. **2010**, 285, 16341-50	58
1363	Interaction of the human prostacyclin receptor with Rab11: characterization of a novel Rab11 binding domain within alpha-helix 8 that is regulated by palmitoylation. **2010**, 285, 18709-26	27
1362	Induced effects of sodium ions on dopaminergic G-protein coupled receptors. **2010**, 6, e1000884	77
1361	Structure and Function of G-Protein-Coupled Receptors. **2010**, 151-156	0
1360	Structural Bioinformatics of Membrane Proteins. **2010**,	6

1359	GPCRRD: G protein-coupled receptor spatial restraint database for 3D structure modeling and function annotation. **2010**, 26, 3004-5	44
1358	Identification of determinants of glucose-dependent insulinotropic polypeptide receptor that interact with N-terminal biologically active region of the natural ligand. **2010**, 77, 547-58	48
1357	Ligand-based peptide design and combinatorial peptide libraries to target G protein-coupled receptors. **2010**, 16, 3071-88	78
1356	Receptor-driven identification of novel human A adenosine receptor antagonists as potential therapeutic agents. **2010**, 485, 225-44	7
1355	Thyrotropin (TSH) receptor residue E251 in the extracellular leucine-rich repeat domain is critical for linking TSH binding to receptor activation. **2010**, 151, 1940-7	17
1354	Pharmacophoric models and 3D QSAR studies of the adenosine receptor ligands. **2010**, 10, 1019-35	7
1353	Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown. **2010**, 17, 1468-86	111
1352	Adenosine receptor modeling: what does the A2A crystal structure tell us?. **2010**, 10, 993-1018	39
1351	Understanding functional residues of the cannabinoid CB1. **2010**, 10, 779-98	24
1350	Modeling the interactions between alpha(1)-adrenergic receptors and their antagonists. **2010**, 6, 165-78	9
1349	The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. **2010**, 31, 506-43	357
1348	Hydration Site Thermodynamics Explain SARs for Triazolylpurines Analogues Binding to the A2A Receptor. **2010**, 1, 160-4	91
1347	Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist. **2010**, 53, 1546-62	17
1346	Discovery of New Human A(2A) Adenosine Receptor Agonists: Design, Synthesis, and Binding Mode of Truncated 2-Hexynyl-4'-thioadenosine. **2010**, 2010, 516-520	13
1345	Heterodimerization of the GABAB receptor-implications for GPCR signaling and drug discovery. **2010**, 58, 63-91	16
1344	Concerted interconversion between ionic lock substates of the beta(2) adrenergic receptor revealed by microsecond timescale molecular dynamics. **2010**, 98, 76-84	61
1343	LCP-Tm: an assay to measure and understand stability of membrane proteins in a membrane environment. **2010**, 98, 1539-48	55
1342	Platforms for the identification of GPCR targets, and of orthosteric and allosteric modulators. **2010**, 5, 391-403	5

1341	NMR analyses of the interaction between CCR5 and its ligand using functional reconstitution of CCR5 in lipid bilayers. **2010**, 132, 6768-77		65
1340	Scope and difficulty in generating theoretical insights regarding ligand recognition and activation of the beta 2 adrenergic receptor. **2010**, 53, 923-32		15
1339	Using the □2-Adrenoceptor for Structure-Based Drug Design. **2010**, 87, 625-627		6
1338	Hydrophobic residues in helix 8 of cannabinoid receptor 1 are critical for structural and functional properties. **2010**, 49, 502-11		33
1337	Structure of a GPCR ligand in its receptor-bound state: leukotriene B4 adopts a highly constrained conformation when associated to human BLT2. **2010**, 132, 9049-57		63
1336	Functionalized congeners of P2Y1 receptor antagonists: 2-alkynyl (N)-methanocarba 2'-deoxyadenosine 3',5'-bisphosphate analogues and conjugation to a polyamidoamine (PAMAM) dendrimer carrier. **2010**, 21, 1190-205		19
1335	Ligand-steered modeling and docking: A benchmarking study in class A G-protein-coupled receptors. **2010**, 50, 2119-28		57
1334	Molecular Dynamics Simulation at High Sodium Chloride Concentration: Toward the Inactive Conformation of the Human Adenosine A2A Receptor. **2010**, 1, 1008-1013		8
1333	Recombinant expression, in vitro refolding, and biophysical characterization of the human glucagon-like peptide-1 receptor. **2010**, 49, 7956-65		21
1332	Visualizing water molecules in transmembrane proteins using radiolytic labeling methods. **2010**, 49, 827-34		41
1331	Analysis of adenosine A□ receptor stability: effects of ligands and disulfide bonds. **2010**, 49, 9181-9		20
1330	High-throughput virtual screening of proteins using GRID molecular interaction fields. **2010**, 50, 155-69		61
1329	Atom-centered interacting fragments and similarity search applications. **2010**, 50, 79-86		16
1328	Mass spectrometry-based GPCR proteomics: comprehensive characterization of the human cannabinoid 1 receptor. **2010**, 9, 1746-53		18
1327	Novel N2-substituted pyrazolo[3,4-d]pyrimidine adenosine A3 receptor antagonists: inhibition of A3-mediated human glioblastoma cell proliferation. **2010**, 53, 3954-63		46
1326	Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. *Science*, **2010**, 330, 1091-5	33.3	938
1325	Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. **2010**, 62, 265-304		491
1324	Frontal affinity chromatography-mass spectrometry useful for characterization of new ligands for GPR17 receptor. **2010**, 53, 3489-501		51

1323	Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. *Science*, **2010**, 330, 1066-71	33.3	1432
1322	Predicted 3D structures for adenosine receptors bound to ligands: comparison to the crystal structure. **2010**, 170, 10-20		48
1321	The membrane complex between transducin and dark-state rhodopsin exhibits large-amplitude interface dynamics on the sub-microsecond timescale: insights from all-atom MD simulations. **2010**, 398, 161-73		19
1320	Increasingly accurate dynamic molecular models of G-protein coupled receptor oligomers: Panacea or Pandora's box for novel drug discovery?. **2010**, 86, 590-7		33
1319	Adenosine receptors interacting proteins (ARIPs): Behind the biology of adenosine signaling. **2010**, 1798, 9-20		51
1318	Purification of transmembrane proteins from Saccharomyces cerevisiae for X-ray crystallography. **2010**, 71, 207-23		30
1317	Expression, purification and characterization of leukotriene B(4) receptor, BLT1 in Pichia pastoris. **2010**, 72, 66-74		9
1316	A purified C-terminally truncated human adenosine A(2A) receptor construct is functionally stable and degradation resistant. **2010**, 74, 80-7		20
1315	Expression of neurotransmitter transporters for structural and biochemical studies. **2010**, 73, 152-60		6
1314	Heterologous high yield expression and purification of neurotensin and its functional fragment in Escherichia coli. **2010**, 74, 65-8		7
1313	Functional coupling of Cys-226 and Cys-296 in the glucagon-like peptide-1 (GLP-1) receptor indicates a disulfide bond that is close to the activation pocket. **2010**, 31, 2289-93		17
1312	The minor binding pocket: a major player in 7TM receptor activation. **2010**, 31, 567-74		93
1311	Multiple interests in structural models of DARC transmembrane protein. **2010**, 17, 184-96		8
1310	Mutagenesis of human neuropeptide Y/peptide YY receptor Y2 reveals additional differences to Y1 in interactions with highly conserved ligand positions. **2010**, 163, 120-9		14
1309	Recent progress in the structure determination of GPCRs, a membrane protein family with high potential as pharmaceutical targets. **2010**, 654, 141-68		49
1308	Practical considerations of membrane protein instability during purification and crystallisation. **2010**, 601, 187-203		88
1307	G Protein-Coupled Receptor Structures. **2010**, 129-138		
1306	Rational design of CCR2 antagonists: a survey of computational studies. **2010**, 5, 543-57		12

1305	Structure and activation of the visual pigment rhodopsin. **2010**, 39, 309-28	147
1304	Homology modeling and docking evaluation of aminergic G protein-coupled receptors. **2010**, 50, 626-37	88
1303	Hybrid ortho/allosteric ligands for the adenosine A(1) receptor. **2010**, 53, 3028-37	74
1302	Structure-based discovery of A2A adenosine receptor ligands. **2010**, 53, 3748-55	195
1301	In silico fragment-based drug design. **2010**, 5, 1047-65	19
1300	Nonlinear optical imaging of integral membrane protein crystals in lipidic mesophases. **2010**, 82, 491-7	66
1299	Probing the structural determinants for the function of intracellular loop 2 in structurally cognate G-protein-coupled receptors. **2010**, 49, 10691-701	16
1298	The year in G protein-coupled receptor research. **2010**, 24, 261-74	117
1297	Structural basis for ligand recognition of incretin receptors. **2010**, 84, 251-78	9
1296	Therapeutic and Diagnostic Agents for Parkinson's Disease. **2010**, 529-568	
1295	Neurotransmitter Receptors in the Basal Ganglia. **2010**, 75-96	3
1294	Membrane Protein Structure Determination. **2010**,	4
1293	Heterologous Expression of Membrane Proteins. **2010**,	2
1292	Modeling Protein-Ligand Binding by Mining Minima. **2010**, 6, 3540-3557	50
1291	Engineering a GPCR-ligand pair that simulates the activation of D(2L) by Dopamine. **2010**, 1, 25-35	19
1290	Dimerization of G protein-coupled purinergic receptors: increasing the diversity of purinergic receptor signal responses and receptor functions. **2010**, 30, 337-46	19
1289	Structural divergence and functional versatility of the rhodopsin superfamily. **2010**, 9, 1458-65	32
1288	Incorporation of the dopamine D2L receptor and bacteriorhodopsin within bicontinuous cubic lipid phases. 1. Relevance to in meso crystallization of integral membrane proteins in monoolein systems. **2010**, 6, 4828	39

1287	Incorporation of the dopamine D2L receptor and bacteriorhodopsin within bicontinuous cubic lipid phases. 2. Relevance to in meso crystallization of integral membrane proteins in novel lipid systems. **2010**, 6, 4838	33
1286	Functional analysis of the second extracellular loop of rhodopsin by characterizing split variants. **2010**, 9, 1490-7	9
1285	Preparation of an activated rhodopsin/transducin complex using a constitutively active mutant of rhodopsin. **2011**, 50, 10399-407	16
1284	Molecular modeling of the human serotonin(1A) receptor: role of membrane cholesterol in ligand binding of the receptor. **2011**, 7, 224-34	55
1283	International Union of Basic and Clinical Pharmacology. LXXXII: Nomenclature and Classification of Hydroxy-carboxylic Acid Receptors (GPR81, GPR109A, and GPR109B). **2011**, 63, 269-90	126
1282	Development of Polar Adenosine A2A Receptor Agonists for Inflammatory Bowel Disease: Synergism with A2B Antagonists. **2011**, 2, 890-5	30
1281	Adverse and protective influences of adenosine on the newborn and embryo: implications for preterm white matter injury and embryo protection. **2011**, 69, 271-8	59
1280	Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands. **2011**, 50, 5633-47	55
1279	Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist. **2011**, 54, 751-64	26
1278	MIF-chemokine receptor interactions in atherogenesis are dependent on an N-loop-based 2-site binding mechanism. **2011**, 25, 894-906	40
1277	New 2-heterocyclyl-imidazo[2,1-i]purin-5-one derivatives as potent and selective human A3 adenosine receptor antagonists. **2011**, 54, 5205-20	12
1276	Changes in conformation at the cytoplasmic ends of the fifth and sixth transmembrane helices of a yeast G protein-coupled receptor in response to ligand binding. **2011**, 50, 6841-54	20
1275	Structural elements of the signal propagation pathway in squid rhodopsin and bovine rhodopsin. **2011**, 115, 6172-9	9
1274	International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update. **2011**, 63, 1-34	948
1273	Homology Model Versus X-ray Structure in Receptor-based Drug Design: A Retrospective Analysis with the Dopamine D3 Receptor. **2011**, 2, 293-7	19
1272	The Implication of the First Agonist Bound Activated GPCR X-ray Structure on GPCR in Silico Modeling. **2011**, 2, 414-8	10
1271	Recombinant expression and functional characterization of mouse olfactory receptor mOR256-17 in mammalian cells. **2011**, 50, 7228-35	20
1270	Development of an Automated High Throughput LCP-FRAP Assay to Guide Membrane Protein Crystallization in Lipid Mesophases. **2011**, 11, 1193-1201	45

1269	Quantification of functional selectivity at the human [illegible]1A)-adrenoceptor. **2011**, 79, 298-307	64
1268	The morphology and composition of cholesterol-rich micellar nanostructures determine transmembrane protein (GPCR) activity. **2011**, 100, L11-3	37
1267	Toward rational design of protein detergent complexes: determinants of mixed micelles that are critical for the in vitro stabilization of a G-protein coupled receptor. **2011**, 101, 1938-48	38
1266	Salt effects on the conformational stability of the visual G-protein-coupled receptor rhodopsin. **2011**, 101, 2798-806	11
1265	The use of GPCR structures in drug design. **2011**, 62, 1-36	34
1264	Molecular modeling of neurokinin B and tachykinin NK[illegible]receptor complex. **2011**, 51, 2932-8	17
1263	Structural basis for the [illegible]-adrenergic receptor subtype selectivity of the representative agonists and antagonists. **2011**, 51, 1405-22	18
1262	Computational study of the binding modes of caffeine to the adenosine A2A receptor. **2011**, 115, 13880-90	15
1261	Fragment screening of stabilized G-protein-coupled receptors using biophysical methods. **2011**, 493, 115-36	91
1260	The use of G-protein coupled receptor models in lead optimization. **2011**, 3, 709-21	14
1259	G protein-coupled receptors: mutations and endocrine diseases. **2011**, 7, 362-72	110
1258	Synthesis, biological evaluation, and automated docking of constrained analogues of the opioid peptide H-Dmt-D-Ala-Phe-Gly-NH[illegible]using the 4- or 5-methyl substituted 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one scaffold. **2011**, 54, 6538-47	12
1257	Homology modeling of class a G protein-coupled receptors. **2012**, 857, 259-79	41
1256	Biological and pharmacological roles of HCA receptors. **2011**, 62, 219-50	38
1255	Genome-Wide Protein Structure Prediction. **2011**, 255-279	2
1254	Allosteric modulation of metabotropic glutamate receptors. **2011**, 62, 37-77	42
1253	A new drug design targeting the adenosinergic system for Huntington's disease. **2011**, 6, e20934	67
1252	The mouse eugenol odorant receptor: structural and functional plasticity of a broadly tuned odorant binding pocket. **2011**, 50, 843-53	72

1251	The identification of the 2-phenylphthalazin-1(2H)-one scaffold as a new decorable core skeleton for the design of potent and selective human A3 adenosine receptor antagonists. **2011**, 54, 2102-13	50
1250	Experimental challenges to targeting poorly characterized GPCRs: uncovering the therapeutic potential for free fatty acid receptors. **2011**, 62, 175-218	41
1249	The splice variant of the V2 vasopressin receptor adopts alternative topologies. **2011**, 50, 4981-6	6
1248	Virtual Screening on Homology Models. **2011**, 381-410	3
1247	Dissecting the functions of conserved prolines within transmembrane helices of the D2 dopamine receptor. **2011**, 6, 1063-8	21
1246	Chemoinformatics and Computational Chemical Biology. **2011**,	6
1245	Methods for the Discovery and Characterization of G Protein-Coupled Receptors. **2011**,	
1244	Crystallizing Membrane Proteins in Lipidic Mesophases. A Host Lipid Screen. **2011**, 11, 530-537	43
1243	Structure-based prediction of subtype selectivity of histamine H3 receptor selective antagonists in clinical trials. **2011**, 51, 3262-74	36
1242	New QSAR prediction models derived from GPCR CB2-antagonistic triaryl bis-sulfone analogues by a combined molecular morphological and pharmacophoric approach. **2011**, 22, 525-44	9
1241	Ligand discovery from a dopamine D3 receptor homology model and crystal structure. **2011**, 7, 769-78	250
1240	From cradle to twilight: the carboxyl terminus directs the fate of the A(2A)-adenosine receptor. **2011**, 1808, 1350-7	30
1239	Structural features of adenosine receptors: from crystal to function. **2011**, 1808, 1233-44	47
1238	Allosteric modulation of adenosine receptors. **2011**, 1808, 1309-18	53
1237	Solution- and solid-state NMR studies of GPCRs and their ligands. **2011**, 1808, 1462-75	37
1236	Lipid-binding surfaces of membrane proteins: evidence from evolutionary and structural analysis. **2011**, 1808, 1092-102	63
1235	Recent developments in adenosine receptor ligands and their potential as novel drugs. **2011**, 1808, 1290-308	315
1234	Identification of a novel endoplasmic reticulum export motif within the eighth □helical domain (□H8) of the human prostacyclin receptor. **2011**, 1808, 1202-18	11

1233	Recent progress in the study of G protein-coupled receptors with molecular dynamics computer simulations. **2011**, 1808, 1868-78	67
1232	Comparative NMR analysis of an 80-residue G protein-coupled receptor fragment in two membrane mimetic environments. **2011**, 1808, 2674-84	11
1231	Dimerization and ligand binding affect the structure network of A(2A) adenosine receptor. **2011**, 1808, 1256-66	53
1230	Molecular dynamics simulations reveal insights into key structural elements of adenosine receptors. **2011**, 50, 4194-208	60
1229	Novel 8-(furan-2-yl)-3-benzyl thiazolo [5,4-e][1,2,4] triazolo [1,5-c] pyrimidine-2(3H)-thione as selective adenosine A(2A) receptor antagonist. **2011**, 488, 1-5	8
1228	When simple agonism is not enough: emerging modalities of GPCR ligands. **2011**, 331, 241-7	49
1227	Evolution of three human GPCRs for higher expression and stability. **2011**, 408, 599-615	68
1226	Differential interactions of fluorescent agonists and antagonists with the yeast G protein coupled receptor Ste2p. **2011**, 409, 513-28	21
1225	Thermostabilisation of an agonist-bound conformation of the human adenosine A(2A) receptor. **2011**, 409, 298-310	98
1224	Engineering an ultra-thermostable □(1)-adrenoceptor. **2011**, 413, 628-38	45
1223	Chapter 18:Structure-based Virtual Screening for Ligands of G Protein-coupled Receptors. **2011**, 359-374	4
1222	Pyrimidine derivatives as potent and selective A3 adenosine receptor antagonists. **2011**, 54, 457-71	47
1221	Progress in structure based drug design for G protein-coupled receptors. **2011**, 54, 4283-311	191
1220	Ligand functional selectivity and quantitative pharmacology at G protein-coupled receptors. **2011**, 6, 811-25	61
1219	Crystallization chaperone strategies for membrane proteins. **2011**, 55, 293-302	28
1218	Characterization of lipid matrices for membrane protein crystallization by high-throughput small angle X-ray scattering. **2011**, 55, 342-9	28
1217	Production of the stable human histamine H□receptor in Pichia pastoris for structural determination. **2011**, 55, 281-6	28
1216	New amphiphiles for membrane protein structural biology. **2011**, 55, 318-23	64

1215	Crystallizing membrane proteins using lipidic bicelles. **2011**, 55, 337-41	92
1214	GPCR stabilization using the bicelle-like architecture of mixed sterol-detergent micelles. **2011**, 55, 310-7	66
1213	Characterizing and predicting the functional and conformational diversity of seven-transmembrane proteins. **2011**, 55, 405-14	15
1212	Importance of the extracellular loops in G protein-coupled receptors for ligand recognition and receptor activation. **2011**, 32, 35-42	166
1211	Structural insights into adrenergic receptor function and pharmacology. **2011**, 32, 213-8	139
1210	Structural insights into RAMP modification of secretin family G protein-coupled receptors: implications for drug development. **2011**, 32, 591-600	63
1209	GPCR agonist binding revealed by modeling and crystallography. **2011**, 32, 637-43	52
1208	Optimization of Escherichia coli cultivation methods for high yield neuropeptide Y receptor type 2 production. **2011**, 76, 25-35	14
1207	Heterologous expression and purification of membrane-bound pyrophosphatases. **2011**, 79, 25-34	12
1206	Open conformation of adipokinetic hormone receptor from the malaria mosquito facilitates hormone binding. **2011**, 32, 553-9	10
1205	Analysis of the glucagon receptor first extracellular loop by the substituted cysteine accessibility method. **2011**, 32, 1593-9	17
1204	Role of membrane integrity on G protein-coupled receptors: Rhodopsin stability and function. **2011** , 50, 267-77	52
1203	Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential. **2011**, 60, 66-81	99
1202	Structure based prediction of subtype-selectivity for adenosine receptor antagonists. **2011**, 60, 108-15	71
1201	Allosteric modulation of G protein-coupled receptors: a pharmacological perspective. **2011**, 60, 24-35	218
1200	Structure-based drug discovery and protein targets in the CNS. **2011**, 60, 7-23	21
1199	Transmembrane signaling by GPCRs: insight from rhodopsin and opsin structures. **2011**, 60, 52-7	42
1198	Exploration of structure-based drug design opportunities for mGluRs. **2011**, 60, 93-101	14

1197	Importance of receptor flexibility in binding of cyclam compounds to the chemokine receptor CXCR4. **2011**, 51, 139-47		14
1196	Leukotriene receptors. **2011**, 111, 6231-98		63
1195	Biophysical mapping of the adenosine A2A receptor. **2011**, 54, 4312-23		99
1194	Synthesis and biological evaluation of a new series of 1,2,4-triazolo[1,5-a]-1,3,5-triazines as human A(2A) adenosine receptor antagonists with improved water solubility. **2011**, 54, 877-89		30
1193	Exploring a model of a chemokine receptor/ligand complex in an explicit membrane environment by molecular dynamics simulation: the human CCR1 receptor. **2011**, 51, 2717-30		21
1192	Substituted pyrazolo[3,4-b]pyridines as human A1 adenosine antagonists: developments in understanding the receptor stereoselectivity. **2011**, 9, 4448-55		15
1191	Structure of an agonist-bound human A2A adenosine receptor. *Science*, **2011**, 332, 322-7	33.3	706
1190	Identification of essential cannabinoid-binding domains: structural insights into early dynamic events in receptor activation. **2011**, 286, 33422-35		30
1189	[Structure of the adenosine-bound conformation of the human adenosine A(2A) receptor]. **2011**, 27, 926-8		3
1188	Knowledge Based Membrane Protein Structure Prediction: From X-Ray Crystallography to Bioinformatics and Back to Molecular Biology. **2011**,		
1187	Probing Structure and Dynamics of the Cell Membrane with Single Fluorescent Proteins. **2011**, 185-212		2
1186	Functional and Structural Overview of G-Protein-Coupled Receptors Comprehensively Obtained from Genome Sequences. **2011**, 4, 652-664		19
1185	High resolution structure of the ba3 cytochrome c oxidase from Thermus thermophilus in a lipidic environment. **2011**, 6, e22348		94
1184	Production of a bioengineered G-protein coupled receptor of human formyl peptide receptor 3. **2011**, 6, e23076		15
1183	Differential modulation of Beta-adrenergic receptor signaling by trace amine-associated receptor 1 agonists. **2011**, 6, e27073		42
1182	Modeling of human prokineticin receptors: interactions with novel small-molecule binders and potential off-target drugs. **2011**, 6, e27990		26
1181	The importance of alkynyl chain presence for the activity of adenine nucleosides/nucleotides on purinergic receptors. **2011**, 18, 1444-63		9
1180	P-glycoprotein inhibition: the past, the present and the future. **2011**, 12, 722-31		67

1179	Homology models in docking and high-throughput docking. **2011**, 11, 1528-34	36
1178	Collation and data-mining of literature bioactivity data for drug discovery. **2011**, 39, 1365-70	27
1177	Introduction. **2011**, 1-9	
1176	Heterologous Production of Active Mammalian G-Protein-Coupled Receptors Using Baculovirus-Infected Insect Cells. **2011**, 109-138	
1175	Expression of G-Protein-Coupled Receptors. **2011**, 219-248	3
1174	The cannabinoid type-1 receptor carboxyl-terminus, more than just a tail. **2011**, 117, 1-18	19
1173	Endocannabinoid tone versus constitutive activity of cannabinoid receptors. **2011**, 163, 1329-43	87
1172	Involvement of the first transmembrane segment of human ₂) -adrenoceptors in the subtype-selective binding of chlorpromazine, spiperone and spiroxatrine. **2011**, 164, 1558-72	10
1171	Guide to Receptors and Channels (GRAC), 5th edition. **2011**, 164 Suppl 1, S1-324	702
1170	Consultants. **2011**, 164, S3-S3	7
1169	G PROTEIN-COUPLED RECEPTORS. **2011**, 164, S5-S113	14
1168	LIGAND-GATED ION CHANNELS. **2011**, 164, S115-S135	5
1167	ION CHANNELS. **2011**, 164, S137-S174	9
1166	NUCLEAR RECEPTORS. **2011**, 164, S175-S188	78
1165	CATALYTIC RECEPTORS. **2011**, 164, S189-S212	1
1164	TRANSPORTERS. **2011**, 164, S213-S278	2
1163	ENZYMES. **2011**, 164, S279-S324	2
1162	Alterations in the photoactivation pathway of rhodopsin mutants associated with retinitis pigmentosa. **2011**, 278, 1493-505	8

1161	Structure of a nanobody-stabilized active state of the □(2) adrenoceptor. **2011**, 469, 175-80	1299
1160	The structural basis of agonist-induced activation in constitutively active rhodopsin. **2011**, 471, 656-60	395
1159	Overcoming barriers to membrane protein structure determination. **2011**, 29, 335-40	293
1158	ePMV embeds molecular modeling into professional animation software environments. **2011**, 19, 293-303	60
1157	Status of GPCR modeling and docking as reflected by community-wide GPCR Dock 2010 assessment. **2011**, 19, 1108-26	243
1156	Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC and caffeine. **2011**, 19, 1283-93	433
1155	Ligand-dependent perturbation of the conformational ensemble for the GPCR □2 adrenergic receptor revealed by HDX. **2011**, 19, 1424-32	111
1154	Structural basis for □opioid receptor binding and activation. **2011**, 19, 1683-90	23
1153	Assembling good amyloid: some structures at last. **2011**, 19, 1207-9	5
1152	Trapping small caffeine in a large GPCR pocket. **2011**, 19, 1204-7	5
1151	Allostery in GPCRs: 'MWC' revisited. **2011**, 36, 663-72	55
1150	New advances in production and functional folding of G-protein-coupled receptors. **2011**, 29, 314-22	68
1149	Identification of positions in the human neuropeptide Y/peptide YY receptor Y2 that contribute to pharmacological differences between receptor subtypes. **2011**, 45, 293-300	11
1148	Structural insights into agonist-induced activation of G-protein-coupled receptors. **2011**, 21, 541-51	180
1147	Nanobody stabilization of G protein-coupled receptor conformational states. **2011**, 21, 567-72	186
1146	High throughput platforms for structural genomics of integral membrane proteins. **2011**, 21, 517-22	23
1145	Uncovering the intimate relationship between lipids, cholesterol and GPCR activation. **2011**, 21, 802-7	183
1144	Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. **2011**, 132, 280-99	143

1143	Comprehensive analysis of host gene expression in Autographa californica nucleopolyhedrovirus-infected Spodoptera frugiperda cells. **2011**, 412, 167-78	55
1142	Homology modeling in tandem with 3D-QSAR analyses: a computational approach to depict the agonist binding site of the human CB2 receptor. **2011**, 46, 4489-505	32
1141	Agonist-dependent effects of mutations in the sphingosine-1-phosphate type 1 receptor. **2011**, 667, 105-12	13
1140	The structure of active opsin as a basis for identification of GPCR agonists by dynamic homology modelling and virtual screening assays. **2011**, 585, 3587-92	12
1139	Strategies for the identification of allosteric modulators of G-protein-coupled receptors. **2011**, 81, 691-702	64
1138	The four cysteine residues in the second extracellular loop of the human adenosine A2B receptor: role in ligand binding and receptor function. **2011**, 82, 389-99	33
1137	CH/π hydrogen bonds play a role in ligand recognition and equilibrium between active and inactive states of the β2 adrenergic receptor: an ab initio fragment molecular orbital (FMO) study. **2011**, 19, 5231-7	40
1136	Does the combination of optimal substitutions at the C2-, N6- and N6-positions of the pyrazolo-triazolo-pyrimidine scaffold guarantee selective modulation of the human A2A adenosine receptors?. **2011**, 19, 6120-34	10
1135	The hydrophobic amino acids in putative helix 8 in carboxy-terminus of histamine H(3) receptor are involved in receptor-G-protein coupling. **2011**, 23, 1843-9	7
1134	Enhanced Inter-helical Residue Contact Prediction in Transmembrane Proteins. **2011**, 66, 4356-4369	6
1133	Chemogenomic discovery of allosteric antagonists at the GPRC6A receptor. **2011**, 18, 1489-98	30
1132	Predicted structures and dynamics for agonists and antagonists bound to serotonin 5-HT2B and 5-HT2C receptors. **2011**, 51, 420-33	25
1131	Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. **2011**, 474, 521-5	685
1130	Methods of protein structure comparison. **2012**, 857, 231-57	190
1129	The significance of G protein-coupled receptor crystallography for drug discovery. **2011**, 63, 901-37	163
1128	Prostanoid receptors. **2011**, 111, 6209-30	101
1127	Update 1 of: computational modeling approaches to structure-function analysis of G protein-coupled receptors. **2011**, 111, PR438-535	61
1126	Chapter 15:Activation of G Protein-Coupled Receptor (GPCR) Kinases by GPCRs. **2011**, 297-315	1

1125	Chapter 17:The Mechanics of ArrestinReceptor Interaction: How GPCRs and Arrestins Talk to Each Other. **2011**, 335-355	
1124	G protein- and agonist-bound serotonin 5-HT2A receptor model activated by steered molecular dynamics simulations. **2011**, 51, 315-25	44
1123	Snooker: a structure-based pharmacophore generation tool applied to class A GPCRs. **2011**, 51, 2277-92	51
1122	Conformational dynamics of single G protein-coupled receptors in solution. **2011**, 115, 13328-38	81
1121	Structure of the human histamine H1 receptor complex with doxepin. **2011**, 475, 65-70	630
1120	Lipidic cubic phase technologies for membrane protein structural studies. **2011**, 21, 559-66	165
1119	Human cannabinoid 1 GPCR C-terminal domain interacts with bilayer phospholipids to modulate the structure of its membrane environment. **2011**, 13, 92-8	18
1118	Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. **2011**, 51, 117-44	152
1117	Synthesis of heterologous G protein-coupled receptors in the methylotrophic yeast P. pastoris. **2011**, 441, 280-2	
1116	Comparison of three GPCR structural templates for modeling of the P2Y12 nucleotide receptor. **2011**, 25, 329-38	30
1115	In silico identification of new ligands for GPR17: a promising therapeutic target for neurodegenerative diseases. **2011**, 25, 743-52	45
1114	Pharmacochemistry of the platelet purinergic receptors. **2011**, 7, 305-24	40
1113	Class A GPCRs: a multifaceted reality. **2011**, 7, 279-81	
1112	Homology model and docking studies on porcine □□adrenoceptor: description of two binding sites. **2011**, 17, 2525-38	8
1111	Modeling of ligand binding to G protein coupled receptors: cannabinoid CB1, CB2 and adrenergic □ 2 AR. **2011**, 17, 2353-66	27
1110	Conserved amino acids participate in the structure networks deputed to intramolecular communication in the lutropin receptor. **2011**, 68, 1227-39	46
1109	Homology modeling of human CCR2 receptor. **2011**, 20, 1704-1712	8
1108	Effects of lipid-analog detergent solubilization on the functionality and lipidic cubic phase mobility of the Torpedo californica nicotinic acetylcholine receptor. **2011**, 243, 47-58	8

1107	Structural determinants of the alpha2 adrenoceptor subtype selectivity. **2011**, 29, 1030-8	13
1106	Hydrogen/deuterium exchange mass spectrometry and optical spectroscopy as complementary tools for studying the structure and dynamics of a membrane protein. **2011**, 302, 3-11	20
1105	Cell-free synthesis of a functional G protein-coupled receptor complexed with nanometer scale bilayer discs. **2011**, 11, 57	48
1104	Evaluation of the Pichia pastoris expression system for the production of GPCRs for structural analysis. **2011**, 10, 24	28
1103	Automated sample-scanning methods for radiation damage mitigation and diffraction-based centering of macromolecular crystals. **2011**, 18, 717-22	57
1102	GPCR-SSFE: a comprehensive database of G-protein-coupled receptor template predictions and homology models. **2011**, 12, 185	46
1101	ss-TEA: Entropy based identification of receptor specific ligand binding residues from a multiple sequence alignment of class A GPCRs. **2011**, 12, 332	20
1100	Distinct second extracellular loop structures of the brain cannabinoid CB(1) receptor: implication in ligand binding and receptor function. **2011**, 79, 581-97	3
1099	Simplified modeling approach suggests structural mechanisms for constitutive activation of the C5a receptor. **2011**, 79, 787-802	6
1098	Modeling GPCR active state conformations: the □(2)-adrenergic receptor. **2011**, 79, 1441-57	23
1097	Predicted structures of agonist and antagonist bound complexes of adenosine A3 receptor. **2011**, 79, 1878-97	27
1096	Progress in the structural prediction of G protein-coupled receptors: D3 receptor in complex with eticlopride. **2011**, 79, 1695-703	21
1095	Polymer-based cell-free expression of ligand-binding family B G-protein coupled receptors without detergents. **2011**, 20, 1030-41	41
1094	Challenges and advances in computational docking: 2009 in review. **2011**, 24, 149-64	210
1093	Differential Virtual Screening (DVS) with Active and Inactive Molecular Models for Finding and Profiling GPCR Modulators: Case of the CCK1 Receptor. **2011**, 30, 345-58	4
1092	Structure-based discovery of allosteric modulators of two related class B G-protein-coupled receptors. **2011**, 6, 2159-69	57
1091	Substructure-based virtual screening for adenosine A2A receptor ligands. **2011**, 6, 2302-11	21
1090	Applying in silico tools to the discovery of novel CXCR4 inhibitors. **2011**, 72, 95-111	3

1089	Solution conformation of non-mammalian tachykinin physalaemin in lipid micelles by nuclear magnetic resonance. **2011**, 96, 252-9	3
1088	Comparison analysis of primary ligand-binding sites in seven-helix membrane proteins. **2011**, 95, 31-8	1
1087	Expression and biophysical analysis of a triple-transmembrane domain-containing fragment from a yeast G protein-coupled receptor. **2011**, 96, 757-71	9
1086	A chimeric GPCR model mimicking the ligand binding site of the human Y1 receptor studied by NMR spectroscopy. **2011**, 12, 1690-3	4
1085	Site-specific in vitro and in vivo incorporation of molecular probes to study G-protein-coupled receptors. **2011**, 15, 392-8	37
1084	Structure-based druggability assessment--identifying suitable targets for small molecule therapeutics. **2011**, 15, 463-8	121
1083	Synthesis, structure-affinity relationships, and molecular modeling studies of novel pyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists. **2011**, 19, 3757-68	20
1082	Molecular probes for the A2A adenosine receptor based on a pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine scaffold. **2011**, 21, 2740-5	22
1081	The structural and topological analysis of membrane-associated polypeptides by oriented solid-state NMR spectroscopy: established concepts and novel developments. **2011**, 153, 115-25	68
1080	Theoretical study of 3-D molecular similarity and ligand binding modes of orthologous human and rat D2 dopamine receptors. **2011**, 41, 537-45	13
1079	Biacore analysis with stabilized G-protein-coupled receptors. **2011**, 409, 267-72	56
1078	Lipoic acid stimulates cAMP production via G protein-coupled receptor-dependent and -independent mechanisms. **2011**, 22, 681-90	26
1077	Structure-function relationships of the human bitter taste receptor hTAS2R1: insights from molecular modeling studies. **2011**, 31, 229-40	17
1076	Regulation of G-Protein-Coupled Receptor Signalling by the Scaffolding Proteins Spinophilin/Neurabin 2 and Neurabin 1. **2011**, 5,	
1075	Organizational complexity of □adrenergic receptor signaling systems. **2011**, 67, 19-49	3
1074	Molecular pharmacology, physiology, and structure of the P2Y receptors. **2011**, 61, 373-415	96
1073	Oligomerization of G protein-coupled receptors: computational methods. **2011**, 18, 4588-605	28
1072	Drug design of GPCR ligands using physicogenetics and chemogenomics--principles and case studies. **2011**, 11, 1882-901	12

1071	G protein-coupled receptor transmembrane binding pockets and their applications in GPCR research and drug discovery: a survey. **2011**, 11, 1902-24	17
1070	Chemogenomics approaches for receptor deorphanization and extensions of the chemogenomics concept to phenotypic space. **2011**, 11, 1964-77	18
1069	A ligand's view of target similarity: chemogenomic binding site-directed techniques for drug discovery. **2011**, 11, 1872-81	13
1068	Lipid cubic phase as a membrane mimetic for integral membrane protein enzymes. **2011**, 108, 8639-44	52
1067	Computational methods for the discovery of mood disorder therapies. **2011**, 6, 1227-45	7
1066	Molecular basis of secretin docking to its intact receptor using multiple photolabile probes distributed throughout the pharmacophore. **2011**, 286, 23888-99	28
1065	Solid-state 2H NMR relaxation illuminates functional dynamics of retinal cofactor in membrane activation of rhodopsin. **2011**, 108, 8263-8	47
1064	A structural insight into the reorientation of transmembrane domains 3 and 5 during family A G protein-coupled receptor activation. **2011**, 79, 262-9	53
1063	Role of the transmembrane domain 4/extracellular loop 2 junction of the human gonadotropin-releasing hormone receptor in ligand binding and receptor conformational selection. **2011**, 286, 34617-26	11
1062	Allosteric modulation of purine and pyrimidine receptors. **2011**, 61, 187-220	28
1061	GPCR Conformations: Implications for Rational Drug Design. **2011**, 4, 7-43	14
1060	In Silico Veritas: The Pitfalls and Challenges of Predicting GPCR-Ligand Interactions. **2011**, 4, 1196-1215	16
1059	Helix 8 of the M1 muscarinic acetylcholine receptor: scanning mutagenesis delineates a G protein recognition site. **2011**, 79, 701-9	23
1058	Structural model of ligand-G protein-coupled receptor (GPCR) complex based on experimental double mutant cycle data: MT7 snake toxin bound to dimeric hM1 muscarinic receptor. **2011**, 286, 31661-75	33
1057	Crystallizing membrane proteins for structure-function studies using lipidic mesophases. **2011**, 39, 725-32	41
1056	Cholesterol-induced conformational changes in the oxytocin receptor. **2011**, 437, 541-53	27
1055	Thematic Analysis□a chemogenomic approach to GPCR drug discovery. **2011**, 11, 1925-43	6
1054	Arrestin-rhodopsin binding stoichiometry in isolated rod outer segment membranes depends on the percentage of activated receptors. **2011**, 286, 7359-69	42

1053	From molecular details of the interplay between transmembrane helices of the thyrotropin receptor to general aspects of signal transduction in family a G-protein-coupled receptors (GPCRs). **2011**, 286, 25859-71	20
1052	Engineering a prokaryotic Cys-loop receptor with a third functional domain. **2011**, 286, 34635-42	27
1051	Recognition in the face of diversity: interactions of heterotrimeric G proteins and G protein-coupled receptor (GPCR) kinases with activated GPCRs. **2011**, 286, 7715-7721	49
1050	Allosteric and orthosteric sites in CC chemokine receptor (CCR5), a chimeric receptor approach. **2011**, 286, 37543-54	37
1049	Two distinct conformations of helix 6 observed in antagonist-bound structures of a beta1-adrenergic receptor. **2011**, 108, 8228-32	154
1048	Successful prediction of the intra- and extracellular loops of four G-protein-coupled receptors. **2011**, 108, 8275-80	58
1047	Unique interaction pattern for a functionally biased ghrelin receptor agonist. **2011**, 286, 20845-60	39
1046	GPCR structure and activation: an essential role for the first extracellular loop in activating the adenosine A2B receptor. **2011**, 25, 632-43	41
1045	Structural Biology of Membrane Proteins. **2011**, 249-273	2
1044	Structural Insights for Homology Modeling of Chemokine Receptors. **2011**, 33-50	
1043	Expression and Purification of G-Protein-Coupled Receptors for Nuclear Magnetic Resonance Structural Studies. **2011**, 297-316	3
1042	Efficient Synthesis of Unsaturated 1-Monoacyl Glycerols for in meso Crystallization of Membrane Proteins. **2010**, 2011, 809-812	7
1041	Molecular modelling study on human histamine H1 receptor and its applications in virtual lead identification for designing novel inverse agonists. **2011**, 37, 100-114	
1040	NMR structures of polytopic integral membrane proteins. **2011**, 28, 370-97	16
1039	GPCRs Revisited: New Insights Lead to Novel Drugs. **2011**, 4, 244-272	14
1038	Prediction of the Human EP1 Receptor Binding Site by Homology Modeling and Molecular Dynamics Simulation. **2011**, 79, 793-816	6
1037	The structure of the adenosine receptors: implications for drug discovery. **2011**, 61, 1-40	9
1036	Differential determinants for coupling of distinct G proteins with the class B secretin receptor. **2012**, 302, C1202-12	18

1035	Ligand-dependent conformations and dynamics of the serotonin 5-HT(2A) receptor determine its activation and membrane-driven oligomerization properties. **2012**, 8, e1002473	84
1034	Molecular modeling of the M3 acetylcholine muscarinic receptor and its binding site. **2012**, 2012, 789741	9
1033	Functions of transmembrane domain 3 of human melanocortin-4 receptor. **2012**, 49, 221-35	34
1032	Small molecule drug discovery at the glucagon-like peptide-1 receptor. **2012**, 2012, 709893	53
1031	The VPAC1 receptor: structure and function of a class B GPCR prototype. **2012**, 3, 139	13
1030	Pleiotropic functions of the transmembrane domain 6 of human melanocortin-4 receptor. **2012**, 49, 237-48	25
1029	Pocketome: an encyclopedia of small-molecule binding sites in 4D. **2012**, 40, D535-40	123
1028	GPCR heteromers and their allosteric receptor-receptor interactions. **2012**, 19, 356-63	71
1027	Structure-based design in the GPCR target space. **2012**, 19, 544-56	20
1026	Clinical implications of recent insights into the structural biology of beta2 adrenoceptors. **2012**, 13, 1336-46	6
1025	Compound activity prediction using models of binding pockets or ligand properties in 3D. **2012**, 12, 1869-82	33
1024	Functional selectivity in GPCR signaling: understanding the full spectrum of receptor conformations. **2012**, 12, 817-30	20
1023	The G-protein coupled receptor family: actors with many faces. **2012**, 18, 175-85	28
1022	Ice breaking in GPCR structural biology. **2012**, 33, 324-34	39
1021	The essential role for aromatic cluster in the □B adrenergic receptor. **2012**, 33, 1062-8	3
1020	Recent Advances in the Rationale Design of GPER Ligands. **2012**, 19, 6199-6206	12
1019	Modeling and simulation studies of human □B adrenergic receptor and its interactions with agonists. **2012**, 8, 283-95	4
1018	Automatic modeling of mammalian olfactory receptors and docking of odorants. **2012**, 25, 377-86	47

1017	Allostery. **2012**,	4
1016	Tools for GPCR drug discovery. **2012**, 33, 372-84	214
1015	Identification of three residues essential for 5-hydroxytryptamine 2A-metabotropic glutamate 2 (5-HT2A□mGlu2) receptor heteromerization and its psychoactive behavioral function. **2012**, 287, 44301-19	94
1014	Reengineering the collision coupling and diffusion mode of the A2A-adenosine receptor: palmitoylation in helix 8 relieves confinement. **2012**, 287, 42104-18	8
1013	Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development. **2012**, 287, 12787-96	113
1012	A novel nonribose agonist, LUF5834, engages residues that are distinct from those of adenosine-like ligands to activate the adenosine A(2a) receptor. **2012**, 81, 475-87	31
1011	Modulation of constitutive activity and signaling bias of the ghrelin receptor by conformational constraint in the second extracellular loop. **2012**, 287, 33488-502	30
1010	Naturally evolved G protein-coupled receptors adopt metastable conformations. **2012**, 109, 13284-9	40
1009	Pharmacological characterization and modeling of the binding sites of novel 1,3-bis(pyridinylethynyl)benzenes as metabotropic glutamate receptor 5-selective negative allosteric modulators. **2012**, 82, 929-37	32
1008	The thyrotropin receptor hinge region as a surrogate ligand: identification of loci contributing to the coupling of thyrotropin binding and receptor activation. **2012**, 153, 5058-67	9
1007	Spatial proximity between the VPAC1 receptor and the amino terminus of agonist and antagonist peptides reveals distinct sites of interaction. **2012**, 26, 2060-71	21
1006	Limits of ligand selectivity from docking to models: in silico screening for A(1) adenosine receptor antagonists. **2012**, 7, e49910	46
1005	Intracellular Loop 2 Peptides of the Human 5HT1a Receptor are Differential Activators of Gi. **2012**, 2012, 490734	2
1004	The arginine of the DRY motif in transmembrane segment III functions as a balancing micro-switch in the activation of the □2-adrenergic receptor. **2012**, 287, 31973-82	24
1003	Ligand-mimicking receptor variant discloses binding and activation mode of prolactin-releasing peptide. **2012**, 287, 32181-94	7
1002	PheVI:09 (Phe6.44) as a sliding microswitch in seven-transmembrane (7TM) G protein-coupled receptor activation. **2012**, 287, 43516-26	27
1001	The importance of the adenosine A(2A) receptor-dopamine D(2) receptor interaction in drug addiction. **2012**, 19, 317-55	63
1000	Evolution of class A G-protein-coupled receptors: implications for molecular modeling. **2012**, 19, 1110-8	10

999	Homology Modeling and Antagonist Binding Site Study of the Human Histamine H2 Receptor. **2012**, 8, 1084-1092		2
998	A closer look into G protein coupled receptor activation: X-ray crystallography and long-scale molecular dynamics simulations. **2012**, 19, 1135-45		16
997	The family B1 GPCR: structural aspects and interaction with accessory proteins. **2012**, 13, 103-15		36
996	Structure-Based Design, Synthesis and Molecular Modeling Studies of Thiazolyl Urea Derivatives as Novel Anti-Parkinsonian Agents. **2012**, 8, 1057-1068		0
995	Action of molecular switches in GPCRs--theoretical and experimental studies. **2012**, 19, 1090-109		298
994	Harvesting and cryo-cooling crystals of membrane proteins grown in lipidic mesophases for structure determination by macromolecular crystallography. **2012**, e4001		35
993	9.8 G Protein Coupled Receptors. **2012**, 123-148		
992	Adenosiland: walking through adenosine receptors landscape. **2012**, 58, 248-57		27
991	Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. **2012**, 55, 1445-64		184
990	Membrane protein structure determination using crystallography and lipidic mesophases: recent advances and successes. **2012**, 51, 6266-88		96
989	Structural basis for allosteric regulation of GPCRs by sodium ions. *Science*, **2012**, 337, 232-6	33.3	714
988	Exploring the directionality of 5-substitutions in a new series of 5-alkylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine as a strategy to design novel human a(3) adenosine receptor antagonists. **2012**, 55, 9654-68		16
987	Molecular dynamics simulations reveal specific interactions of post-translational palmitoyl modifications with rhodopsin in membranes. **2012**, 134, 4324-31		29
986	Homology modeling of cannabinoid receptors: discovery of cannabinoid analogues for therapeutic use. **2012**, 819, 595-613		8
985	Critical features for biosynthesis, stability, and functionality of a G protein-coupled receptor uncovered by all-versus-all mutations. **2012**, 109, 9810-5		62
984	Identification of residues involved in homodimer formation located within a □-strand region of the N-terminus of a Yeast G protein-coupled receptor. **2012**, 32, 65-75		20
983	Target based virtual screening by docking into automatically generated GPCR models. **2012**, 914, 255-70		1
982	Chapter 7:A Nuclear G Protein-coupled Estrogen Receptor, GPER. Homology Modeling Studies Toward Its Ligand-binding Mode Characterization. **2012**, 117-137		5

981	C(X)CR in silico: Computer-aided prediction of chemokine receptor-ligand interactions. **2012**, 9, e227-314		16
980	Predicted structure of agonist-bound glucagon-like peptide 1 receptor, a class B G protein-coupled receptor. **2012**, 109, 19988-93		41
979	Crystal structure of a lipid G protein-coupled receptor. *Science*, **2012**, 335, 851-5	33.3	538
978	Comparison of the binding and functional properties of two structurally different D2 dopamine receptor subtype selective compounds. **2012**, 3, 1050-62		25
977	Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. **2012**, 482, 547-51		625
976	Current assessment of docking into GPCR crystal structures and homology models: successes, challenges, and guidelines. **2012**, 52, 3263-77		74
975	Ligand-, structure- and pharmacophore-based molecular fingerprints: a case study on adenosine A(1), A (2A), A (2B), and A (3) receptor antagonists. **2012**, 26, 1247-66		41
974	Structure-based design, synthesis, and molecular modeling studies of 1-(benzo[d]thiazol-2-yl)-3-(substituted aryl)urea derivatives as novel anti-Parkinsonian agents. **2012** , 21, 2630-2643		13
973	Homology modeling of the human 5-HT1A, 5-HT 2A, D1, and D2 receptors: model refinement with molecular dynamics simulations and docking evaluation. **2012**, 18, 3639-55		24
972	Fractal dimension as a measure of surface roughness of G protein-coupled receptors: implications for structure and function. **2012**, 18, 4465-75		14
971	Restructuring G-protein- coupled receptor activation. **2012**, 151, 14-23		208
970	Fragment screening at adenosine-A(3) receptors in living cells using a fluorescence-based binding assay. **2012**, 19, 1105-15		67
969	Ligand and decoy sets for docking to G protein-coupled receptors. **2012**, 52, 1-6		88
968	Fabrication of X-ray compatible microfluidic platforms for protein crystallization. **2012**, 174, 1-9		53
967	The role of protein structural analysis in the next generation sequencing era. **2014**, 336, 67-98		12
966	Pharmacophore mapping and in silico screening to identify new potent leads for A(2A) adenosine receptor as antagonists. **2012**, 32, 102-13		10
965	Insertion of T4-lysozyme (T4L) can be a useful tool for studying olfactory-related GPCRs. **2012**, 8, 1750-9		11
964	Post-translational modifications of the serotonin type 4 receptor heterologously expressed in mouse rod cells. **2012**, 51, 214-24		12

963	An aromatic region to induce a switch between agonism and inverse agonism at the ghrelin receptor. **2012**, 55, 7437-49	39
962	Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation. **2012**, 287, 3642-58	74
961	New insights for drug design from the X-ray crystallographic structures of G-protein-coupled receptors. **2012**, 82, 361-71	75
960	A structure-based approach to understanding somatostatin receptor-4 agonism (sst4). **2012**, 52, 171-86	16
959	Synthesis and pharmacological evaluation of dual acting antioxidant A(2A) adenosine receptor agonists. **2012**, 55, 3521-34	17
958	Predictions for cholesterol interaction sites on the A2A adenosine receptor. **2012**, 134, 16512-5	81
957	Structural transitions of transmembrane helix 6 in the formation of metarhodopsin I. **2012**, 116, 10477-89	16
956	Microscopic binding of M5 muscarinic acetylcholine receptor with antagonists by homology modeling, molecular docking, and molecular dynamics simulation. **2012**, 116, 532-41	10
955	Homology model-assisted elucidation of binding sites in GPCRs. **2012**, 914, 179-205	31
954	Mistic and TarCF as fusion protein partners for functional expression of the cannabinoid receptor 2 in Escherichia coli. **2012**, 83, 128-34	13
953	An expression and purification system for the biosynthesis of adenosine receptor peptides for biophysical and structural characterization. **2012**, 84, 224-35	3
952	Ligand-specific interactions modulate kinetic, energetic, and mechanical properties of the human □2 adrenergic receptor. **2012**, 20, 1391-402	79
951	Diversity and modularity of G protein-coupled receptor structures. **2012**, 33, 17-27	348
950	Domain coupling in GPCRs: the engine for induced conformational changes. **2012**, 33, 79-88	59
949	New insights from structural biology into the druggability of G protein-coupled receptors. **2012**, 33, 249-60	150
948	Biomolecular membrane protein crystallization. **2012**, 92, 2648-2661	9
947	Ligand binding and activation of the secretin receptor, a prototypic family B G protein-coupled receptor. **2012**, 166, 18-26	13
946	Conformational switches in the VPAC(1) receptor. **2012**, 166, 79-84	5

945	Reversed binding of a small molecule ligand in homologous chemokine receptors - differential role of extracellular loop 2. **2012**, 166, 258-75	13
944	Functional efficacy of adenosine A□A receptor agonists is positively correlated to their receptor residence time. **2012**, 166, 1846-59	124
943	Vibrationally assisted electron transfer mechanism of olfaction: myth or reality?. **2012**, 14, 13861-71	47
942	Comparative modeling of lipid receptors. **2012**, 914, 207-18	2
941	Structure prediction of G protein-coupled receptors and their ensemble of functionally important conformations. **2012**, 914, 237-54	22
940	Dopamine D1 receptor and serotonin 5-HT1A receptor agonist effects of the natural product (□)-stepholidine: molecular modelling and dynamics simulations. **2012**, 38, 970-979	1
939	Modeling of mammalian olfactory receptors and docking of odorants. **2012**, 4, 255-269	15
938	Maximizing detergent stability and functional expression of a GPCR by exhaustive recombination and evolution. **2012**, 422, 414-28	46
937	Artificial membrane-like environments for in vitro studies of purified G-protein coupled receptors. **2012**, 1818, 225-33	65
936	Molecular simulations and solid-state NMR investigate dynamical structure in rhodopsin activation. **2012**, 1818, 241-51	26
935	Optimization of purification and refolding of the human chemokine receptor CXCR1 improves the stability of proteoliposomes for structure determination. **2012**, 1818, 584-91	30
934	The role of cholesterol on the activity and stability of neurotensin receptor 1. **2012**, 1818, 2228-33	58
933	Structure and activation of rhodopsin. **2012**, 33, 291-9	42
932	Structure-activity relationships and molecular modeling of 1,2,4-triazoles as adenosine receptor antagonists. **2012**, 3, 715-720	15
931	Structure-based drug screening for G-protein-coupled receptors. **2012**, 33, 268-72	229
930	Large multiple transmembrane domain fragments of a G protein-coupled receptor: biosynthesis, purification, and biophysical studies. **2012**, 98, 485-500	6
929	MT1-selective melatonin receptor ligands: synthesis, pharmacological evaluation, and molecular dynamics investigation of N-{[(3-O-substituted)anilino]alkyl}amides. **2012**, 7, 1954-64	21
928	Platform for the rapid construction and evaluation of GPCRs for crystallography in Saccharomyces cerevisiae. **2012**, 11, 78	37

927	Identifying novel adenosine receptor ligands by simultaneous proteochemometric modeling of rat and human bioactivity data. **2012**, 55, 7010-20	42
926	Structure-function studies of muscarinic acetylcholine receptors. **2012**, 29-48	14
925	G Protein-Coupled Receptors. **2012**, 31-70	
924	Ligand-receptor interaction platforms and their applications for drug discovery. **2012**, 7, 969-88	81
923	The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors. **2012**, 52, 153-78	133
922	Non-HLA-antibodies targeting Angiotensin type 1 receptor and antibody mediated rejection. **2012**, 73, 1282-6	37
921	Topogenesis of heterologously expressed fragments of the human Y4 GPCR. **2012**, 1818, 3055-63	5
920	Agonist dynamics and conformational selection during microsecond simulations of the A(2A) adenosine receptor. **2012**, 102, 2114-20	32
919	Comparison of fragments comprising the first two helices of the human Y4 and the yeast Ste2p G-protein-coupled receptors. **2012**, 103, 817-26	4
918	New chromene scaffolds for adenosine A(2A) receptors: synthesis, pharmacology and structure-activity relationships. **2012**, 54, 303-10	28
917	Antihypertensive profile of 2-thienyl-3,4-methylenedioxybenzoylhydrazone is mediated by activation of the A2A adenosine receptor. **2012**, 55, 49-57	26
916	Agonist-bound structures of G protein-coupled receptors. **2012**, 22, 482-90	85
915	Ligand-specific homology modeling of human cannabinoid (CB1) receptor. **2012**, 38, 155-64	13
914	Identification of structural determinants of ligand selectivity in 5-HT receptor subtypes on the basis of protein-ligand interactions. **2012**, 38, 342-53	1
913	Receptors for Purines and Pyrimidines. **2012**, 119-244	12
912	Modeling the structural communication in supramolecular complexes involving GPCRs. **2012**, 914, 319-36	4
911	[Handling G-protein-coupled receptors: expression, purification and in vitro stabilization]. **2012**, 28, 837-44	2
910	Early History of Purinergic Signalling. **2012**, 7-66	2

909	Highly potent and selective fluorescent antagonists of the human adenosine A receptor based on the 1,2,4-triazolo[4,3-a]quinoxalin-1-one scaffold. **2012**, 55, 1771-82	36
908	Comparative pharmacophore modeling of human adenosine receptor A1 and A3 antagonists. **2012**, 55, 2407-2418	1
907	Contributions of fluorescence techniques to understanding G protein-coupled receptor dimerisation. **2012**, 4, 291-298	12
906	Molecular Docking and Prediction of Pharmacokinetic Properties of Dual Mechanism Drugs that Block MAO-B and Adenosine A(2A) Receptors for the Treatment of Parkinson's Disease. **2012**, 4, 184-92	32
905	Water-soluble pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines as human A adenosine receptor antagonists. **2012**, 55, 5380-90	10
904	Screening for high-yielding Pichia pastoris clones: the production of G protein-coupled receptors as a case study. **2012**, 866, 65-73	6
903	1.4 X-Ray Crystallography: Crystallization. **2012**, 34-63	
902	Neuroendocrine GPCR Signaling. **2012**, 21-53	4
901	Cannabinoid receptor type 2 (CB2)-selective N-aryl-oxadiazolyl-propionamides: synthesis, radiolabelling, molecular modelling and biological evaluation. **2012**, 2, 32	30
900	Identification of a crucial amino acid in the helix position 6.51 of human tachykinin neurokinin 1 and 3 receptors contributing to the insurmountable mode of antagonism by dual NK/NK antagonists. **2012**, 55, 5061-76	5
899	3-aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one: a novel template for the design of highly selective AB adenosine receptor antagonists. **2012**, 55, 1490-9	23
898	Molecular evolution of a peptide GPCR ligand driven by artificial neural networks. **2012**, 7, e36948	10
897	N-terminal T4 lysozyme fusion facilitates crystallization of a G protein coupled receptor. **2012**, 7, e46039	99
896	Stabilization of functional recombinant cannabinoid receptor CB(2) in detergent micelles and lipid bilayers. **2012**, 7, e46290	38
895	Structural Diversity in Conserved Regions Like the DRY-Motif among Viral 7TM Receptors-A Consequence of Evolutionary Pressure?. **2012**, 2012, 231813	12
894	Beyond modeling: all-atom olfactory receptor model simulations. **2012**, 3, 61	20
893	[G protein-coupled receptors in the spotlight]. **2012**, 28, 876-82	3
892	Purinergic signalling: what is missing and needed next? The use of transgenic mice, crystallographic analysis and MicroRNA. **2012**, 11, 751-67	6

891	Farnesyl pyrophosphate is an endogenous antagonist to ADP-stimulated P2Y receptor-mediated platelet aggregation. **2012**, 108, 119-32	8
890	Novel computational methodologies for structural modeling of spacious ligand binding sites of G-protein-coupled receptors: development and application to human leukotriene B4 receptor. **2012**, 2012, 691579	1
889	Human Serotonin 5-HT G Protein-Coupled Receptor Homology Model from the Adrenoceptor Structure: Ligand Docking and Mutagenesis Studies. **2012**, 112, 140	8
888	Bihelix: Towards de novo structure prediction of an ensemble of G-protein coupled receptor conformations. **2012**, 80, 505-18	37
887	Do crystal structures obviate the need for theoretical models of GPCRs for structure-based virtual screening?. **2012**, 80, 1503-21	26
886	Homology modeling and molecular dynamics simulations of the active state of the nociceptin receptor reveal new insights into agonist binding and activation. **2012**, 80, 1948-61	26
885	Molecular Determinants for Ligand Binding at Serotonin 5-HT and 5-HT GPCRs: Experimental Affinity Results Analyzed by Molecular Modeling and Ligand Docking Studies. **2012**, 112, 3807-3814	14
884	Structure of the first sphingosine 1-phosphate receptor. **2012**, 5, pe23	13
883	Chemistry and biology of multicomponent reactions. **2012**, 112, 3083-135	1678
882	Characterization of adenosine receptor in its native environment: insights from molecular dynamics simulations of palmitoylated/glycosylated, membrane-integrated human A(2B) adenosine receptor. **2012**, 18, 4309-24	15
881	Structure of the human opioid receptor in complex with JDTic. **2012**, 485, 327-32	695
880	Optimization of adenosine 5'-carboxamide derivatives as adenosine receptor agonists using structure-based ligand design and fragment screening. **2012**, 55, 4297-308	55
879	A prospective cross-screening study on G-protein-coupled receptors: lessons learned in virtual compound library design. **2012**, 55, 5311-25	28
878	Chapter 2:Thermodynamics of Ligand Binding. **2012**, 23-79	4
877	A new era of GPCR structural and chemical biology. **2012**, 8, 670-3	160
876	Interpreting the structural mechanism of action for MT7 and human muscarinic acetylcholine receptor 1 complex by modeling protein-protein interaction. **2012**, 30, 30-44	6
875	G-protein-coupled receptor dynamics: dimerization and activation models compared with experiment. **2012**, 40, 394-9	13
874	Structural insights into human GPCR protein OA1: a computational perspective. **2012**, 18, 2117-33	9

873	Evaluation of molecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound A2A adenosine receptor. **2012**, 55, 538-52	36
872	G-protein-coupled receptor inactivation by an allosteric inverse-agonist antibody. **2012**, 482, 237-40	240
871	Computational studies of the binding modes of CCR1 antagonists. **2012**, 38, 953-960	1
870	Molecular Dynamics Simulations of G Protein-Coupled Receptors. **2012**, 31, 222-30	15
869	Structure-activity relationships of truncated C2- or C8-substituted adenosine derivatives as dual acting A2A and A3 adenosine receptor ligands. **2012**, 55, 342-56	31
868	Molecular insights into the D1R agonist and D2R/D3R antagonist effects of the natural product (-)-stepholidine: molecular modeling and dynamics simulations. **2012**, 116, 8121-30	12
867	Vorhersage der Ligandenerkennung in einem Geruchsrezeptor durch Kombination von ortsgerichteter Mutagenese und dynamischer Homologie-Modellierung. **2012**, 124, 1300-1304	9
866	Biosynthesis and spectroscopic characterization of 2-TM fragments encompassing the sequence of a human GPCR, the Y4 receptor. **2012**, 13, 818-28	6
865	Impact of helix irregularities on sequence alignment and homology modeling of G protein-coupled receptors. **2012**, 13, 1393-9	35
864	Investigation of D3 receptor-agonist interactions using a combination of pharmacophore and receptor homology modeling. **2012**, 7, 471-82, 338	11
863	Structure-activity relationships for negative allosteric mGluR5 modulators. **2012**, 7, 440-51	16
862	Allostery and the Monod-Wyman-Changeux model after 50 years. **2012**, 41, 103-33	265
861	Allosteric mechanisms of G protein-Coupled Receptor signaling: a structural perspective. **2012**, 796, 133-74	11
860	Fragment-based approaches in drug discovery and chemical biology. **2012**, 51, 4990-5003	315
859	Ligand-based virtual screening approach using a new scoring function. **2012**, 52, 963-74	58
858	Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. **2012**, 52, 179-97	461
857	G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactions. **2012**, 8, 419-36	71
856	h2R-Gs complex: prediction versus crystal structure--how valuable are predictions based on molecular modeling studies?. **2012**, 18, 3439-44	1

855	Structural modelling and dynamics of proteins for insights into drug interactions. **2012**, 64, 323-43	24
854	Characterization of the Drosophila adenosine receptor: the effect of adenosine analogs on cAMP signaling in Drosophila cells and their utility for in vivo experiments. **2012**, 121, 383-95	5
853	Pharmacological modulation of chemokine receptor function. **2012**, 165, 1617-1643	175
852	Lifting the lid on GPCRs: the role of extracellular loops. **2012**, 165, 1688-1703	190
851	Identification and analysis of functionally important amino acids in human purinergic 12 receptor using a Saccharomyces cerevisiae expression system. **2012**, 279, 180-91	16
850	Binding sites in membrane proteins--diversity, druggability and prospects. **2012**, 91, 326-39	6
849	Specification of the cholesterol interaction with the oxytocin receptor using a chimeric receptor approach. **2012**, 676, 12-9	13
848	Novel fluorescent antagonist as a molecular probe in A(3) adenosine receptor binding assays using flow cytometry. **2012**, 83, 1552-61	28
847	Discovery of novel A3 adenosine receptor ligands based on chromone scaffold. **2012**, 84, 21-9	41
846	The role of the second and third extracellular loops of the adenosine A1 receptor in activation and allosteric modulation. **2012**, 84, 76-87	45
845	Determination of different putative allosteric binding pockets at the lutropin receptor by using diverse drug-like low molecular weight ligands. **2012**, 351, 326-36	28
844	Computational design of membrane proteins. **2012**, 20, 5-14	31
843	Fusion partner toolchest for the stabilization and crystallization of G protein-coupled receptors. **2012**, 20, 967-76	272
842	G protein-coupled receptors in the hypothalamic paraventricular and supraoptic nuclei--serpentine gateways to neuroendocrine homeostasis. **2012**, 33, 45-66	57
841	Crystallographic study and molecular modeling on the oxidation product of N-[(8R)-2-methoxy-5,6,7,8,9,10-hexahydro-6,9-methanocyclohepta[b]indol-8-yl]acetamide. **2012**, 48, 552-555	1
840	Palmitoylation and membrane cholesterol stabilize μ-opioid receptor homodimerization and G protein coupling. **2012**, 13, 6	77
839	Prediction of a ligand-binding niche within a human olfactory receptor by combining site-directed mutagenesis with dynamic homology modeling. **2012**, 51, 1274-8	74
838	Three "hotspots" important for adenosine A(2B) receptor activation: a mutational analysis of transmembrane domains 4 and 5 and the second extracellular loop. **2012**, 8, 23-38	17

837	The A3 adenosine receptor as multifaceted therapeutic target: pharmacology, medicinal chemistry, and in silico approaches. **2013**, 33, 235-335	35
836	endoCANNABINOIDS. **2013**,	6
835	Development of new chromatographic tools based on A2A adenosine receptor subtype for ligand characterization and screening by FAC-MS. **2013**, 405, 837-45	15
834	Design, synthesis, binding and docking-based 3D-QSAR studies of 2-pyridylbenzimidazoles--a new family of high affinity CB1 cannabinoid ligands. **2013**, 18, 3972-4001	17
833	Synthesis, biological activity and molecular modelling studies of tricyclic alkylimidazo-, pyrimido- and diazepinopurinediones. **2013**, 9, 395-414	12
832	Quaternary structure predictions and structural communication features of GPCR dimers. **2013**, 117, 105-42	12
831	Probing GPCR structure: adenosine and P2Y nucleotide receptors. **2013**, 520, 199-217	4
830	In vitro modification of substituted cysteines as tool to study receptor functionality and structure-activity relationships. **2013**, 439, 173-83	3
829	Production of GPCR and GPCR complexes for structure determination. **2013**, 23, 381-92	30
828	A microfluidic approach for protein structure determination at room temperature via on-chip anomalous diffraction. **2013**, 13, 3183-7	35
827	Structure of the human glucagon class B G-protein-coupled receptor. **2013**, 499, 444-9	312
826	Conversion of a non-selective adenosine receptor antagonist into A3-selective high affinity fluorescent probes using peptide-based linkers. **2013**, 11, 5673-82	40
825	Development of 7TM receptor-ligand complex models using ligand-biased, semi-empirical helix-bundle repacking in torsion space: application to the agonist interaction of the human dopamine D2 receptor. **2013**, 27, 277-91	3
824	Synthesis of substituted diphenyl sulfones and their structure-activity relationship with the antagonism of 5-[illegible] receptors. **2013**, 21, 4614-27	17
823	Molecular modeling of adenosine receptors. **2013**, 522, 37-59	3
822	Functionally biased signalling properties of 7TM receptors - opportunities for drug development for the ghrelin receptor. **2013**, 170, 1349-62	50
821	Olfactory Receptors. **2013**,	1
820	Conformational ensemble view of G protein-coupled receptors and the effect of mutations and ligand binding. **2013**, 520, 31-48	14

819	Novel approaches to drug design for the treatment of schizophrenia. **2013**, 8, 1285-96	19
818	Synthesis, molecular structure, NMR spectroscopic and computational analysis of a selective adenosine A2A antagonist, ZM 241385. **2013**, 24, 1241-1251	9
817	Structure-based virtual screening of MT2 melatonin receptor: influence of template choice and structural refinement. **2013**, 53, 821-35	28
816	The role of a sodium ion binding site in the allosteric modulation of the A(2A) adenosine G protein-coupled receptor. **2013**, 21, 2175-85	98
815	Ligand-dependent cholesterol interactions with the human A(2A) adenosine receptor. **2013**, 169, 39-45	22
814	Molecular modeling of vasopressin receptor and in silico screening of V1b receptor antagonists. **2013**, 8, 951-64	1
813	Design and evaluation of xanthine based adenosine receptor antagonists: potential hypoxia targeted immunotherapies. **2013**, 21, 7453-64	8
812	Kink characterization and modeling in transmembrane protein structures. **2013**, 53, 2926-36	6
811	G protein-coupled receptors as regulators of energy homeostasis. **2013**, 114, 1-43	13
810	Development of a cysteine-deprived and C-terminally truncated GLP-1 receptor. **2013**, 49, 100-8	6
809	Unlocking the secrets of the gatekeeper: methods for stabilizing and crystallizing GPCRs. **2013**, 1828, 2583-91	27
808	Conformational restriction of G-proteins Coupled Receptors (GPCRs) upon complexation to G-proteins: a putative activation mode of GPCRs?. **2013**, 587, 2656-61	10
807	4th International Conference on Biomedical Engineering in Vietnam. **2013**,	3
806	The protein local optimization program and G-protein-coupled receptors: loop restoration and applications to homology modeling. **2013**, 522, 1-20	1
805	Computational design and experimental characterization of GPCR segment models. **2013**, 522, 81-95	
804	Magic angle spinning nuclear magnetic resonance spectroscopy of G protein-coupled receptors. **2013**, 522, 365-89	8
803	Amino acid residues of G-protein-coupled receptors critical for endoplasmic reticulum export and trafficking. **2013**, 521, 203-16	3
802	An overview of biological macromolecule crystallization. **2013**, 14, 11643-91	83

801	8-(2-Furyl)adenine derivatives as A adenosine receptor ligands. **2013**, 70, 525-35	11
800	GPCR activation: protonation and membrane potential. **2013**, 4, 747-60	17
799	Study of the selectivity of -adrenergic antagonists by molecular modeling of a-, b-, and d-adrenergic receptor subtypes and docking simulations. **2013**, 144, 903-912	1
798	Implementing the "Best Template Searching" tool into Adenosiland platform. **2013**, 1, 25	10
797	Crystal structures of the A adenosine receptor and their use in medicinal chemistry. **2013**, 1, 22	8
796	Simulation and comparative analysis of binding modes of nucleoside and non-nucleoside agonists at the A2B adenosine receptor. **2013**, 1, 24	19
795	Advances in the study of structure and function of G protein-coupled receptors (about awarding the Nobel Prize for Chemistry in 2012 to Robert Lefkowitz and Brian Kobilka). **2013**, 49, 469-480	0
794	Solid-state NMR spectroscopy structure determination of a lipid-embedded heptahelical membrane protein. **2013**, 10, 1007-12	172
793	Modulation of A receptor antagonist on D receptor internalization and ERK phosphorylation. **2013**, 34, 1292-300	15
792	adrenergic receptor activation by agonists studied with F NMR spectroscopy. **2013**, 52, 10762-5	60
791	Complementarity between in silico and biophysical screening approaches in fragment-based lead discovery against the A(2A) adenosine receptor. **2013**, 53, 2701-14	55
790	To fuse or not to fuse: what is your purpose?. **2013**, 22, 1466-77	76
789	G Protein-Coupled Estrogen Receptor (GPER) Agonist Dual Binding Mode Analyses toward Understanding of its Activation Mechanism: A Comparative Homology Modeling Approach. **2013**, 32, 647-658	22
788	The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. **2013**, 170, 1459-581	509
787	A Strategy Combining Differential Low-Throughput Screening and Virtual Screening (DLS-VS) Accelerating the Discovery of new Modulators for the Orphan GPR34 Receptor. **2013**, 32, 213-29	10
786	The role of hydrophobic amino acids in the structure and function of the rhodopsin family of G protein-coupled receptors. **2013**, 520, 99-115	10
785	Conopeptide TIA defines a new allosteric site on the extracellular surface of the B-adrenoceptor. **2013**, 288, 1814-27	20
784	The GPCR Network: a large-scale collaboration to determine human GPCR structure and function. **2013**, 12, 25-34	207

783	Molecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors. **2013**, 52, 508-16	64
782	Molecular basis for dramatic changes in cannabinoid CB1 G protein-coupled receptor activation upon single and double point mutations. **2013**, 22, 101-13	33
781	Ligand-specific binding and activation of the human adenosine A(2B) receptor. **2013**, 52, 726-40	35
780	Mapping the functional binding sites of cholesterol in β2-adrenergic receptor by long-time molecular dynamics simulations. **2013**, 117, 1085-94	65
779	Identification of novel amino acid derived CCK-2R antagonists as potential antiulcer agent: homology modeling, design, synthesis, and pharmacology. **2013**, 53, 176-87	12
778	Biophysical and structural investigation of bacterially expressed and engineered CCR5, a G protein-coupled receptor. **2013**, 55, 79-95	16
777	Molecular signatures of G-protein-coupled receptors. **2013**, 494, 185-94	1071
776	Characterization of the dynamic events of GPCRs by automated computational simulations. **2013**, 41, 205-12	35
775	Computationally-predicted CB1 cannabinoid receptor mutants show distinct patterns of salt-bridges that correlate with their level of constitutive activity reflected in G protein coupling levels, thermal stability, and ligand binding. **2013**, 81, 1304-17	30
774	Structure-function of the G protein-coupled receptor superfamily. **2013**, 53, 531-56	758
773	Loop prediction for a GPCR homology model: algorithms and results. **2013**, 81, 214-28	18
772	Molekulare Allianz von orthosterischen und allosterischen Liganden zu dualsterischen/bitopischen Agonisten G-Protein-gekoppelter Rezeptoren. **2013**, 125, 530-538	5
771	A structural chemogenomics analysis of aminergic GPCRs: lessons for histamine receptor ligand design. **2013**, 170, 101-26	60
770	Modulation of A2B adenosine receptor by 1-Benzyl-3-ketoindole derivatives. **2013**, 69, 331-7	24
769	Identification of transmembrane domain 3, 4 & 5 residues that contribute to the formation of the ligand-binding pocket of the urotensin-II receptor. **2013**, 86, 1584-93	7
768	The second extracellular loop of GPCRs determines subtype-selectivity and controls efficacy as evidenced by loop exchange study at A2 adenosine receptors. **2013**, 85, 1317-29	30
767	Structure of β-adrenergic receptors. **2013**, 520, 117-51	7
766	Directed evolution of G-protein-coupled receptors for high functional expression and detergent stability. **2013**, 520, 67-97	15

765	Enrichment factor analyses on G-protein coupled receptors with known crystal structure. **2013**, 53, 739-43	19
764	Loss of constitutive activity is correlated with increased thermostability of the human adenosine A2A receptor. **2013**, 169, 988-98	24
763	Endogenous lipid activated G protein-coupled receptors: emerging structural features from crystallography and molecular dynamics simulations. **2013**, 169, 46-56	30
762	Structural features of the apelin receptor N-terminal tail and first transmembrane segment implicated in ligand binding and receptor trafficking. **2013**, 1828, 1471-83	29
761	Optimising the combination of thermostabilising mutations in the neurotensin receptor for structure determination. **2013**, 1828, 1293-301	28
760	Antagonist binding and induced conformational dynamics of GPCR A2A adenosine receptor. **2013**, 81, 1399-410	17
759	Paracrine Regulation of Renal Function by Dopamine. **2013**, 539-591	1
758	2-Arylpyrazolo[4,3-d]pyrimidin-7-amino derivatives as new potent and selective human A3 adenosine receptor antagonists. Molecular modeling studies and pharmacological evaluation. **2013**, 56, 2256-69	24
757	From heptahelical bundle to hits from the Haystack: structure-based virtual screening for GPCR ligands. **2013**, 522, 279-336	44
756	Crystal structure of oligomeric □1-adrenergic G protein-coupled receptors in ligand-free basal state. **2013**, 20, 419-25	207
755	Design, synthesis and biological evaluation of bivalent ligands against A(1)-D(1) receptor heteromers. **2013**, 34, 441-52	14
754	A homology modeling study toward the understanding of three-dimensional structure and putative pharmacological profile of the G-protein coupled receptor GPR55. **2013**, 39, 50-60	21
753	Bridging the gap: bitopic ligands of G-protein-coupled receptors. **2013**, 34, 59-66	132
752	Critical analysis of the successes and failures of homology models of G protein-coupled receptors. **2013**, 81, 729-39	20
751	GPCR activation: a mutagenic spotlight on crystal structures. **2013**, 34, 67-84	57
750	Adenosine receptors as drug targets--what are the challenges?. **2013**, 12, 265-86	573
749	Molecular dynamics simulations of the adenosine A2a receptor: structural stability, sampling, and convergence. **2013**, 53, 1168-78	36
748	X-ray structural information of GPCRs in drug design: what are the limitations and where do we go?. **2013**, 8, 607-20	15

747	Interactions of the β subunits of heterotrimeric G-proteins with GPCRs, effectors and RGS proteins: a critical review and analysis of interacting surfaces, conformational shifts, structural diversity and electrostatic potentials. **2013**, 182, 209-18	50
746	Conformational flexibility and structural dynamics in GPCR-mediated G protein activation: a perspective. **2013**, 425, 2288-98	72
745	Synthesis and structure-activity relationships of 2-hydrazinyladenosine derivatives as A(2A) adenosine receptor ligands. **2013**, 21, 436-47	4
744	Structure-based approaches to ligands for G-protein-coupled adenosine and P2Y receptors, from small molecules to nanoconjugates. **2013**, 56, 3749-67	27
743	Biophysical fragment screening of the β1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design. **2013**, 56, 3446-55	129
742	Novel adenosine A(2A) receptor ligands: a synthetic, functional and computational investigation of selected literature adenosine A(2A) receptor antagonists for extending into extracellular space. **2013**, 23, 3427-33	22
741	Breaking the barriers in membrane protein crystallography. **2013**, 45, 636-44	73
740	A3 adenosine receptor: homology modeling and 3D-QSAR studies. **2013**, 42, 60-72	24
739	Synthesis and biological evaluation of metabolites of 2-n-butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535), a potent antagonist of the A2A adenosine receptor for the treatment of Parkinson's disease. **2013**, 56, 5456-63	13
738	Water network perturbation in ligand binding: adenosine A(2A) antagonists as a case study. **2013**, 53, 1700-13	103
737	Generation of functional antibodies for mammalian membrane protein crystallography. **2013**, 23, 563-8	29
736	Ligand-dependent activation and deactivation of the human adenosine A(2A) receptor. **2013**, 135, 8749-59	83
735	Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits. **2013**, 4, 1026-48	54
734	Retinal conformation governs pKa of protonated Schiff base in rhodopsin activation. **2013**, 135, 9391-8	30
733	Stabilizing membrane proteins through protein engineering. **2013**, 17, 427-35	65
732	Revisiting a receptor-based pharmacophore hypothesis for human A(2A) adenosine receptor antagonists. **2013**, 53, 1620-37	12
731	Expression of GPCRs in Pichia pastoris for structural studies. **2013**, 520, 1-29	10
730	Binding site exploration of CCR5 using in silico methodologies: a 3D-QSAR approach. **2013**, 36, 6-31	9

729	Structure-based studies of chemokine receptors. **2013**, 23, 539-46	19
728	Rational design of sulfonated A3 adenosine receptor-selective nucleosides as pharmacological tools to study chronic neuropathic pain. **2013**, 56, 5949-63	37
727	G-protein-coupled receptor structure, ligand binding and activation as studied by solid-state NMR spectroscopy. **2013**, 450, 443-57	31
726	Optimized method of G-protein-coupled receptor homology modeling: its application to the discovery of novel CXCR7 ligands. **2013**, 56, 4236-51	32
725	Molecular modelling of odorant/olfactory receptor complexes. **2013**, 1003, 53-65	15
724	Chemical genomics approach for GPCR-ligand interaction prediction and extraction of ligand binding determinants. **2013**, 53, 1253-62	8
723	Pyrazolo[1,5-c]quinazoline derivatives and their simplified analogues as adenosine receptor antagonists: synthesis, structure-affinity relationships and molecular modeling studies. **2013**, 21, 283-94	37
722	Methods for recombinant expression and functional characterization of human cannabinoid receptor CB2. **2013**, 6, e201303011	6
721	Distinct CCK-2 receptor conformations associated with β-arrestin-2 recruitment or phospholipase-C activation revealed by a biased antagonist. **2013**, 135, 2560-73	25
720	Mutagenesis and computational modeling of human G-protein-coupled receptor Y2 for neuropeptide Y and peptide YY. **2013**, 52, 7987-98	20
719	Self-organized criticality in proteins: Hydropathic roughening profiles of G-protein-coupled receptors. **2013**, 87,	5
718	Selective and potent adenosine A3 receptor antagonists by methoxyaryl substitution on the N-(2,6-diarylpyrimidin-4-yl)acetamide scaffold. **2013**, 59, 235-42	11
717	Structural determinants of arrestin functions. **2013**, 118, 57-92	52
716	Synthesis of novel pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives: potent and selective adenosine A3 receptor antagonists. **2013**, 346, 699-707	8
715	Emerging opportunities for allosteric modulation of G-protein coupled receptors. **2013**, 85, 153-62	43
714	Stabilised G protein-coupled receptors in structure-based drug design: a case study with adenosine A2A receptor. **2013**, 4, 52-67	23
713	Advances in methods to characterize ligand-induced ionic lock and rotamer toggle molecular switch in G protein-coupled receptors. **2013**, 520, 153-74	7
712	Strategies for studying the ligand binding site of GPCRs: photoaffinity labeling of the VPAC1 receptor, a prototype of class B GPCRs. **2013**, 520, 219-37	4

711	Preparation of purified GPCRs for structural studies. **2013**, 41, 185-90	11
710	Functional fusions of T4 lysozyme in the third intracellular loop of a G protein-coupled receptor identified by a random screening approach in yeast. **2013**, 26, 59-71	12
709	Insights into the molecular evolution of oxytocin receptor ligand binding. **2013**, 41, 197-204	45
708	Structural Characterization of an LPA1 Second Extracellular Loop Mimetic with a Self-Assembling Coiled-Coil Folding Constraint. **2013**, 14, 2788-807	3
707	An efficient nanolitre-volume multi-channel device for highly viscous materials used in membrane protein crystallization. **2013**, 46, 829-831	
706	Extracellular disulfide bridges serve different purposes in two homologous chemokine receptors, CCR1 and CCR5. **2013**, 84, 335-45	17
705	Biased and constitutive signaling in the CC-chemokine receptor CCR5 by manipulating the interface between transmembrane helices 6 and 7. **2013**, 288, 12511-21	51
704	Modelling of GPCRs. **2013**,	2
703	Visualization of membrane protein crystals in lipid cubic phase using X-ray imaging. **2013**, 69, 1252-9	19
702	Crystallogenesis of adenosine A(2A) receptor-T4 lysozyme fusion protein: a practical route for the structure. **2013**, 520, 175-98	3
701	Efficient isotopic tryptophan labeling of membrane proteins by an indole controlled process conduct. **2013**, 110, 1681-90	5
700	Detailed analysis of biased histamine H□receptor signalling by JNJ 7777120 analogues. **2013**, 170, 78-88	26
699	Structure of the human angiotensin II type 1 (AT1) receptor bound to angiotensin II from multiple chemoselective photoprobe contacts reveals a unique peptide binding mode. **2013**, 288, 8187-8197	37
698	[Strategies for the structural determination of G protein-coupled receptors: from an example of histamine H□receptor]. **2013**, 133, 539-47	
697	□2-Adrenergic Receptor Activation by Agonists Studied with 19F NMR Spectroscopy. **2013**, 125, 10962-10965	11
696	Computational approaches for ligand discovery and design in class-A G protein- coupled receptors. **2013**, 19, 2216-36	15
695	A computationally designed water-soluble variant of a G-protein-coupled receptor: the human mu opioid receptor. **2013**, 8, e66009	28
694	Assessment and challenges of ligand docking into comparative models of G-protein coupled receptors. **2013**, 8, e67302	29

693	The therapeutic potential of allosteric ligands for free fatty acid sensitive GPCRs. **2013**, 13, 14-25	24
692	The 2.1 Å resolution structure of cyanopindolol-bound β1-adrenoceptor identifies an intramembrane Na+ ion that stabilises the ligand-free receptor. **2014**, 9, e92727	129
691	Pharmacology of Adenosine Receptors and Their Signaling Role in Immunity and Inflammation. **2014**,	3
690	. **2014**,	20
689	GPCR A2AAR Agonist Binding and Induced Conformation Changes of Functional Switches. **2014**, 27, 29-38	1
688	Molecular dynamics simulations reveal initial structural and dynamic features for the A2AR as a result of ligand binding. **2014**, 40, 996-1014	4
687	Structural basis for constitutive activity and agonist-induced activation of the enteroendocrine fat sensor GPR119. **2014**, 171, 5774-89	17
686	Identification of functionally important residues of the silkmoth pheromone biosynthesis-activating neuropeptide receptor, an insect ortholog of the vertebrate neuromedin U receptor. **2014**, 289, 19150-63	18
685	The identification of high-affinity G protein-coupled receptor ligands from large combinatorial libraries using multicolor quantum dot-labeled cell-based screening. **2014**, 6, 809-23	4
684	Reflections on the Many Facets of Protein Microcrystallography. **2014**, 67, 1793	6
683	A combination of in vitro techniques for efficient discovery of functional monoclonal antibodies against human CXC chemokine receptor-2 (CXCR2). **2014**, 6, 1415-24	19
682	Functions of the DRY motif and intracellular loop 2 of human melanocortin 3 receptor. **2014**, 53, 319-30	16
681	Discovery of GPCR ligands for probing signal transduction pathways. **2014**, 5, 255	25
680	Structural basis of G protein-coupled receptor-Gi protein interaction: formation of the cannabinoid CB2 receptor-Gi protein complex. **2014**, 289, 20259-72	27
679	Somatostatin Receptor-4 Agonists as Candidates for Treatment of Alzheimer's Disease. **2014**, 566-597	2
678	Computational prediction of alanine scanning and ligand binding energetics in G-protein coupled receptors. **2014**, 10, e1003585	52
677	Alpha-bulges in G protein-coupled receptors. **2014**, 15, 7841-64	27
676	Membrane Protein Production for Structural Analysis. **2014**, 1-44	1

675	Applications for mass spectrometry in the study of ion channel structure and function. **2014**, 806, 237-61	1
674	Insight into the interactions between novel coumarin derivatives and human A3 adenosine receptors. **2014**, 9, 2245-53	11
673	Allosteric interactions at adenosine A(1) and A(3) receptors: new insights into the role of small molecules and receptor dimerization. **2014**, 171, 1102-13	47
672	Insights into the role of Asp79(2.50) in □2 adrenergic receptor activation from molecular dynamics simulations. **2014**, 53, 7283-96	40
671	The molecular basis of ligand interaction at free fatty acid receptor 4 (FFA4/GPR120). **2014**, 289, 20345-58	52
670	Pancreatic polypeptide is recognized by two hydrophobic domains of the human Y4 receptor binding pocket. **2014**, 289, 5846-59	24
669	Mapping the intramolecular signal transduction of G-protein coupled receptors. **2014**, 82, 727-43	35
668	Global fold of human cannabinoid type 2 receptor probed by solid-state 13C-, 15N-MAS NMR and molecular dynamics simulations. **2014**, 82, 452-65	16
667	Structure-based drug design for G protein-coupled receptors. **2014**, 53, 1-63	57
666	CHAPTER 8:Macrocyclic Inhibitors of GPCR's, Integrins and Protein□Protein Interactions. **2014**, 283-338	2
665	Abstracts from Purines 2014, an International Conference on Nucleotides, Nucleosides and Nucleobases, held in Bonn, Germany, from July 23□27, 2014. **2014**, 10, 657-854	4
664	Do plants contain g protein-coupled receptors?. **2014**, 164, 287-307	45
663	W246(6.48) opens a gate for a continuous intrinsic water pathway during activation of the adenosine A2A receptor. **2015**, 54, 556-9	46
662	From three-dimensional GPCR structure to rational ligand discovery. **2014**, 796, 129-57	26
661	Structural biology of the S1P1 receptor. **2014**, 378, 23-53	4
660	Proteochemometric modeling in a Bayesian framework. **2014**, 6, 35	32
659	Chlorogenic acid inhibits human platelet activation and thrombus formation. **2014**, 9, e90699	59
658	GPCRDB: an information system for G protein-coupled receptors. **2014**, 42, D422-5	82

657	Structural basis for the binding of the membrane-proximal C-terminal region of chemokine receptor CCR2 with the cytosolic regulator FROUNT. **2014**, 281, 5552-66	8
656	Isothermal titration calorimetry in membrane protein research. **2014**, 87, 313-25	25
655	Fluorescent approaches for understanding interactions of ligands with G protein coupled receptors. **2014**, 1838, 15-33	78
654	T4-lysozyme fusion for the production of human formyl peptide receptors for structural determination. **2014**, 172, 2571-81	1
653	Protein Conformational Dynamics. **2014**,	9
652	Structure-based and fragment-based GPCR drug discovery. **2014**, 9, 256-75	53
651	mGluR5: exploration of orthosteric and allosteric ligand binding pockets and their applications to drug discovery. **2014**, 39, 1862-75	24
650	Protease-activated-receptor-2 affects protease-activated-receptor-1-driven breast cancer. **2014**, 71, 2517-33	29
649	Surface plasmon resonance spectroscopy for characterisation of membrane protein-ligand interactions and its potential for drug discovery. **2014**, 1838, 43-55	268
648	Membrane Transport Mechanism. **2014**,	2
647	Structural features of the G-protein/GPCR interactions. **2014**, 1840, 16-33	73
646	Allosteric sodium in class A GPCR signaling. **2014**, 39, 233-44	314
645	The Mechanism of Olfaction. **2014**, 32-187	1
644	8-Substituted 2-alkynyl-N(9)-propargyladenines as A2A adenosine receptor antagonists. **2014**, 22, 3072-82	8
643	Impact of template choice on homology model efficiency in virtual screening. **2014**, 54, 1661-8	34
642	SuperBiHelix method for predicting the pleiotropic ensemble of G-protein-coupled receptor conformations. **2014**, 111, E72-8	25
641	Adenosine A2A receptor as a drug discovery target. **2014**, 57, 3623-50	185
640	G Protein-Coupled Receptors - Modeling and Simulation. **2014**,	7

639	Amino acid conservation and interactions in rhodopsin: probing receptor activation by NMR spectroscopy. **2014**, 1837, 683-93	14
638	Multiscale modelling to understand the self-assembly mechanism of human □2-adrenergic receptor in lipid bilayer. **2014**, 48, 29-39	26
637	Bridging molecular docking to membrane molecular dynamics to investigate GPCR-ligand recognition: the human A□A adenosine receptor as a key study. **2014**, 54, 169-83	54
636	Adenosine A2A Receptor Antagonists. **2014**, 1-42	
635	Elastic network normal mode dynamics reveal the GPCR activation mechanism. **2014**, 82, 579-86	15
634	Identification of transmembrane domain 1 & 2 residues that contribute to the formation of the ligand-binding pocket of the urotensin-II receptor. **2014**, 92, 280-8	4
633	Crucial positively charged residues for ligand activation of the GPR35 receptor. **2014**, 289, 3625-38	13
632	Computational Studies of Smell and Taste Receptors. **2014**, 54, 1205-1218	31
631	Predicted ligands for the human urotensin-II G protein-coupled receptor with some experimental validation. **2014**, 9, 1732-43	5
630	Ligand induced change of □2 adrenergic receptor from active to inactive conformation and its implication for the closed/open state of the water channel: insight from molecular dynamics simulation, free energy calculation and Markov state model analysis. **2014**, 16, 15874-85	33
629	Design, synthesis and evaluation of N6-substituted 2-aminoadenosine-5?-N-methylcarboxamides as A3 adenosine receptor agonists. **2014**, 5, 192-196	6
628	Mapping the binding pocket of a novel, high-affinity, slow dissociating tachykinin NK3 receptor antagonist: biochemical and electrophysiological characterization. **2014**, 86, 259-72	3
627	Predicted 3D structures of olfactory receptors with details of odorant binding to OR1G1. **2014**, 28, 1175-90	12
626	Advancements of Mass Spectrometry in Biomedical Research. **2014**,	4
625	Structural basis for Smoothened receptor modulation and chemoresistance to anticancer drugs. **2014**, 5, 4355	175
624	Development of [18F]-labeled pyrazolo[4,3-e]-1,2,4- triazolo[1,5-c]pyrimidine (SCH442416) analogs for the imaging of cerebral adenosine A2A receptors with positron emission tomography. **2014**, 57, 6765-80	24
623	Exploration of the antagonist CP-376395 escape pathway for the corticotropin-releasing factor receptor 1 by random acceleration molecular dynamics simulations. **2014**, 10, 1958-67	20
622	Aromatic interactions impact ligand binding and function at serotonin 5-HT G protein-coupled receptors: Receptor homology modeling, ligand docking, and molecular dynamics results validated by experimental studies. **2014**, 112, 398-407	11

621	Moonlighting proteins and protein-protein interactions as neurotherapeutic targets in the G protein-coupled receptor field. **2014**, 39, 131-55	78
620	Selecting an optimal number of binding site waters to improve virtual screening enrichments against the adenosine A2A receptor. **2014**, 54, 1737-46	43
619	Intelligent Computing in Bioinformatics. **2014**,	3
618	Overexpression of membrane proteins from higher eukaryotes in yeasts. **2014**, 98, 7671-98	23
617	Constitutive activities in the thyrotropin receptor: regulation and significance. **2014**, 70, 81-119	20
616	Improving the apo-state detergent stability of NTS1 with CHESS for pharmacological and structural studies. **2014**, 1838, 2817-24	28
615	Recent advances in magic angle spinning solid state NMR of membrane proteins. **2014**, 82, 1-26	70
614	Strategies for improved modeling of GPCR-drug complexes: blind predictions of serotonin receptors bound to ergotamine. **2014**, 54, 2004-21	19
613	1,3,5-Triazine-based analogues of purine: from isosteres to privileged scaffolds in medicinal chemistry. **2014**, 85, 371-90	59
612	Biased agonism at G protein-coupled receptors: the promise and the challenges--a medicinal chemistry perspective. **2014**, 34, 1286-330	81
611	Adenosine receptor neurobiology: overview. **2014**, 119, 1-49	81
610	The recombinant expression systems for structure determination of eukaryotic membrane proteins. **2014**, 5, 658-72	66
609	Adenosine-insensitive right ventricular tachycardia: novel variant of idiopathic outflow tract tachycardia. **2014**, 11, 1770-8	9
608	Examining the critical roles of human CB2 receptor residues Valine 3.32 (113) and Leucine 5.41 (192) in ligand recognition and downstream signaling activities. **2014**, 452, 334-9	6
607	Domains for activation and inactivation in G protein-coupled receptors--a mutational analysis of constitutive activity of the adenosine A2B receptor. **2014**, 92, 348-57	9
606	Invited review: GPCR structural characterization: Using fragments as building blocks to determine a complete structure. **2014**, 102, 223-43	8
605	Elucidation of conformational states, dynamics, and mechanism of binding in human δ-opioid receptor complexes. **2014**, 54, 2294-308	25
604	Extended N(6) substitution of rigid C2-arylethynyl nucleosides for exploring the role of extracellular loops in ligand recognition at the A3 adenosine receptor. **2014**, 24, 3302-6	7

603	Mapping substance P binding sites on the neurokinin-1 receptor using genetic incorporation of a photoreactive amino acid. **2014**, 289, 18045-54	43
602	Ligand- and mutation-induced conformational selection in the CCR5 chemokine G protein-coupled receptor. **2014**, 111, 13040-5	28
601	Dualsteric muscarinic antagonists--orthosteric binding pose controls allosteric subtype selectivity. **2014**, 57, 6739-50	25
600	Perturbation of fluid dynamics properties of water molecules during G protein-coupled receptor-ligand recognition: the human A2A adenosine receptor as a key study. **2014**, 54, 2846-55	23
599	Alternative quality assessment strategy to compare performances of GPCR-ligand docking protocols: the human adenosine A(2A) receptor as a case study. **2014**, 54, 2243-54	22
598	Optimization of 6-heterocyclic-2-(1H-pyrazol-1-yl)-N-(pyridin-2-yl)pyrimidin-4-amine as potent adenosine A2A receptor antagonists for the treatment of Parkinson's disease. **2014**, 5, 674-82	15
597	Supervised molecular dynamics (SuMD) as a helpful tool to depict GPCR-ligand recognition pathway in a nanosecond time scale. **2014**, 54, 372-6	97
596	Dynamic behavior of the active and inactive states of the adenosine A(2A) receptor. **2014**, 118, 3355-65	21
595	Expression, stabilization and purification of membrane proteins via diverse protein synthesis systems and detergents involving cell-free associated with self-assembly peptide surfactants. **2014**, 32, 564-74	14
594	N-acylhydrazone derivative ameliorates monocrotaline-induced pulmonary hypertension through the modulation of adenosine AA2R activity. **2014**, 173, 154-62	28
593	Conserved residues in RF-NH□receptor models identify predicted contact sites in ligand-receptor binding. **2014**, 53, 278-85	13
592	Different efficacy of adenosine and NECA derivatives at the human A3 adenosine receptor: insight into the receptor activation switch. **2014**, 87, 321-31	16
591	Unifying family A GPCR theories of activation. **2014**, 143, 51-60	141
590	Computational insights into the binding mechanism of antagonists with neuropeptide B/W receptor 1. **2014**, 10, 2236-46	1
589	Computational study of possible complexes of caffeine and adenosine with adenosine receptor fragments. **2014**, 1043, 17-23	
588	Agonist-bound structure of the human P2Y12 receptor. **2014**, 509, 119-22	222
587	Molecular dynamics simulations of the adenosine A2a receptor in POPC and POPE lipid bilayers: effects of membrane on protein behavior. **2014**, 54, 573-81	31
586	Comparative genomic analysis of eutherian Mas-related G protein-coupled receptor genes. **2014**, 540, 16-9	7

585	Discovery of simplified N□-substituted pyrazolo[3,4-d]pyrimidine derivatives as novel adenosine receptor antagonists: efficient synthetic approaches, biological evaluations and molecular docking studies. **2014**, 22, 1751-65	12
584	Insight into the binding mode and the structural features of the pyrimidine derivatives as human A2A adenosine receptor antagonists. **2014**, 115, 13-22	11
583	Structural and biophysical characterisation of G protein-coupled receptor ligand binding using resonance energy transfer and fluorescent labelling techniques. **2014**, 1838, 3-14	25
582	Nonlamellar Lipid Aggregates. **2014**, 48-65	1
581	Functional importance of two conserved residues in intracellular loop 1 and transmembrane region 2 of Family A GPCRs: insights from ligand binding and signal transduction responses of D1 and D5 dopaminergic receptor mutants. **2015**, 27, 2014-25	5
580	Molecular interaction studies of green tea catechins as multitarget drug candidates for the treatment of Parkinson's disease: computational and structural insights. **2015**, 26, 97-115	20
579	Investigation of Inhibition Mechanism of Chemokine Receptor CCR5 by Micro-second Molecular Dynamics Simulations. **2015**, 5, 13180	33
578	Helix 8 of the angiotensin- II type 1A receptor interacts with phosphatidylinositol phosphates and modulates membrane insertion. **2015**, 5, 9972	10
577	Structure-Based Design Strategies for Targeting G-Protein-Coupled Receptors (GPCRs). **2015**, 199-216	
576	Micelle-Enhanced Bioorthogonal Labeling of Genetically Encoded Azido Groups on the Lipid-Embedded Surface of a GPCR. **2015**, 16, 1314-22	16
575	In-Membrane Chemical Modification (IMCM) for Site-Specific Chromophore Labeling of GPCRs. **2015**, 127, 15461-15464	2
574	In-Membrane Chemical Modification (IMCM) for Site-Specific Chromophore Labeling of GPCRs. **2015**, 54, 15246-9	9
573	Potent, Metabolically Stable 2-Alkyl-8-(2H-1,2,3-triazol-2-yl)-9H-adenines as Adenosine A2A Receptor Ligands. **2015**, 10, 1149-52	2
572	Integrating Pharmacophore into Membrane Molecular Dynamics Simulations to Improve Homology Modeling of G Protein-coupled Receptors with Ligand Selectivity: A2A Adenosine Receptor as an Example. **2015**, 86, 1438-50	5
571	Investigation of the conformational dynamics of the apo A2A adenosine receptor. **2015**, 24, 1004-12	10
570	Structural characterization of triple transmembrane domain containing fragments of a yeast G protein-coupled receptor in an organic : aqueous environment by solution-state NMR spectroscopy. **2015**, 21, 212-22	3
569	Structural Studies of G Protein-Coupled Receptors. **2015**, 38, 836-42	64
568	Charting a Path to Success in Virtual Screening. **2015**, 20, 18732-58	52

567	Cardiac contractility structure-activity relationship and ligand-receptor interactions; the discovery of unique and novel molecular switches in myosuppressin signaling. **2015**, 10, e0120492	10
566	Discovery and cardioprotective effects of the first non-Peptide agonists of the G protein-coupled prokineticin receptor-1. **2015**, 10, e0121027	39
565	Sequence, structure and ligand binding evolution of rhodopsin-like G protein-coupled receptors: a crystal structure-based phylogenetic analysis. **2015**, 10, e0123533	33
564	Binding of the Antagonist Caffeine to the Human Adenosine Receptor hA2AR in Nearly Physiological Conditions. **2015**, 10, e0126833	11
563	Transmembrane signal transduction by peptide hormones via family B G protein-coupled receptors. **2015**, 6, 264	45
562	Free energy calculations of A(2A) adenosine receptor mutation effects on agonist binding. **2015**, 51, 3522-5	27
561	Molecular recognition of ketamine by a subset of olfactory G protein-coupled receptors. **2015**, 8, ra33	14
560	Use of molecular modeling aided design to dial out hERG liability in adenosine A(2A) receptor antagonists. **2015**, 25, 2958-62	9
559	Opioid receptors: Structural and mechanistic insights into pharmacology and signaling. **2015**, 763, 206-13	47
558	References. **2015**, 633-722	
557	Development of novel adenosine receptor ligands based on the 3-amidocoumarin scaffold. **2015**, 61, 1-6	8
556	Studying the binding interactions of allosteric agonists and antagonists of the CXCR4 receptor. **2015**, 60, 1-14	15
555	Quantifying conformational changes in GPCRs: glimpse of a common functional mechanism. **2015**, 16, 124	35
554	New substituted 9-propyladenine derivatives as A2Aadenosine receptor antagonists. **2015**, 6, 963-970	8
553	The molecular basis of oligomeric organization of the human M3 muscarinic acetylcholine receptor. **2015**, 87, 936-53	17
552	Selectivity in the Use of Gi/o Proteins Is Determined by the DRF Motif in CXCR6 and Is Cell-Type Specific. **2015**, 88, 894-910	8
551	GPCR crystal structures: Medicinal chemistry in the pocket. **2015**, 23, 3880-906	88
550	Characteristic molecular vibrations of adenosine receptor ligands. **2015**, 589, 548-52	6

549	Modeling and protein engineering studies of active and inactive states of human dopamine D2 receptor (D2R) and investigation of drug/receptor interactions. **2015**, 19, 321-32	25
548	Human adenosine A2A receptor binds calmodulin with high affinity in a calcium-dependent manner. **2015**, 108, 903-917	11
547	Molecular docking screening using agonist-bound GPCR structures: probing the A2A adenosine receptor. **2015**, 55, 550-63	55
546	Identification of destabilizing and stabilizing mutations of Ste2p, a G protein-coupled receptor in Saccharomyces cerevisiae. **2015**, 54, 1787-806	6
545	Crystallization Optimization of Pharmaceutical Solid Forms with X-ray Compatible Microfluidic Platforms. **2015**, 15, 1201-1209	23
544	Structure and function of serotonin G protein-coupled receptors. **2015**, 150, 129-42	200
543	The importance of ligands for G protein-coupled receptor stability. **2015**, 40, 79-87	53
542	A facile and novel synthesis of N(2)-, C(6)-substituted pyrazolo[3,4-d]pyrimidine-4 carboxylate derivatives as adenosine receptor antagonists. **2015**, 92, 784-98	5
541	Methodological advances: the unsung heroes of the GPCR structural revolution. **2015**, 16, 69-81	146
540	G Protein-Coupled Receptor Screening Assays. **2015**,	
539	Extracellular surface residues of the β1B-adrenoceptor critical for G protein-coupled receptor function. **2015**, 87, 121-9	9
538	The role of experimental and computational structural approaches in 7TM drug discovery. **2015**, 10, 1071-84	12
537	From G Protein-coupled Receptor Structure Resolution to Rational Drug Design. **2015**, 290, 19489-95	74
536	Selectivity is species-dependent: Characterization of standard agonists and antagonists at human, rat, and mouse adenosine receptors. **2015**, 11, 389-407	81
535	Characterization of G protein coupling mediated by the conserved D134(3.49) of DRY motif, M241(6.34), and F251(6.44) residues on human CXCR1. **2015**, 5, 182-90	12
534	X-ray structure of a mammalian stearoyl-CoA desaturase. **2015**, 524, 252-6	136
533	Communication over the network of binary switches regulates the activation of A2A adenosine receptor. **2015**, 11, e1004044	24
532	Role of Lipids in Folding, Misfolding and Function of Integral Membrane Proteins. **2015**, 855, 1-31	7

531	Selective Protonation of Acidic Residues Triggers Opsin Activation. **2015**, 119, 9510-9	8
530	GPCR-I-TASSER: A Hybrid Approach to G Protein-Coupled Receptor Structure Modeling and the Application to the Human Genome. **2015**, 23, 1538-1549	121
529	Expanding the horizons of G protein-coupled receptor structure-based ligand discovery and optimization using homology models. **2015**, 51, 13576-94	36
528	Insights into the human A1 adenosine receptor from molecular dynamics simulation: structural study in the presence of lipid membrane. **2015**, 24, 3645-3659	13
527	A Molecular Pharmacologist's Guide to G Protein-Coupled Receptor Crystallography. **2015**, 88, 536-51	45
526	G-protein coupled receptor solubilization and purification for biophysical analysis and functional studies, in the total absence of detergent. **2015**, 35,	121
525	Inhibition and Reversal of Microbial Attachment by an Antibody with Parasteric Activity against the FimH Adhesin of Uropathogenic E. coli. **2015**, 11, e1004857	35
524	Capture-stabilize approach for membrane protein SPR assays. **2014**, 4, 7360	20
523	Large-scale production and protein engineering of G protein-coupled receptors for structural studies. **2015**, 6, 66	46
522	Cross-linking strategies to study peptide ligand-receptor interactions. **2015**, 556, 527-47	4
521	Molecular Determinants of CGS21680 Binding to the Human Adenosine A2A Receptor. **2015**, 87, 907-15	95
520	Structure-Based Prediction of G-Protein-Coupled Receptor Ligand Function: A □-Adrenoceptor Case Study. **2015**, 55, 1045-61	35
519	Exploring the 7-oxo-thiazolo[5,4-d]pyrimidine core for the design of new human adenosine A3 receptor antagonists. Synthesis, molecular modeling studies and pharmacological evaluation. **2015**, 96, 105-21	19
518	Design, synthesis, and biological evaluation of novel 2-((2-(4-(substituted)phenylpiperazin-1-yl)ethyl)amino)-5'-N-ethylcarboxamidoadenosines as potent and selective agonists of the A2A adenosine receptor. **2015**, 58, 3253-67	13
517	Fingerprint-based consensus virtual screening towards structurally new 5-HT(6)R ligands. **2015**, 25, 1827-30	13
516	Engineering G Protein-Coupled Receptors for Drug Design. **2015**, 1-18	2
515	An insight into antagonist binding and induced conformational dynamics of class B GPCR corticotropin-releasing factor receptor 1. **2015**, 11, 2042-50	8
514	A Novel Screening Approach for Optimal and Functional Fusion of T4 Lysozyme in GPCRs. **2015**, 557, 27-43	1

513	History and perspectives of A2A adenosine receptor antagonists as potential therapeutic agents. **2015**, 35, 790-848	74
512	Studying G protein-coupled receptors: immunoblotting, immunoprecipitation, phosphorylation, surface labeling, and cross-linking protocols. **2015**, 127, 303-22	8
511	Molecular modeling of the human P2Y14 receptor: A template for structure-based design of selective agonist ligands. **2015**, 23, 4056-64	18
510	Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists. **2015**, 104, 57-72	22
509	GPCRtm: An amino acid substitution matrix for the transmembrane region of class A G Protein-Coupled Receptors. **2015**, 16, 206	15
508	Biased Gs versus Gq proteins and □-arrestin signaling in the NK1 receptor determined by interactions in the water hydrogen bond network. **2015**, 290, 24495-508	25
507	Defining thermostability of membrane proteins by western blotting. **2015**, 28, 539-42	20
506	Purification and Crystallization of a Thermostabilized Agonist-Bound Conformation of the Human Adenosine A(2A) Receptor. **2015**, 1335, 17-27	2
505	Helix 3 acts as a conformational hinge in Class A GPCR activation: An analysis of interhelical interaction energies in crystal structures. **2015**, 192, 545-553	15
504	Design and synthesis of fused tetrahydroisoquinoline-iminoimidazolines. **2015**, 106, 15-25	1
503	Paeoniflorin ameliorates ischemic neuronal damage in vitro via adenosine A1 receptor-mediated transactivation of epidermal growth factor receptor. **2015**, 36, 298-310	21
502	Emerging Approaches to GPCR Ligand Screening for Drug Discovery. **2015**, 21, 687-701	62
501	Adenosine A2A Receptor Antagonists in Drug Development. **2015**, 39-56	1
500	Structures of G protein-coupled receptors reveal new opportunities for drug discovery. **2015**, 20, 1355-64	111
499	Expression, purification and functional characterization of human equilibrative nucleoside transporter subtype-1 (hENT1) protein from Sf9 insect cells. **2015**, 114, 99-107	21
498	Navigating in chromone chemical space: discovery of novel and distinct A3 adenosine receptor ligands. **2015**, 5, 78572-78585	10
497	A Pipeline To Enhance Ligand Virtual Screening: Integrating Molecular Dynamics and Fingerprints for Ligand and Proteins. **2015**, 55, 2256-74	52
496	Post-expression strategies for structural investigations of membrane proteins. **2015**, 32, 131-8	14

495	Pyrazin-2(1H)-ones as a novel class of selective A3 adenosine receptor antagonists. **2015**, 7, 1373-80	7
494	Discovery of Novel Potent and Selective Agonists at the Melanocortin-3 Receptor. **2015**, 58, 9773-8	15
493	John Daly Lecture: Structure-guided Drug Design for Adenosine and P2Y Receptors. **2015**, 13, 286-98	14
492	Structure and function of G protein-coupled receptor oligomers: implications for drug discovery. **2015**, 7, 408-27	18
491	Mammalian olfactory receptors: molecular mechanisms of odorant detection, 3D-modeling, and structure-activity relationships. **2015**, 130, 1-36	11
490	A Conformational Analysis Study on the Melanocortin 4 Receptor Using Multiple Molecular Dynamics Simulations. **2015**, 86, 309-21	8
489	Molecular interactions of agonist and inverse agonist ligands at serotonin 5-HT2C G protein-coupled receptors: computational ligand docking and molecular dynamics studies validated by experimental mutagenesis results. **2015**, 113, 348-358	3
488	Synthesis and pharmacological evaluation of dual acting ligands targeting the adenosine A2A and dopamine D2 receptors for the potential treatment of Parkinson's disease. **2015**, 58, 718-38	37
487	Uptake of the butyrate receptors, GPR41 and GPR43, in lipidic bicontinuous cubic phases suitable for in meso crystallization. **2015**, 441, 78-84	8
486	Conserved disulfide bond is not essential for the adenosine A2A receptor: Extracellular cysteines influence receptor distribution within the cell and ligand-binding recognition. **2015**, 1848, 603-14	15
485	Biochemical Roles of Eukaryotic Cell Surface Macromolecules. **2015**,	4
484	W2466.48 Opens a Gate for a Continuous Intrinsic Water Pathway during Activation of the Adenosine A2A Receptor. **2015**, 127, 566-569	13
483	Pyrazoloquinazolines: Synthetic strategies and bioactivities. **2015**, 97, 444-61	33
482	Hologram quantitative structure activity relationship, docking, and molecular dynamics studies of inhibitors for CXCR4. **2015**, 85, 119-36	16
481	Moonlighting adenosine deaminase: a target protein for drug development. **2015**, 35, 85-125	40
480	A new crystal structure fragment-based pharmacophore method for G protein-coupled receptors. **2015**, 71, 104-12	15
479	Novel approaches for targeting the adenosine A2A receptor. **2015**, 10, 63-80	9
478	QSAR and docking analysis of A2B adenosine receptor antagonists based on non-xanthine scaffold. **2015**, 24, 394-407	15

477	In Silico ADMET Profiling. **2016**, 225-268	1
476	In silico modeling techniques for predicting the tertiary structure of human H4 receptor. **2016**, 21, 597-619	11
475	Cholesterol and nicotinic acetylcholine receptor: An intimate nanometer-scale spatial relationship spanning the billion year time-scale. **2016**, 5, S67-S86	1
474	Homology Modeling and Ligand-Based Molecule Design. **2016**, 109-160	0
473	G Protein-Coupled Receptors (GPCRs) in Alzheimer's Disease: A Focus on BACE1 Related GPCRs. **2016**, 8, 58	39
472	Structure-Based Sequence Alignment of the Transmembrane Domains of All Human GPCRs: Phylogenetic, Structural and Functional Implications. **2016**, 12, e1004805	56
471	Macrophage Migration Inhibitory Factor-CXCR4 Receptor Interactions: EVIDENCE FOR PARTIAL ALLOSTERIC AGONISM IN COMPARISON WITH CXCL12 CHEMOKINE. **2016**, 291, 15881-95	46
470	Novel Scaffold Identification of mGlu1 Receptor Negative Allosteric Modulators Using a Hierarchical Virtual Screening Approach. **2016**, 87, 239-56	14
469	The Length and Flexibility of the 2-Substituent of 9-Ethyladenine Derivatives Modulate Affinity and Selectivity for the Human A2A Adenosine Receptor. **2016**, 11, 1829-39	8
468	Extracellular Loop 2 of the Adenosine A1 Receptor Has a Key Role in Orthosteric Ligand Affinity and Agonist Efficacy. **2016**, 90, 703-714	39
467	Role of the Second Extracellular Loop of the Adenosine A1 Receptor on Allosteric Modulator Binding, Signaling, and Cooperativity. **2016**, 90, 715-725	35
466	Novel Irreversible Agonists Acting at the A Adenosine Receptor. **2016**, 59, 11182-11194	15
465	Effect of Lipidic Cubic Phase Structure on Functionality of the Dopamine 2L Receptor: Implications for in Meso Crystallization. **2016**, 16, 5014-5022	10
464	Nanodisc-Tm: Rapid functional assessment of nanodisc reconstituted membrane proteins by CPM assay. **2016**, 3, 212-8	6
463	Non-equivalence of Key Positively Charged Residues of the Free Fatty Acid 2 Receptor in the Recognition and Function of Agonist Versus Antagonist Ligands. **2016**, 291, 303-17	35
462	Activation of the A2A adenosine G-protein-coupled receptor by conformational selection. **2016**, 533, 265-8	202
461	Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors. **2016**, 24, 2794-808	13
460	Ultraslow Water-Mediated Transmembrane Interactions Regulate the Activation of A2A Adenosine Receptor. **2016**, 111, 1180-1191	22

459	How does adenosine control neuronal dysfunction and neurodegeneration?. **2016**, 139, 1019-1055	222
458	Synthesis, binding assays, cytotoxic activity and docking studies of benzimidazole and benzothiophene derivatives with selective affinity for the CB2 cannabinoid receptor. **2016**, 124, 17-35	17
457	Adenosine A2a receptors form distinct oligomers in protein detergent complexes. **2016**, 590, 3295-306	9
456	How to Choose the Suitable Template for Homology Modelling of GPCRs: 5-HT7 Receptor as a Test Case. **2016**, 35, 414-23	11
455	Similarities and differences in affinity and binding modes of tricyclic pyrimido- and pyrazinoxanthines at human and rat adenosine receptors. **2016**, 24, 4347-4362	13
454	[Structural Life Science towards the Regulation of Selective GPCR Signaling]. **2016**, 136, 179-84	
453	[In Silico Drug Design Using an Evolutionary Algorithm and Compound Database]. **2016**, 136, 107-12	
452	In search of novel ligands using a structure-based approach: a case study on the adenosine A receptor. **2016**, 30, 863-874	13
451	More than Meets the Eye: Hidden Structures in the Proteome. **2016**, 3, 373-386	8
450	Structure of the adenosine A(2A) receptor bound to an engineered G protein. **2016**, 536, 104-7	283
449	New Trends in Inspecting GPCR-ligand Recognition Process: the Contribution of the Molecular Modeling Section (MMS) at the University of Padova. **2016**, 35, 440-8	3
448	An Fc-Small Molecule Conjugate for Targeted Inhibition of the Adenosine 2A Receptor. **2016**, 17, 1951-1960	1
447	Multivalent approaches and beyond: novel tools for the investigation of dopamine D2 receptor pharmacology. **2016**, 8, 1349-72	5
446	Structural Analysis of the Histamine H Receptor. **2017**, 241, 21-30	6
445	-Adrenergic Receptor Conformational Response to Fusion Protein in the Third Intracellular Loop. **2016**, 24, 2190-2197	37
444	Structural assemblies of the di- and oligomeric G-protein coupled receptor TGR5 in live cells: an MFIS-FRET and integrative modelling study. **2016**, 6, 36792	17
443	Predicting Subtype Selectivity for Adenosine Receptor Ligands with Three-Dimensional Biologically Relevant Spectrum (BRS-3D). **2016**, 6, 36595	10
442	Structural studies of G protein-coupled receptors. **2016**, 68, 894-903	27

441	Pharmacophore-Map-Pick: A Method to Generate Pharmacophore Models for All Human GPCRs. **2016**, 35, 81-91	4
440	Structure-Activity Analysis of Biased Agonism at the Human Adenosine A3 Receptor. **2016**, 90, 12-22	31
439	Conformational and Thermodynamic Landscape of GPCR Activation from Theory and Computation. **2016**, 110, 2618-2629	7
438	Novel Therapeutic Approaches to the Treatment of Parkinson Disease. **2016**,	
437	Binding mode similarity measures for ranking of docking poses: a case study on the adenosine A2A receptor. **2016**, 30, 447-56	10
436	Controlling the Dissociation of Ligands from the Adenosine A2A Receptor through Modulation of Salt Bridge Strength. **2016**, 59, 6470-9	115
435	Role of Conserved Disulfide Bridges and Aromatic Residues in Extracellular Loop 2 of Chemokine Receptor CCR8 for Chemokine and Small Molecule Binding. **2016**, 291, 16208-20	10
434	Carbamate substituted 2-amino-4,6-diphenylpyrimidines as adenosine receptor antagonists. **2016**, 26, 734-738	11
433	Computational Prediction and Biochemical Analyses of New Inverse Agonists for the CB1 Receptor. **2016**, 56, 201-12	4
432	Prediction of Loops in G Protein-Coupled Receptor Homology Models: Effect of Imprecise Surroundings and Constraints. **2016**, 56, 671-86	6
431	Role of extracellular cysteine residues in the adenosine A2A receptor. **2016**, 12, 313-29	20
430	Homology modeling and molecular docking studies of Drosophila and Aedes sex peptide receptors. **2016**, 66, 115-22	5
429	Towards a structural understanding of allosteric drugs at the human calcium-sensing receptor. **2016**, 26, 574-92	56
428	Progress in the development of small molecules as new human A3 adenosine receptor ligands based on the 3-thiophenylcoumarin core. **2016**, 7, 845-852	2
427	Discovery of Potent and Highly Selective A2B Adenosine Receptor Antagonist Chemotypes. **2016**, 59, 1967-83	44
426	Molecular Basis of Ligand Dissociation from the Adenosine A2A Receptor. **2016**, 89, 485-91	63
425	Synthesis and structure activity relationship investigation of triazolo[1,5-a]pyrimidines as CB2 cannabinoid receptor inverse agonists. **2016**, 113, 11-27	27
424	Understanding the molecular basis of agonist/antagonist mechanism of GPER1/GPR30 through structural and energetic analyses. **2016**, 158, 104-116	18

423	Medicinal chemistry of adenosine, P2Y and P2X receptors. **2016**, 104, 31-49	158
422	Discovery of aminoquinazoline derivatives as human A(2A) adenosine receptor antagonists. **2016**, 26, 1348-54	10
421	Structural refinement of pyrazolo[4,3-d]pyrimidine derivatives to obtain highly potent and selective antagonists for the human A3 adenosine receptor. **2016**, 108, 117-133	16
420	Biased signaling: potential agonist and antagonist of PAR2. **2016**, 34, 1363-76	4
419	Structurally Enabled Discovery of Adenosine A Receptor Antagonists. **2017**, 117, 21-37	54
418	Labeling and Single-Molecule Methods To Monitor G Protein-Coupled Receptor Dynamics. **2017**, 117, 186-245	75
417	Kinetic Aspects of the Interaction between Ligand and G Protein-Coupled Receptor: The Case of the Adenosine Receptors. **2017**, 117, 38-66	41
416	The signaling pathway of dopamine D2 receptor (D2R) activation using normal mode analysis (NMA) and the construction of pharmacophore models for D2R ligands. **2017**, 35, 2040-2048	9
415	From Homology Models to a Set of Predictive Binding Pockets-a 5-HT Receptor Case Study. **2017**, 57, 311-321	22
414	An update on the physiological and therapeutic relevance of GPCR oligomers. **2017**, 117, 303-327	71
413	Prediction of consensus binding mode geometries for related chemical series of positive allosteric modulators of adenosine and muscarinic acetylcholine receptors. **2017**, 38, 1209-1228	5
412	Membrane cholesterol access into a G-protein-coupled receptor. **2017**, 8, 14505	89
411	7⍰ RMSD matrix: A new method for quantitative comparison of the transmembrane domain structures in the G-protein coupled receptors. **2017**, 199, 87-101	3
410	Structure of the Adenosine A Receptor Reveals the Basis for Subtype Selectivity. **2017**, 168, 867-877.e13	167
409	Crystal structure of the adenosine A receptor bound to an antagonist reveals a potential allosteric pocket. **2017**, 114, 2066-2071	87
408	Method for rapid optimization of recombinant GPCR protein expression and stability using virus-like particles. **2017**, 133, 41-49	6
407	Fast iodide-SAD phasing for high-throughput membrane protein structure determination. **2017**, 3, e1602952	27
406	Chemically Stable Lipids for Membrane Protein Crystallization. **2017**, 17, 3502-3511	19

405	Active state structures of G protein-coupled receptors highlight the similarities and differences in the G protein and arrestin coupling interfaces. **2017**, 45, 124-132	42
404	Homology-based Modeling of Rhodopsin-like Family Members in the Inactive State: Structural Analysis and Deduction of Tips for Modeling and Optimization. **2017**, 36, 1700014	7
403	Discovery of Novel and Selective Adenosine A Receptor Antagonists for Treating Parkinson's Disease through Comparative Structure-Based Virtual Screening. **2017**, 57, 1474-1487	35
402	The Roles of Water in the Protein Matrix: A Largely Untapped Resource for Drug Discovery. **2017**, 60, 6781-6827	77
401	Understanding the common themes and diverse roles of the second extracellular loop (ECL2) of the GPCR super-family. **2017**, 449, 3-11	35
400	Identification of potent cholecystokinin-B receptor antagonists: synthesis, molecular modeling and anti-cancer activity against pancreatic cancer cells. **2017**, 8, 1561-1574	5
399	Structural Basis for Apelin Control of the Human Apelin Receptor. **2017**, 25, 858-866.e4	74
398	Binding Kinetics and Pathways of Ligands to GPCRs. **2017**, 38, 717-732	42
397	Classification Models. **2017**, 175-192	0
396	Regression Models. **2017**, 193-208	1
395	Structure-Based Discovery of GPCR Ligands from Crystal Structures and Homology Models. **2017**, 65-99	1
394	The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A Receptor Subtype. **2017**, 60, 5772-5790	27
393	Photoaffinity Labeling of the Human A Adenosine Receptor and Cross-link Position Analysis by Mass Spectrometry. **2017**, 8, 660-665	13
392	New approaches towards the understanding of integral membrane proteins: A structural perspective on G protein-coupled receptors. **2017**, 26, 1493-1504	34
391	An Ensemble-Based Protocol for the Computational Prediction of Helix-Helix Interactions in G Protein-Coupled Receptors using Coarse-Grained Molecular Dynamics. **2017**, 13, 2254-2270	21
390	Enantiospecific Recognition at the A Adenosine Receptor by Alkyl 2-Cyanoimino-4-substituted-6-methyl-1,2,3,4-tetrahydropyrimidine-5-carboxylates. **2017**, 60, 3372-3382	19
389	Metal ions-binding T4 lysozyme as an intramolecular protein purification tag compatible with X-ray crystallography. **2017**, 26, 1116-1123	5
388	Pharmacological Characterization of Human Histamine Receptors and Histamine Receptor Mutants in the Sf9 Cell Expression System. **2017**, 241, 63-118	3

387	Integration on Ligand and Structure Based Approaches in GPCRs. **2017**, 101-161	0
386	A covalent antagonist for the human adenosine A receptor. **2017**, 13, 191-201	17
385	Structure and activation of the TSH receptor transmembrane domain. **2017**, 8, 2	14
384	Functional characterization of human equilibrative nucleoside transporter 1. **2017**, 8, 284-295	22
383	Photoaffinity Labeling in Drug Discovery Research. **2017**, 241-265	1
382	Targeting immunosuppressive adenosine in cancer. **2017**, 17, 709-724	304
381	A kinetic view of GPCR allostery and biased agonism. **2017**, 13, 929-937	89
380	A New Class of Fluorinated A Adenosine Receptor Agonist with Application to Last-Step Enzymatic [F]Fluorination for PET Imaging. **2017**, 18, 2156-2164	12
379	Overexpression and purification of Dicer and accessory proteins for biochemical and structural studies. **2017**, 126, 54-65	5
378	Structures of Human A and A Adenosine Receptors with Xanthines Reveal Determinants of Selectivity. **2017**, 25, 1275-1285.e4	126
377	Identification of -helix 4 (4) of Rab11a as a novel Rab11-binding domain (RBD): Interaction of Rab11a with the Prostacyclin Receptor. **2017**, 1864, 1819-1832	3
376	Effects of 4(1H)-quinolinone derivative, a novel non-nucleotide allosteric purinergic P2Y agonist, on cardiomyocytes in neonatal rats. **2017**, 7, 6050	8
375	Effect of Nitrogen Atom Substitution in A Adenosine Receptor Binding: N-(4,6-Diarylpyridin-2-yl)acetamides as Potent and Selective Antagonists. **2017**, 60, 7502-7511	10
374	Allosteric Communication Networks in Proteins Revealed through Pocket Crosstalk Analysis. **2017**, 3, 949-960	37
373	Machine learning unifies the modeling of materials and molecules. **2017**, 3, e1701816	346
372	Hot-Spot Residues to be Mutated Common in G Protein-Coupled Receptors of Class A: Identification of Thermostabilizing Mutations Followed by Determination of Three-Dimensional Structures for Two Example Receptors. **2017**, 121, 6341-6350	19
371	Bitopic fluorescent antagonists of the A adenosine receptor based on pyrazolo[4,3-][1,2,4]triazolo[1,5-]pyrimidin-5-amine functionalized congeners. **2017**, 8, 1659-1667	10
370	Design, synthesis and evaluation of 2-aryl benzoxazoles as promising hit for the A receptor. **2017**, 32, 850-864	8

369	Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPR40. **2017**, 24, 570-577	99
368	Prodrug approach: An overview of recent cases. **2017**, 127, 810-827	73
367	Imidazo[1,2-a]pyrazin-8-amine core for the design of new adenosine receptor antagonists: Structural exploration to target the A and A subtypes. **2017**, 125, 611-628	15
366	Impact of protein-ligand solvation and desolvation on transition state thermodynamic properties of adenosine A ligand binding kinetics. **2017**, 5, 16	15
365	Structures of Non-rhodopsin GPCRs Elucidated Through X-Ray Crystallography. **2017**, 1-26	
364	Human Adenosine A Receptor: Molecular Mechanism of Ligand Binding and Activation. **2017**, 8, 898	42
363	Expression, Purification, and Monitoring of Conformational Changes of hCB2 TMH67H8 in Different Membrane-Mimetic Lipid Mixtures Using Circular Dichroism and NMR Techniques. **2017**, 7,	2
362	Exploring Adenosine Receptor Ligands: Potential Role in the Treatment of Cardiovascular Diseases. **2017**, 22,	16
361	Structure-Based Design of Potent and Selective Ligands at the Four Adenosine Receptors. **2017**, 22,	18
360	Gonadotropin-Releasing Hormone (GnRH) Receptor Structure and GnRH Binding. **2017**, 8, 274	31
359	Adenosine ?. **2017**,	
358	Fluorinated Adenosine A Receptor Antagonists Inspired by Preladenant as Potential Cancer Immunotherapeutics. **2017**, 2017, 4852537	5
357	Ligand modulation of sidechain dynamics in a wild-type human GPCR. **2017**, 6,	49
356	Structural Probing and Molecular Modeling of the A Adenosine Receptor: A Focus on Agonist Binding. **2017**, 22,	20
355	Modeling and Design for Membrane Protein Targets. **2017**, 145-188	2
354	GPCR Modulation of Thieno[2,3-b]pyridine Anti-Proliferative Agents. **2017**, 22,	8
353	Structural features embedded in G protein-coupled receptor co-crystal structures are key to their success in virtual screening. **2017**, 12, e0174719	9
352	Improving virtual screening of G protein-coupled receptors via ligand-directed modeling. **2017**, 13, e1005819	7

351	Computer-aided design of multi-target ligands at AR, AR and PDE10A, key proteins in neurodegenerative diseases. **2017**, 9, 67	10
350	Emerging Roles for MAS-Related G Protein-Coupled Receptor-X2 in Host Defense Peptide, Opioid, and Neuropeptide-Mediated Inflammatory Reactions. **2017**, 136, 123-162	45
349	Molecular Affinity of Mabolo Extracts to an Octopamine Receptor of a Fruit Fly. **2017**, 22,	4
348	Discovery of Novel Adenosine Receptor Antagonists through a Combined Structure- and Ligand-Based Approach Followed by Molecular Dynamics Investigation of Ligand Binding Mode. **2018**, 58, 794-815	14
347	Structural Basis for G Protein-Coupled Receptor Signaling. **2018**, 47, 1-18	72
346	Fluorescent-Labeled Selective Adenosine A Receptor Antagonist Enables Competition Binding Assay by Flow Cytometry. **2018**, 61, 4301-4316	18
345	Microbial expression systems for membrane proteins. **2018**, 147, 3-39	39
344	Structural Connection between Activation Microswitch and Allosteric Sodium Site in GPCR Signaling. **2018**, 26, 259-269.e5	77
343	An efficient screening method for purifying and crystallizing membrane proteins using modified clear-native PAGE. **2018**, 548, 7-14	10
342	Yeast surface display platform for rapid discovery of conformationally selective nanobodies. **2018**, 25, 289-296	193
341	Allosteric Coupling of Drug Binding and Intracellular Signaling in the A Adenosine Receptor. **2018**, 172, 68-80.e12	119
340	Purinergic Receptors: Novel Targets for Cancer Immunotherapy. **2018**, 115-141	2
339	Increasing the Stability of Recombinant Human Green Cone Pigment. **2018**, 57, 1022-1030	2
338	Biased signalling: from simple switches to allosteric microprocessors. **2018**, 17, 243-260	319
337	Structural Properties of the Human Protease-Activated Receptor 1 Changing by a Strong Antagonist. **2018**, 26, 829-838.e4	6
336	Design and synthesis of 2,6-disubstituted-8-amino imidazo[1,2a]pyridines, a promising privileged structure. **2018**, 26, 3296-3307	4
335	The yin and yang of solubilization and stabilization for wild-type and full-length membrane protein. **2018**, 147, 118-125	25
334	New potent and selective A adenosine receptor antagonists as potential tools for the treatment of gastrointestinal diseases. **2018**, 151, 199-213	11

333	Chemical Diversity in the G Protein-Coupled Receptor Superfamily. **2018**, 39, 494-512	54
332	Discovery of benzothiazolylquinoline conjugates as novel human A receptor antagonists: biological evaluations and molecular docking studies. **2018**, 5, 171622	4
331	Adenosine A receptor agonists with potent antiplatelet activity. **2018**, 29, 292-300	14
330	Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer. **2018**, 233, 2032-2057	80
329	Recent Advances in Structure-Based Drug Design Targeting Class A G Protein-Coupled Receptors Utilizing Crystal Structures and Computational Simulations. **2018**, 61, 1-46	55
328	Mapping the allosteric sites of the A adenosine receptor. **2018**, 91, 5-16	18
327	Coumarins and adenosine receptors: New perceptions in structure-affinity relationships. **2018**, 91, 245-256	5
326	Biased signaling of G protein-coupled receptors - From a chemokine receptor CCR7 perspective. **2018**, 258, 4-14	18
325	Characterisation of endogenous A and A receptor-mediated cyclic AMP responses in HEK 293 cells using the GloSensor biosensor: Evidence for an allosteric mechanism of action for the A-selective antagonist PSB 603. **2018**, 147, 55-66	14
324	Natural product modulators of human sensations and mood: molecular mechanisms and therapeutic potential. **2018**, 47, 1592-1637	18
323	Importance of the second extracellular loop for melatonin MT receptor function and absence of melatonin binding in GPR50. **2018**, 175, 3281-3297	18
322	Assessment of the transmembrane domain structures in GPCR Dock 2013 models. **2018**, 201, 210-220	1
321	Solid-State Nuclear Magnetic Resonance Spectroscopy of Membrane Proteins. **2018**, 251-283	
320	AquaMMapS: An Alternative Tool to Monitor the Role of Water Molecules During Protein-Ligand Association. **2018**, 13, 522-531	17
319	Current and Future Challenges in GPCR Drug Discovery. **2018**, 1705, 1-21	11
318	Modeling and Deorphanization of Orphan GPCRs. **2018**, 1705, 413-429	3
317	Breakthrough in GPCR Crystallography and Its Impact on Computer-Aided Drug Design. **2018**, 1705, 45-72	12
316	A Structural Framework for GPCR Chemogenomics: What's In a Residue Number?. **2018**, 1705, 73-113	6

315	GPCRs: What Can We Learn from Molecular Dynamics Simulations?. **2018**, 1705, 133-158	9
314	AMP and adenosine are both ligands for adenosine 2B receptor signaling. **2018**, 28, 202-206	7
313	Structural Mapping of Adenosine Receptor Mutations: Ligand Binding and Signaling Mechanisms. **2018**, 39, 75-89	40
312	A monoclonal antibody raised against a thermo-stabilised -adrenoceptor interacts with extracellular loop 2 and acts as a negative allosteric modulator of a sub-set of -adrenoceptors expressed in stable cell lines. **2018**, 147, 38-54	11
311	Membrane Biophysics. **2018**,	
310	Muscarinic receptor oligomerization. **2018**, 136, 401-410	10
309	. **2018**,	0
308	Structure activity relationship of 2-arylalkynyl-adenine derivatives as human A adenosine receptor antagonists. **2018**, 9, 1920-1932	3
307	Structural Basis for Binding of Allosteric Drug Leads in the Adenosine A Receptor. **2018**, 8, 16836	38
306	A adenosine receptor functional states characterized by F-NMR. **2018**, 115, 12733-12738	56
305	Targeting the Oncoprotein Smoothened by Small Molecules: Focus on Novel Acylguanidine Derivatives as Potent Smoothened Inhibitors. **2018**, 7,	27
304	New Expression Systems for GPCRs. **2018**, 29-69	
303	Probing structure-activity relationship in -arrestin2 recruitment of diversely substituted adenosine derivatives. **2018**, 158, 103-113	8
302	Computational Studies for Structure-Based Drug Designing Against Transmembrane Receptors: pLGICs and Class A GPCRs. **2018**, 6,	4
301	Role of Extracellular Loops and Membrane Lipids for Ligand Recognition in the Neuronal Adenosine Receptor Type 2A: An Enhanced Sampling Simulation Study. **2018**, 23,	9
300	Could the presence of sodium ion influence the accuracy and precision of the ligand-posing in the human A adenosine receptor orthosteric binding site using a molecular docking approach? Insights from Dockbench. **2018**, 32, 1337-1346	6
299	Targeting adenosine A receptor antagonism for treatment of cancer. **2018**, 13, 997-1003	30
298	Molecular Determinants for Ligand Selectivity of the Cell-Free Synthesized Human Endothelin B Receptor. **2018**, 430, 5105-5119	3

297	The A2aR C-terminus provides improved total and active expression yields for adenosine receptor chimeras. **2018**, 64, 4297-4307	4
296	Cannabidiol skews biased agonism at cannabinoid CB and CB receptors with smaller effect in CB-CB heteroreceptor complexes. **2018**, 157, 148-158	51
295	Born This Way: Using Intrinsic Disorder to Map the Connections between SLITRKs, TSHR, and Male Sexual Orientation. **2018**, 18, e1800307	0
294	Functional roles of tyrosine 185 during the bacteriorhodopsin photocycle as revealed by in situ spectroscopic studies. **2018**, 1859, 1006-1014	6
293	Tritium-labeled agonists as tools for studying adenosine A receptors. **2018**, 14, 223-233	13
292	Enabling STD-NMR fragment screening using stabilized native GPCR: A case study of adenosine receptor. **2018**, 8, 8142	35
291	Cryo-EM structure of the adenosine A receptor coupled to an engineered heterotrimeric G protein. **2018**, 7,	137
290	Identifying G protein-coupled receptor dimers from crystal packings. **2018**, 74, 655-670	13
289	Medicinal Chemistry of A2B Adenosine Receptors. **2018**, 137-168	9
288	Adenosine Receptors: Structure, Distribution, and Signal Transduction. **2018**, 33-57	9
287	An Affinity-Based Probe for the Human Adenosine A Receptor. **2018**, 61, 7892-7901	27
286	The Role of Adenosine Receptors in Psychostimulant Addiction. **2017**, 8, 985	46
285	Molecular Evidence of Adenosine Deaminase Linking Adenosine A Receptor and CD26 Proteins. **2018**, 9, 106	34
284	Exploring G Protein-Coupled Receptors (GPCRs) Ligand Space via Cheminformatics Approaches: Impact on Rational Drug Design. **2018**, 9, 128	43
283	Pharmacology of Adenosine Receptors: The State of the Art. **2018**, 98, 1591-1625	259
282	Supervised Molecular Dynamics (SuMD) Approaches in Drug Design. **2018**, 1824, 287-298	9
281	Investigation into Improving the Aqueous Solubility of the Thieno[2,3-b]pyridine Anti-Proliferative Agents. **2018**, 23,	11
280	A Transmembrane Single-Polypeptide-Chain (sc) Linker to Connect the Two G-Protein□Coupled Receptors in Tandem and the Design for an In Vivo Analysis of Their Allosteric Receptor- Receptor Interactions. **2018**,	

279	Extrinsic Tryptophans as NMR Probes of Allosteric Coupling in Membrane Proteins: Application to the A Adenosine Receptor. **2018**, 140, 8228-8235	24
278	Prediction of Conformation Specific Thermostabilizing Mutations for Class A G Protein-Coupled Receptors. **2019**, 59, 3744-3754	1
277	G-protein-coupled receptor-based sensors for imaging neurochemicals with high sensitivity and specificity. **2019**, 151, 279-288	21
276	High-throughput identification of peptide agonists against GPCRs by co-culture of mammalian reporter cells and peptide-secreting yeast cells using droplet microfluidics. **2019**, 9, 10920	9
275	Use of syngeneic cells expressing membrane-bound GM-CSF as an adjuvant to induce antibodies against native multi-pass transmembrane protein. **2019**, 9, 9931	4
274	Free-Energy Calculations for Bioisosteric Modifications of A Adenosine Receptor Antagonists. **2019**, 20,	1
273	Structure and Function of GPCRs. **2019**,	
272	Structural Insights from Recent CB1 X-Ray Crystal Structures. **2019**,	1
271	Identification of functional divergence sites in dopamine receptors of vertebrates. **2019**, 83, 107140	7
270	Adenosine A2A Receptor as a Potential Drug Target - Current Status and Future Perspectives. **2019**, 25, 2716-2740	12
269	Antioxidant-Conjugated 1,2,4-Triazolo[4,3-]pyrazin-3-one Derivatives: Highly Potent and Selective Human A Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain. **2019**, 62, 8511-8531	9
268	Structural Characterization of Agonist Binding to an A Adenosine Receptor through Biomolecular Simulations and Mutagenesis Experiments. **2019**, 62, 8831-8846	6
267	Reconstruction of apo A2A receptor activation pathways reveal ligand-competent intermediates and state-dependent cholesterol hotspots. **2019**, 9, 14199	15
266	Progress in the Development of Agonists, Antagonists and Allosteric Modulators of Adenosine Receptors. **2019**, 25, 2695-2696	5
265	Studying the collective motions of the adenosine A2A receptor as a result of ligand binding using principal component analysis. **2019**, 37, 4685-4700	7
264	Dynamic Role of the G Protein in Stabilizing the Active State of the Adenosine A Receptor. **2019**, 27, 703-712.e3	18
263	Recent Updates in the Computer Aided Drug Design Strategies for the Discovery of Agonists and Antagonists of Adenosine Receptors. **2019**, 25, 747-749	17
262	Understanding Ligand Binding Selectivity in a Prototypical GPCR Family. **2019**, 59, 2830-2836	16

261	Design, synthesis and biological evaluation of 2-hydrazinyladenosine derivatives as A adenosine receptor ligands. **2019**, 179, 310-324	3
260	Computational prediction of GPCR oligomerization. **2019**, 55, 178-184	7
259	Structure and Activation Mechanism of GPCRs. **2019**, 53-64	3
258	An exploration strategy improves the diversity of de novo ligands using deep reinforcement learning: a case for the adenosine A receptor. **2019**, 11, 35	29
257	Reduced level of docosahexaenoic acid shifts GPCR neuroreceptors to less ordered membrane regions. **2019**, 15, e1007033	11
256	A benchmark study of loop modeling methods applied to G protein-coupled receptors. **2019**, 33, 573-595	9
255	The role of NMR spectroscopy in mapping the conformational landscape of GPCRs. **2019**, 57, 145-156	18
254	Revealing the Mechanism of Agonist-Mediated Cannabinoid Receptor 1 (CB1) Activation and Phospholipid-Mediated Allosteric Modulation. **2019**, 62, 5638-5654	10
253	Molecular modeling approaches for the discovery of adenosine A receptor antagonists: current status and future perspectives. **2019**, 24, 1854-1864	21
252	The lipid phase preference of the adenosine A receptor depends on its ligand binding state. **2019**, 55, 5724-5727	6
251	Structural and energetic basis for novel epicatechin derivatives acting as GPER agonists through the MMGBSA method. **2019**, 189, 176-186	7
250	Mutations in the NPxxY motif stabilize pharmacologically distinct conformational states of the and adrenoceptors. **2019**, 12,	11
249	The Transmembrane Conformation of the Influenza B Virus M2 Protein in Lipid Bilayers. **2019**, 9, 3725	10
248	Molecular Dynamics Simulations of the Allosteric Modulation of the Adenosine A2A Receptor by a Mini-G Protein. **2019**, 9, 5495	8
247	A Chemical Strategy for Amphiphile Replacement in Membrane Protein Research. **2019**, 35, 4319-4327	2
246	Emerging Diversity in Lipid-Protein Interactions. **2019**, 119, 5775-5848	163
245	Hydrogenated Diglucose Detergents for Membrane-Protein Extraction and Stabilization. **2019**, 35, 4287-4295	10
244	Insights to the Binding of a Selective Adenosine A Receptor Antagonist Using Molecular Dynamic Simulations, MM-PBSA and MM-GBSA Free Energy Calculations, and Mutagenesis. **2019**, 59, 5183-5197	8

243	A adenosine receptor activation mechanisms: molecular dynamics analysis of inactive, active, and fully active states. **2019**, 33, 983-996	7
242	Site-selective modification of tryptophan and protein tryptophan residues through PdNP bionanohybrid-catalysed C-H activation in aqueous media. **2019**, 55, 12928-12931	12
241	State-dependent Lipid Interactions with the A2a Receptor Revealed by MD Simulations Using In‐Vivo-Mimetic Membranes. **2019**, 27, 392-403.e3	42
240	Isotopic Labeling of Eukaryotic Membrane Proteins for NMR Studies of Interactions and Dynamics. **2019**, 614, 37-65	6
239	GPCR drug discovery: integrating solution NMR data with crystal and cryo-EM structures. **2019**, 18, 59-82	109
238	Seeing and sensing single G protein-coupled receptors by atomic force microscopy. **2019**, 57, 25-32	12
237	Membrane cholesterol depletion reduces downstream signaling activity of the adenosine A receptor. **2019**, 1861, 760-767	21
236	Probe dependence of allosteric enhancers on the binding affinity of adenosine A -receptor agonists at rat and human A -receptors measured using NanoBRET. **2019**, 176, 864-878	13
235	Conducting Nanomaterial Sensor Using Natural Receptors. **2019**, 119, 36-93	100
234	Computer-aided drug design in new druggable targets for the next generation of immune-oncology therapies. **2019**, 9, e1397	2
233	Emerging structural biology of lipid G protein-coupled receptors. **2019**, 28, 292-304	33
232	In-silico studies on conformational stability of flagellin-receptor complexes. **2020**, 38, 2240-2252	1
231	Progress in GPCR structure determination. **2020**, 3-22	2
230	Subtype-Selective Fluorescent Ligands as Pharmacological Research Tools for the Human Adenosine A Receptor. **2020**, 63, 2656-2672	14
229	Role of cholesterol-mediated effects in GPCR heterodimers. **2020**, 227, 104852	15
228	Structure-Based Optimization of Coumarin hA Adenosine Receptor Antagonists. **2020**, 63, 2577-2587	9
227	Cholesterol impacts chemokine CCR5 receptor ligand-binding activity. **2020**, 287, 2367-2385	5
226	Adenosine Receptor Ligands: Coumarin-Chalcone Hybrids as Modulating Agents on the Activity of ARs. **2020**, 25,	3

225	Adenosine A Receptor Antagonists for Cancer Immunotherapy. **2020**, 63, 12196-12212	21
224	An investigation into the allosteric mechanism of GPCR A adenosine receptor with trajectory-based information theory and complex network model. **2021**, 39, 6431-6439	1
223	Targeting G Protein-Coupled Receptors with Magnetic Carbon Nanotubes: The Case of the A Adenosine Receptor. **2020**, 15, 1909-1920	2
222	Experimental and computational analysis of biased agonism on full-length and a C-terminally truncated adenosine A receptor. **2020**, 18, 2723-2732	9
221	Thermostability of a recombinant G protein-coupled receptor expressed at high level in mammalian cell culture. **2020**, 10, 16805	3
220	Purinergic Signaling: Impact of GPCR Structures on Rational Drug Design. **2020**, 15, 1958-1973	7
219	Tumor Immunotherapy Using A Adenosine Receptor Antagonists. **2020**, 13,	10
218	Pharmacological characterisation of novel adenosine A receptor antagonists. **2020**, 10, 20781	5
217	A guide to membrane protein X-ray crystallography. **2021**, 288, 5788-5804	10
216	The Specificity of Downstream Signaling for A and AR Does Not Depend on the C-Terminus, Despite the Importance of This Domain in Downstream Signaling Strength. **2020**, 8,	1
215	D-limonene Inhibits Pentylenetetrazole-Induced Seizure via Adenosine A2A Receptor Modulation on GABAergic Neuronal Activity. **2020**, 21,	3
214	In silico characterization of adipokinetic hormone receptor and screening for pesticide candidates against stick insect, Carausius morosus. **2020**, 101, 107720	2
213	Adenosine A receptor antagonists: from caffeine to selective non-xanthines. **2020**,	19
212	In Silico Drug Design for Purinergic GPCRs: Overview on Molecular Dynamics Applied to Adenosine and P2Y Receptors. **2020**, 10,	9
211	X-Ray Crystallography and Free Energy Calculations Reveal the Binding Mechanism of A Adenosine Receptor Antagonists. **2020**, 59, 16536-16543	13
210	Nitrogen-Walk Approach to Explore Bioisosteric Replacements in a Series of Potent A Adenosine Receptor Antagonists. **2020**, 63, 7721-7739	10
209	Lipid-Protein Interactions Are a Unique Property and Defining Feature of G Protein-Coupled Receptors. **2020**, 118, 1887-1900	27
208	Exploring the Activation Mechanism of the mGlu5 Transmembrane Domain. **2020**, 7, 38	2

207	P2Y1-like nucleotide receptors: Structures, molecular modeling, mutagenesis, and oligomerization. **2020**, 10, e1464	7
206	Activation of adenosine A receptor by lipids from docosahexaenoic acid revealed by NMR. **2020**, 6, eaay8544	15
205	X-Ray Crystallography and Free Energy Calculations Reveal the Binding Mechanism of A2A Adenosine Receptor Antagonists. **2020**, 132, 16679	1
204	A Taxicab geometry quantification system to evaluate the performance of in silico methods: a case study on adenosine receptors ligands. **2020**, 34, 697-707	
203	Computer simulations of protein-membrane systems. **2020**, 170, 273-403	15
202	Ligand-induced conformational changes in a SMALP-encapsulated GPCR. **2020**, 1862, 183235	16
201	High-Throughput Macromolecular Crystallography in Drug Discovery. **2020**, 211-251	
200	Impact of Recently Determined Crystallographic Structures of GPCRs on Drug Discovery. **2020**, 449-477	1
199	Insights into adenosine A2A receptor activation through cooperative modulation of agonist and allosteric lipid interactions. **2020**, 16, e1007818	11
198	Exploring the molecular structures that confer ligand selectivity for galanin type II and III receptors. **2020**, 15, e0230872	3
197	Discovery of novel 1,3,5-triazine as adenosine A receptor antagonist for benefit in Parkinson's disease. **2021**, 35, e22659	0
196	A Adenosine Receptor Partial Agonism Related to Structural Rearrangements in an Activation Microswitch. **2021**, 29, 170-176.e3	7
195	Therapeutic Path to Double Knockout: Investigating the Selective Dual-Inhibitory Mechanisms of Adenosine Receptors A1 and A2 by a Novel Methoxy-Substituted Benzofuran Derivative in the Treatment of Parkinson's Disease. **2021**, 79, 25-36	0
194	G protein-coupled receptor-G protein interactions: a single-molecule perspective. **2021**, 101, 857-906	10
193	Molecular probes for the human adenosine receptors. **2021**, 17, 85-108	3
192	Medicinal chemistry of P2 and adenosine receptors: Common scaffolds adapted for multiple targets. **2021**, 187, 114311	15
191	Role of Cardiac A Receptors Under Normal and Pathophysiological Conditions. **2020**, 11, 627838	4
190	Synthesis and Biological Evaluation of a Novel F-Labeled Radiotracer for PET Imaging of the Adenosine A Receptor. **2021**, 22,	3

189	Adenosine receptors as promising targets for the management of ocular diseases. **2021**, 30, 1-18	7
188	Development of F-Labeled Radiotracers for PET Imaging of the Adenosine A Receptor: Synthesis, Radiolabeling and Preliminary Biological Evaluation. **2021**, 22,	3
187	Structure and function of adenosine receptor heteromers. **2021**, 78, 3957-3968	5
186	Ligand modulation of the conformational dynamics of the A adenosine receptor revealed by single-molecule fluorescence. **2021**, 11, 5910	5
185	Crystal Structure and Subsequent Ligand Design of a Nonriboside Partial Agonist Bound to the Adenosine A Receptor. **2021**, 64, 3827-3842	5
184	Discovery of novel dual adenosine A1/A2A receptor antagonists using deep learning, pharmacophore modeling and molecular docking. **2021**, 17, e1008821	6
183	Computational evaluation of interactions between olfactory receptor OR2W1 and its ligands. **2021**, 19, e9	0
182	Structure-Based Drug Design for G Protein-Coupled Receptors. 1-59	
181	Pathways and Mechanism of Caffeine Binding to Human Adenosine A Receptor. **2021**, 8, 673170	2
180	Structure-Based Drug Design. 1-54	0
179	Heterologous Expression and Biochemical Characterization of the Human Zinc Transporter 1 (ZnT1) and Its Soluble C-Terminal Domain. **2021**, 9, 667803	2
178	Fragment-Based Lead Discovery. 1-35	
177	Affinity Mass Spectrometry-Based Fragment Screening Identified a New Negative Allosteric Modulator of the Adenosine A Receptor Targeting the Sodium Ion Pocket. **2021**, 16, 991-1002	4
176	Characterization of binding kinetics of AR to G protein by surface plasmon resonance. **2021**, 120, 1641-1649	3
175	Biased agonism at adenosine receptors. **2021**, 82, 109954	8
174	Lighting Up the Plasma Membrane: Development and Applications of Fluorescent Ligands for Transmembrane Proteins. **2021**, 27, 8605-8641	1
173	In Vitro and In Silico Characterization of G-Protein Coupled Receptor (GPCR) Targets of Phlorofucofuroeckol-A and Dieckol. **2021**, 19,	2
172	Critical APJ receptor residues in extracellular domains that influence effector selectivity. **2021**, 288, 6543-6562	0

171	Structure-Based Molecular Generator Combined with Artificial Intelligence and Docking Simulations. **2021**, 61, 3304-3313	4
170	Homo-oligomerization of the human adenosine A receptor is driven by the intrinsically disordered C-terminus. **2021**, 10,	5
169	A novel high-throughput screen for identifying lipids that stabilise membrane proteins in detergent based solution. **2021**, 16, e0254118	4
168	Modulation of adenosine A2a receptor oligomerization by receptor activation and PIP interactions. **2021**, 29, 1312-1325.e3	2
167	Filling of a water-free void explains the allosteric regulation of the □1-adrenergic receptor by cholesterol.	0
166	Subtle Chemical Changes Cross the Boundary between Agonist and Antagonist: New A Adenosine Receptor Homology Models and Structural Network Analysis Can Predict This Boundary. **2021**, 64, 12525-12536	3
165	Structure determination of GPCRs: cryo-EM compared with X-ray crystallography. **2021**, 49, 2345-2355	10
164	Computational design of highly signaling active membrane receptors through de novo solvent-mediated allosteric networks.	
163	PFOA regulate adenosine receptors and downstream concentration-response cAMP-PKA pathway revealed by integrated omics and molecular dynamics analyses. **2022**, 803, 149910	1
162	Structural Insights into Cholesterol Interactions with G-Protein-Coupled Receptors. 231-253	2
161	Mechanism of GPCR-directed autoantibodies in diseases. **2012**, 749, 187-99	18
160	Overview of Non-CB1/CB2 Cannabinoid Receptors: Chemistry and Modeling. **2013**, 29-51	1
159	Computer-aided design of GPCR ligands. **2015**, 1272, 271-91	8
158	Structural Basis of Dopamine Receptor Activation. **2010**, 47-73	3
157	The family of G protein-coupled receptors: an example of membrane proteins. **2010**, 654, 441-54	5
156	Novel Assay Technologies for the Discovery of G Protein-Coupled Receptor Drugs. **2011**, 231-253	1
155	Chemosensorial G-proteins-coupled receptors: a perspective from computational methods. **2014**, 805, 441-57	4
154	Role of lipid-mediated effects in □adrenergic receptor dimerization. **2015**, 842, 247-61	19

153	Molecular Aspects of Histamine Receptors. **2016**, 1-49	3
152	Computer Assisted Peptide Design and Optimization with Topology Preserving Neural Networks. **2010**, 132-139	1
151	Development of Refined Homology Models: Adding the Missing Information to the Medically Relevant Neurotransmitter Transporters. **2014**, 99-120	2
150	GPCRs: Past, present, and future. **2010**, 251-278	1
149	A3 Adenosine Receptor Agonists: History and Future Perspectives. **2010**, 93-120	1
148	Functional and structural studies of TRP channels heterologously expressed in budding yeast. **2011**, 704, 25-40	14
147	The GPCR crystallography boom: providing an invaluable source of structural information and expanding the scope of homology modeling. **2014**, 796, 3-13	20
146	Modeling of G protein-coupled receptors using crystal structures: from monomers to signaling complexes. **2014**, 796, 15-33	11
145	How the dynamic properties and functional mechanisms of GPCRs are modulated by their coupling to the membrane environment. **2014**, 796, 55-74	21
144	Chemometric modeling of PET imaging agents for diagnosis of Parkinson disease: a QSAR approach. **2020**, 31, 1969-1981	2
143	Structures, Limitations, and Pitfalls. **2016**, 3-14	2
142	3,4-Dihydropyrimidin-2(1)-ones as Antagonists of the Human A Adenosine Receptor: Optimization, Structure-Activity Relationship Studies, and Enantiospecific Recognition. **2021**, 64, 458-480	12
141	CHAPTER 5:Fragment Screening of G Protein-Coupled Receptors. **2015**, 101-125	1
140	Membrane protein crystallography in the era of modern structural biology. **2020**, 48, 2505-2524	3
139	Design: An assay based on single-polypeptide-chain heterodimeric A2AR/D2R and non-oligomerized fusions for in vivo analysis of their allosteric receptor-receptor interactions.	0
138	Cryo-EM structure of the adenosine A2A receptor coupled to an engineered heterotrimeric G protein.	2
137	State-Dependent Lipid Interactions with the A2a Receptor Revealed by MD Simulations Using In Vivo-Mimetic Membranes.	10
136	Pharmacological Characterisation of Novel Adenosine Receptor A3R Antagonists.	5

135	3D-printed holders for fixed-target serial X-ray crystallography. **2020**, 53, 854-859	3
134	Using sequence similarity networks for visualization of relationships across diverse protein superfamilies. **2009**, 4, e4345	287
133	Stability of the neurotensin receptor NTS1 free in detergent solution and immobilized to affinity resin. **2010**, 5, e12579	10
132	Monoolein lipid phases as incorporation and enrichment materials for membrane protein crystallization. **2011**, 6, e24488	13
131	The E92K melanocortin 1 receptor mutant induces cAMP production and arrestin recruitment but not ERK activity indicating biased constitutive signaling. **2011**, 6, e24644	23
130	Novel information on the epitope of an inverse agonist monoclonal antibody provides insight into the structure of the TSH receptor. **2012**, 7, e31973	5
129	Membrane-sensitive conformational states of helix 8 in the metabotropic Glu2 receptor, a class C GPCR. **2012**, 7, e42023	25
128	Recombinant production of human Aquaporin-1 to an exceptional high membrane density in Saccharomyces cerevisiae. **2013**, 8, e56431	25
127	GOMoDo: A GPCRs online modeling and docking webserver. **2013**, 8, e74092	65
126	Saccharomyces cerevisiae-based platform for rapid production and evaluation of eukaryotic nutrient transporters and transceptors for biochemical studies and crystallography. **2013**, 8, e76851	13
125	Arginine 199 and leucine 208 have key roles in the control of adenosine A2A receptor signalling function. **2014**, 9, e89613	5
124	Structural and energetic effects of A2A adenosine receptor mutations on agonist and antagonist binding. **2014**, 9, e108492	44
123	Structure-Activity Relationship Studies of N- and C-Terminally Modified Secretin Analogs for the Human Secretin Receptor. **2016**, 11, e0149359	5
122	Structural and Functional Effect of an Oscillating Electric Field on the Dopamine-D3 Receptor: A Molecular Dynamics Simulation Study. **2016**, 11, e0166412	2
121	An Anti-Parkinson's Disease Drug via Targeting Adenosine A2A Receptor Enhances Amyloid-β Generation and β-Secretase Activity. **2016**, 11, e0166415	14
120	Symmetry based assembly of a 2 dimensional protein lattice. **2017**, 12, e0174485	4
119	Epigenetically silenced GNG4 inhibits SDF1α/CXCR4 signaling in mesenchymal glioblastoma. **2016**, 7, 136-47	21
118	Molecular Dynamics Simulations of Adenosine Receptors: Advances, Applications and Trends. **2019**, 25, 783-816	17

117	Recent Advances of In-Silico Modeling of Potent Antagonists for the Adenosine Receptors. **2019**, 25, 750-773	11
116	Recent Advances in the In-silico Structure-based and Ligand-based Approaches for the Design and Discovery of Agonists and Antagonists of A2A Adenosine Receptor. **2019**, 25, 774-782	12
115	Understanding Membrane Protein Drug Targets in Computational Perspective. **2019**, 20, 551-564	16
114	Bivalent ligands targeting chemokine receptor dimerization: molecular design and functional studies. **2014**, 14, 1606-18	14
113	Recent Advances of Small Molecular Regulators Targeting G Protein- Coupled Receptors Family for Oncology Immunotherapy. **2019**, 19, 1464-1483	1
112	In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease. **2018**, 16, 786-848	10
111	The Protein Structure Initiative: achievements and visions for the future. **2012**, 4, 7	37
110	G protein-coupled receptors: the evolution of structural insight. **2017**, 4, 491-527	26
109	Insights into the structural biology of G-protein coupled receptors impacts drug design for central nervous system neurodegenerative processes. **2013**, 8, 2290-302	6
108	Molecular-Docking-Based Drug Design and Discovery. **2016**, 158-185	2
107	Human □Opioid Receptor Models with Evaluation of the Accuracy Using the Crystal Structure of the Murine □Opioid Receptor. **2012**, 3, 218	5
106	Prediction of Binding Mode between Chemokine Receptor CCR2 and Its Known Antagonists using Ligand Supported Homology Modeling. **2012**, 33, 717-720	2
105	Impact of the Protein Data Bank Across Scientific Disciplines. **2020**, 19, 25	9
104	Molecular docking studies of 1-(substituted phenyl)-3-(naphtha [1, 2-d] thiazol-2-yl) urea/thiourea derivatives with human adenosine A(2A) receptor. **2011**, 6, 330-4	7
103	Common activation mechanism of class A GPCRs. **2019**, 8,	117
102	Predicting the Activities of Drug Excipients on Biological Targets using One-Shot Learning.	
101	Synthesis, QSAR modeling, and molecular docking of novel fused 7-deazaxanthine derivatives as adenosine A receptor antagonists. **2021**,	2
100	Molecular Modeling and Reengineering of A3 Adenosine Receptors. **2010**, 149-161	

99 Membrane-Protein Crystallography and Potentiality for Drug Design-An Example from Neurotransmitter Transporter Homolog LeuT. **2010**, 52, 76-80

98 Recent Advances in Biology of Crysteinyl Leukotriene. **2010**, 52, 69-75 1

97 Prediction of three-dimensional transmembrane helical protein structures. **2010**, 231-249

96 Hormone Signaling Via G Protein Coupled Receptors. **2010**, 83-105 0

95 Modeling workshops and methods. **2010**,

94 Homology Modeling of 5-HT2C Receptors. **2011**, 97-127

93 Crystal Structure Analysis of Adenosine A2A Receptor in Complex with Functional Antibody Fragment. **2013**, 55, 103-109

92 Inducing Conformational Changes in G Protein-Coupled Receptors by Domain Coupling. **2014**, 219-237

91 Predicting Potential Ligands for Orphan GPCRs Based on the Improved Laplacian Regularized Least Squares Method. **2014**, 280-287

90 Olfactory Receptor Proteins. **2014**, 47-68

89 Effects of Adenosine Receptors. **2015**, 1-29

88 Adenosine Receptors. **2015**, 1-29

87 Adenosine Receptor. **2016**, 473-496

86 Ultraslow water-mediated transmembrane interactions regulate the activation of A2A adenosine receptor.

85 Molecular-Docking-Based Drug Design and Discovery. **2017**, 656-682

84 Overview of Arrestin Mediated Signaling with Receptors and Non-receptor Binding Partners. **2017**, 19-29

83 Identifying G protein-coupled receptor dimers from crystal packings.

82 Protein-Ligand Docking with Protein-based and Ligand-based Structure Activity Relationships.

81	Adenosine Receptors and Drug Discovery in the Cardiovascular System. **2019**, 65-82	
80	Nonantimicrobial Actions of Macrolides: Overview and Perspectives for Future Development. **2021**, 73, 233-262	5
79	Pharmacology of Adenosine Receptors. **2020**, 325-359	
78	Oligomerization of the Human Adenosine A2A Receptor is Driven by the Intrinsically Disordered C-terminus.	1
77	Adenosine receptor antagonists: Recent advances and therapeutic perspective. **2022**, 227, 113907	3
76	Membrane Protein Production and Purification from Escherichia coli and Sf9 Insect Cells. **2020**, 2168, 3-49	
75	G-Protein-Coupled Receptor Expression and Purification. **2021**, 2178, 439-467	1
74	Ligand Modulation of the Conformational Dynamics of the A2A Adenosine Receptor Revealed by Single-Molecule Fluorescence.	
73	Sub-millisecond conformational dynamics of the A2A adenosine receptor revealed by single-molecule FRET.	
72	Modeling G Protein-Coupled Receptors: a Concrete Possibility. **2010**, 28, 26-31	17
71	Molecular determinants of ligand binding at the human histamine H receptor: Site-directed mutagenesis results analyzed with ligand docking and molecular dynamics studies at H homology and crystal structure models. **2012**, 4, 2937-2951	10
70	G protein-coupled receptors--recent advances. **2012**, 59, 515-29	36
69	Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A Receptor and Histone Deacetylase as Novel Tumor Immunotherapeutic Agents. **2021**, 64, 16573-16597	4
68	State-Targeting Stabilization of Adenosine A Receptor by Fusing a Custom-Made De Novo Designed ⊞Helical Protein. **2021**, 22,	2
67	Purinergic GPCR transmembrane residues involved in ligand recognition and dimerization. **2021**, 166, 133-159	
66	Structure-Based Virtual Screening for Ligands of G Protein-Coupled Receptors: What Can Molecular Docking Do for You?. **2021**, 73, 527-565	4
65	Novel Molecular Targets of Antidepressants.. **2022**, 27,	3
64	Recent developments in the management of Huntington's disease.. **2022**, 120, 105642	2

63	Predicting the Activities of Drug Excipients on Biological Targets using One-Shot Learning.. **2022**,	0
62	Discovery of Pyridone-Substituted Triazolopyrimidine Dual A/A AR Antagonists for the Treatment of Ischemic Stroke.. **2022**, 13, 436-442	
61	A2A Adenosine Receptor Antagonists and their Potential in Neurological Disorders.. **2022**,	1
60	International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update.. **2022**, 74, 340-372	7
59	Discovery of HTL26119. **2022**, 179-200	
58	Single Stabilizing Point Mutation Enables High-Resolution Co-Crystal Structures of the Adenosine A2A Receptor with Preladenant Conjugates.. **2022**,	2
57	Eine einzige stabilisierende Punktmutation ermöglicht hochaufgelöste Co-Kristallstrukturen des Adenosin-A 2A -Rezeptors mit Preladenant-Konjugaten.	
56	SINAPs: A Software Tool for Analysis and Visualization of Interaction Networks of Molecular Dynamics Simulations.. **2022**,	0
55	Cathepsin D interacts with adenosine A2A receptors in mouse macrophages to modulate cell surface localization and inflammatory signaling.. **2022**, 101888	
54	A Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable?. **2022**, 27,	2
53	The Pharmacological Potential of Adenosine A Receptor Antagonists for Treating Parkinson's Disease.. **2022**, 27,	2
52	Wearable Bioelectronics for Chronic Wound Management. 2111022	19
51	Attenuation of Tumor Development in Mammary Carcinoma Rats by Theacrine, an Antagonist of Adenosine 2A Receptor.. **2021**, 26,	3
50	The Structural Basis of Peptide Binding at Class A G Protein-Coupled Receptors.. **2021**, 27,	1
49	CHAPTER 6. A Unifying Approach to the Duality of Energetic Versus Conformational Formulations of Allosteric Coupling: Mechanistic Implications for GPCR Allostery. 131-155	
48	Table_1.pdf. **2020**,	
47	Video_1.MP4. **2020**,	
46	Table_1.XLSX. **2018**,	

45	Table_2.XLSX. **2018**,		
44	Table_3.XLSX. **2018**,		
43	Determination of key residues in MRGPRX2 to enhance pseudo-allergic reactions induced by fluoroquinolones.. **2022**, 12, 6650		0
42	Molecular Simulations and Drug Discovery of Adenosine Receptors.. **2022**, 27,		1
41	Purinergic receptors modulators: An emerging pharmacological tool for disease management.. **2022**,		0
40	A adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models.. **2022**, 10,		2
39	Superconserved receptors expressed in the brain: Expression, function, motifs and evolution of an orphan receptor family. **2022**, 108217		
38	Design, synthesis, and biological evaluation of triazole-pyrimidine-methylbenzonitrile derivatives as dual A2A/A2B adenosine receptor antagonists. **2022**, 37, 1514-1526		0
37	Structural mass spectrometry of membrane proteins. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2022**, 140813	4	4
36	CryoEM Structures of the Human HIV-1 Restriction Factor SERINC3 and Function as a Lipid Transporter.		2
35	A robust approach for MicroED sample preparation of lipidic cubic phase embedded membrane protein crystals.		0
34	Cancer-Associated Mutations of the Adenosine A2A Receptor Have Diverse Influences on Ligand Binding and Receptor Functions. **2022**, 27, 4676		0
33	Filling of a water-free void explains the allosteric regulation of the □1-adrenergic receptor by cholesterol.		2
32	GPCR Agonist-to-Antagonist Conversion: Enabling the Design of Nucleoside Functional Switches for the A2A Adenosine Receptor.		1
31	Ten Years of GPCR Structures. **2022**, 299-345		0
30	Comparative Study of State-Dependent Cholesterol Binding Sites in Adenosine A2A and A1 Receptors Using Coarse-Grained Molecular Dynamics Simulations in Biologically Relevant Membranes.		0
29	Bell-Evans model and steered molecular dynamics in uncovering the dissociation kinetics of ligands targeting G-protein-coupled receptors. **2022**, 12,		0
28	Dual A1/A3 Adenosine Receptor Antagonists: Binding Kinetics and Structure□Activity Relationship Studies Using Mutagenesis and Alchemical Binding Free Energy Calculations.		0

27	Synthesis, Molecular Docking, and Neuroprotective Effect of 2-Methylcinnamic Acid Amide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-Induced Parkinson's Disease Model. **2022**, 12, 1518	0
26	Nucleoside transporters and immunosuppressive adenosine signaling in the tumor microenvironment: Potential therapeutic opportunities. **2022**, 240, 108300	0
25	Activation and signaling mechanism revealed by GPR119-Gs complex structures. **2022**, 13,	0
24	Bifunctional Tools to Study Adenosine Receptors. **2022**,	0
23	Global insights into the fine tuning of human A2AAR conformational dynamics in a ternary complex with an engineered G protein viewed by NMR. **2022**, 41, 111844	0
22	Transactivation of receptor tyrosine kinases by purinergic P2Y and adenosine receptors.	0
21	Cryo-EM structure of the human adenosine A 2B receptor-G s signaling complex. **2022**, 8,	0
20	Comparative Study of Receptor-, Receptor State-, and Membrane-Dependent Cholesterol Binding Sites in A2A and A1 Adenosine Receptors Using Coarse-Grained Molecular Dynamics Simulations.	0
19	Cryo-EM structures of orphan GPR21 signaling complexes. **2023**, 14,	0
18	Anionic Phospholipids Control Mechanisms of GPCR-G Protein Recognition.	0
17	Systematic analyses of the sequence conservation and ligand interaction patterns of purinergic P1 and P2Y receptors provide a structural basis for receptor selectivity. **2023**, 21, 889-898	1
16	Non-ionic cholesterol-based additives for the stabilization of membrane proteins. **2022**,	0
15	G Protein-Coupled Receptors: Conformational "Gatekeepers" of Transmembrane Signal Transduction and Diversification. **2011**, 188-229	0
14	NMR of Membrane Proteins. **2012**, 271-317	0
13	Modeling of Olfactory Receptors. **2023**, 183-193	0
12	Role of adenosine A2a receptor in cancers and autoimmune diseases. **2023**, 11,	0
11	Sub-millisecond conformational dynamics of the A2A adenosine receptor revealed by single-molecule FRET. **2023**, 6,	0
10	Biophysical Dissection of Isolated GPCRs: The Adenosine A2A Receptor under the Bistouries. **2023**, 2, 47-92	0

9	Anionic phospholipids control mechanisms of GPCR-G protein recognition. **2023**, 14,	0
8	A robust approach for MicroED sample preparation of lipidic cubic phase embedded membrane protein crystals. **2023**, 14,	0
7	G Protein-Coupled Receptors. **2023**, 1-28	0
6	Once Upon a Time Adenosine and Its Receptors: Historical Survey and Perspectives as Potential Targets for Therapy in Human Diseases. **2023**,	0
5	Bioengineered Exosomes Bearing Adenosine A2a Receptor for the Treatment of Neuroinflammation. **2022**, 18, 2642-2650	0
4	Structural insights into the human niacin receptor HCA2-Gi signalling complex. **2023**, 14,	0
3	Machine Learning-aided Discovery of Novel Chemotype Antagonists for G Protein-coupled Receptors: The Case of the Adenosine A2AReceptor.	0
2	Structural insight into an anti-BRIL Fab as a G-protein-coupled receptor crystallization chaperone. **2023**, 79, 435-441	0
1	Conformational dynamics of the □pioid receptor determine ligand intrinsic efficacy.	0